<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>10603569</id><passage><infon key="name_2">surname:Kwan;given-names:Justin</infon><infon key="name_1">surname:Vullaganti;given-names:Mithila</infon><infon key="name_0">surname:Ilieva;given-names:Hristelina</infon><infon key="year">2023</infon><infon key="article-id_publisher-id">bmj-2023-075037.R1 kwaj075037</infon><infon key="fn">Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors</infon><infon key="article-id_doi">10.1136/bmj-2023-075037</infon><infon key="type">front</infon><infon key="elocation-id">e075037</infon><infon key="volume">383</infon><infon key="license">This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.</infon><infon key="section_type">TITLE</infon><infon key="article-id_pmc">10603569</infon><infon key="article-id_pmid">37890889</infon><offset>0</offset><text>Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis</text><annotation id="7770"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="61" length="29" /><text>amyotrophic lateral sclerosis</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>91</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>100</offset><text>Although the past two decades have produced exciting discoveries in the genetics and pathology of amyotrophic lateral sclerosis (ALS), progress in developing an effective therapy remains slow. This review summarizes the critical discoveries and outlines the advances in disease characterization, diagnosis, imaging, and biomarkers, along with the current status of approaches to ALS care and treatment. Additional knowledge of the factors driving disease progression and heterogeneity will hopefully soon transform the care for patients with ALS into an individualized, multi-prong approach able to prevent disease progression sufficiently to allow for a dignified life with limited disability.</text><annotation id="7771"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="479" length="3" /><text>ALS</text></annotation><annotation id="7772"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="229" length="3" /><text>ALS</text></annotation><annotation id="7773"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="198" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="7774"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="628" length="8" /><text>patients</text></annotation><annotation id="7775"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="642" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>795</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>808</offset><text>As the most common cause of adult onset motor neuron disease (MND), amyotrophic lateral sclerosis (ALS) is traditionally classified as a neuromuscular disorder because the presenting symptoms are caused by muscle weakness and atrophy. However, clinical, genetic, and molecular discoveries over the past 20 years have challenged this convention. ALS shares features of frontotemporal dementia, a group of neurodegenerative disorders that causes cognitive, behavioral, and motor dysfunction. Nearly half of all patients with ALS have varying degrees of cognitive and/or behavioral impairment, with approximately 15% meeting the diagnostic criteria for frontotemporal dementia. Conversely, about 15% of patients with behavioral variant frontotemporal dementia and 18% of patients with primary progressive aphasia have ALS.  These disorders also have overlapping genetics, with hexanucleotide repeat expansion (HRE) in C9ORF72 being the most common genetic cause of ALS, frontotemporal dementia, or both in people of European ancestry. Additionally, abnormal aggregation of transactive response DNA binding protein 43 (TDP-43) or fused in sarcoma (FUS) is present in the cytoplasm of cortical neurons in ALS and frontotemporal dementia.  As such, ALS is widely recognized as a complex neurodegenerative disorder in the frontotemporal dementia-MND continuum.  The reconceptualization of ALS in this continuum of disorders has allowed for novel approaches toward understanding fundamental disease mechanisms contributing to pathogenesis and has opened new avenues in approaches toward therapy. In this review, we provide a comprehensive summary of the clinical and genetic heterogeneity of ALS and advances in molecular pathology and biomarkers, and we highlight key interventions that improve quality of life. The intended audience includes students, trainees, general neurologists, and neuromuscular subspecialists.</text><annotation id="7776"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="1723" length="7" /><text>C9ORF72</text></annotation><annotation id="7777"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="1923" length="6" /><text>TDP-43</text></annotation><annotation id="7778"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="1952" length="3" /><text>FUS</text></annotation><annotation id="7779"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="876" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="7780"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="1176" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7781"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="2008" length="3" /><text>ALS</text></annotation><annotation id="7782"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="1522" length="42" /><text>behavioral variant frontotemporal dementia</text></annotation><annotation id="7783"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1317" length="8" /><text>patients</text></annotation><annotation id="7784"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="2051" length="3" /><text>ALS</text></annotation><annotation id="7785"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="1034" length="7" /><text>atrophy</text></annotation><annotation id="7786"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="1331" length="3" /><text>ALS</text></annotation><annotation id="7787"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="1458" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7788"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="1014" length="15" /><text>muscle weakness</text></annotation><annotation id="7789"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1252" length="44" /><text>cognitive, behavioral, and motor dysfunction</text></annotation><annotation id="7790"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="1623" length="3" /><text>ALS</text></annotation><annotation id="7791"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="1153" length="3" /><text>ALS</text></annotation><annotation id="7792"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1508" length="8" /><text>patients</text></annotation><annotation id="7793"><infon key="identifier">MESH:D018888</infon><infon key="type">Disease</infon><location offset="1590" length="27" /><text>primary progressive aphasia</text></annotation><annotation id="7794"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1359" length="38" /><text>cognitive and/or behavioral impairment</text></annotation><annotation id="7795"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="1775" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7796"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="2147" length="3" /><text>MND</text></annotation><annotation id="7797"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1576" length="8" /><text>patients</text></annotation><annotation id="7798"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="2089" length="26" /><text>neurodegenerative disorder</text></annotation><annotation id="7799"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="1770" length="3" /><text>ALS</text></annotation><annotation id="7800"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="2123" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7801"><infon key="identifier">MESH:D009468</infon><infon key="type">Disease</infon><location offset="945" length="22" /><text>neuromuscular disorder</text></annotation><annotation id="7802"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="870" length="3" /><text>MND</text></annotation><annotation id="7803"><infon key="identifier">MESH:D000069337</infon><infon key="type">Disease</infon><location offset="1934" length="16" /><text>fused in sarcoma</text></annotation><annotation id="7804"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="907" length="3" /><text>ALS</text></annotation><annotation id="7805"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="2492" length="3" /><text>ALS</text></annotation><annotation id="7806"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="848" length="20" /><text>motor neuron disease</text></annotation><annotation id="7807"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="2016" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7809"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="2190" length="3" /><text>ALS</text></annotation><annotation id="7810"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="1212" length="27" /><text>neurodegenerative disorders</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2720</offset><text>Epidemiology</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2733</offset><text>The worldwide prevalence and incidence of ALS are estimated to be 4.42 per 100 000 population and 1.59 per 100 000 person years, respectively, and population based studies have shown geographic variation with the highest in western Europe (prevalence 9.62 per 100 000 population and incidence 2.76 per 100 000 person years) and lowest in South Asia (prevalence 1.57 per 100 000 population and incidence 0.42 per 100 000 person years). The incidence and prevalence of ALS are higher in developed regions, and a temporal trend has been observed, with the incidence rising by 0.00013 per year.  The prevalence and incidence of ALS is higher in men (prevalence 5.96 per 100 000 population; incidence 1.91 per 100 000 person years) than in women (prevalence 3.90 per 100 000 population; incidence 1.36 per 100 000 person years).   </text><annotation id="7811"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="3200" length="3" /><text>ALS</text></annotation><annotation id="7812"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3374" length="3" /><text>men</text></annotation><annotation id="7813"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="3357" length="3" /><text>ALS</text></annotation><annotation id="7814"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3468" length="5" /><text>women</text></annotation><annotation id="7815"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="2775" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>3580</offset><text>Sources and selection criteria</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3611</offset><text>We independently did searches using the Boolean search criteria in the PubMed and Embase databases, between January 1990 and December 2022, using search terms such as amyotrophic lateral sclerosis, motor neuron disease, frontotemporal dementia, diagnosis, diagnostic criteria, prognosis, genetics, pathology, biomarker, and treatment. We identified articles published in the English language and selected them for inclusion on the basis of other criteria including relevance, peered review, and study type (randomized controlled trials, systematic reviews and meta-analyses, and observational studies). We prioritized publications in high impact and ALS specific journals published in the past 15 years. Several important publications could not be included owing to the scope of this review. We excluded case reports and articles not published in English.</text><annotation id="7816"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="3809" length="20" /><text>motor neuron disease</text></annotation><annotation id="7817"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="3831" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7818"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="4261" length="3" /><text>ALS</text></annotation><annotation id="7819"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="3778" length="29" /><text>amyotrophic lateral sclerosis</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>4467</offset><text>Clinical complexity of ALS</text><annotation id="7820"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="4490" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4494</offset><text>Clinical heterogeneity</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4517</offset><text>ALS is a clinically heterogeneous disorder (fig 1), and the biological underpinning of the heterogeneity is poorly understood. Typically, the symptom onset is localized with spread of motor impairment to adjacent muscle groups and/or regions of the neuroaxis. Usually, the progression rate is linear for any given person, but the rate often varies between patients. ALS of spinal onset with weakness first appearing in limb muscles occurs most frequently (two thirds of patients), followed by bulbar onset with initial weakness in lingual and oropharyngeal muscles (a third of patients). Axial or respiratory muscles are rarely the first to be affected. Uncommon subtypes of ALS with spinal or limb onset exist, with atypical patterns of weakness in which the motor impairment tends to be regionally confined early in the disease course. In brachial amyotrophic diplegia or flail arm syndrome, weakness tends to affect proximal upper extremities symmetrically. Similarly, in flail leg syndrome or lower extremity amyotrophic diplegia, weakness is mainly in the lower extremities. Other rarer ALS phenotypic variants include isolated bulbar ALS and hemiplegic ALS presenting with asymmetric hemibody weakness. Although the symptoms rarely remain restricted in these subtypes, the progression is typically slow. </text><annotation id="7821"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="4908" length="8" /><text>weakness</text></annotation><annotation id="7822"><infon key="identifier">MESH:D005409</infon><infon key="type">Disease</infon><location offset="5492" length="18" /><text>flail leg syndrome</text></annotation><annotation id="7823"><infon key="identifier">MESH:D005409</infon><infon key="type">Disease</infon><location offset="5391" length="18" /><text>flail arm syndrome</text></annotation><annotation id="7824"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="4517" length="3" /><text>ALS</text></annotation><annotation id="7825"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4987" length="8" /><text>patients</text></annotation><annotation id="7826"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="5255" length="8" /><text>weakness</text></annotation><annotation id="7827"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="4883" length="3" /><text>ALS</text></annotation><annotation id="7828"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="5552" length="8" /><text>weakness</text></annotation><annotation id="7829"><infon key="identifier">MESH:D002547</infon><infon key="type">Disease</infon><location offset="5358" length="29" /><text>brachial amyotrophic diplegia</text></annotation><annotation id="7830"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="5036" length="8" /><text>weakness</text></annotation><annotation id="7831"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5192" length="3" /><text>ALS</text></annotation><annotation id="7832"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="5411" length="8" /><text>weakness</text></annotation><annotation id="7833"><infon key="identifier">MESH:D000068079</infon><infon key="type">Disease</infon><location offset="5277" length="16" /><text>motor impairment</text></annotation><annotation id="7834"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5094" length="8" /><text>patients</text></annotation><annotation id="7835"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="5707" length="17" /><text>hemibody weakness</text></annotation><annotation id="7836"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4873" length="8" /><text>patients</text></annotation><annotation id="7837"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5665" length="14" /><text>hemiplegic ALS</text></annotation><annotation id="7838"><infon key="identifier">MESH:D000068079</infon><infon key="type">Disease</infon><location offset="4701" length="16" /><text>motor impairment</text></annotation><annotation id="7839"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5609" length="3" /><text>ALS</text></annotation><annotation id="7840"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5657" length="3" /><text>ALS</text></annotation><annotation id="7841"><infon key="identifier">MESH:D002547</infon><infon key="type">Disease</infon><location offset="5530" length="20" /><text>amyotrophic diplegia</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">kwaj075037.f1.jpg</infon><infon key="id">f1</infon><infon key="type">fig_caption</infon><offset>5828</offset><text>Amyotrophic lateral sclerosis (ALS) phenotypic spectrum. PBP=progressive bulbar palsy; PLS=primary lateral sclerosis; PMA=progressive muscular atrophy. Created using BioRender.com</text><annotation id="7842"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="5950" length="28" /><text>progressive muscular atrophy</text></annotation><annotation id="7843"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5828" length="29" /><text>Amyotrophic lateral sclerosis</text></annotation><annotation id="7844"><infon key="identifier">MESH:D010244</infon><infon key="type">Disease</infon><location offset="5901" length="12" /><text>bulbar palsy</text></annotation><annotation id="7845"><infon key="type">Disease</infon><location offset="5885" length="3" /><text>PBP</text></annotation><annotation id="7846"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="5859" length="3" /><text>ALS</text></annotation><annotation id="7847"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="5919" length="25" /><text>primary lateral sclerosis</text></annotation><annotation id="7848"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="5946" length="3" /><text>PMA</text></annotation><annotation id="7849"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="5915" length="3" /><text>PLS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6008</offset><text>Another contributor to phenotypic heterogeneity is the burden of neuronal degeneration in the cortex (upper motor neuron; UMN), brainstem, and spinal cord (lower motor neuron; LMN). Typically, the neurological examination shows UMN and LMN dysfunction, but the contribution of each likely falls on a continuum and can vary with patients having predominantly upper or lower motor signs (fig 1). One explanation for this variability may be differences in the pattern of spread in the course of the disease.  At the extremes are rare phenotypes such as primary lateral sclerosis (PLS) presenting as a pure UMN disorder and progressive muscular atrophy (PMA) presenting as a pure LMN disorder.   Some clinical features distinguish PLS from typical ALS. In PLS, symptoms are symmetric and slowly progressive, and they frequently have an ascending pattern of spread. PMA is clinically similar to typical ALS in the rate and pattern of symptom spread, but a subgroup of PMA may have slower disease progression. Prognostic factors associated with longer survival include UMN or LMN predominant symptoms, flail arm variant, and younger age at onset. Factors associated with shorter survival include bulbar and/or respiratory onset, comorbid frontotemporal dementia, poor nutritional status, neck flexion weakness, and older age at onset. </text><annotation id="7850"><infon key="identifier">MESH:D009133</infon><infon key="type">Disease</infon><location offset="6640" length="16" /><text>muscular atrophy</text></annotation><annotation id="7851"><infon key="type">Disease</infon><location offset="6184" length="3" /><text>LMN</text></annotation><annotation id="7852"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="6971" length="3" /><text>PMA</text></annotation><annotation id="7853"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="7290" length="21" /><text>neck flexion weakness</text></annotation><annotation id="7854"><infon key="type">Disease</infon><location offset="7078" length="3" /><text>LMN</text></annotation><annotation id="7855"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="6752" length="3" /><text>ALS</text></annotation><annotation id="7856"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="6658" length="3" /><text>PMA</text></annotation><annotation id="7857"><infon key="type">Disease</infon><location offset="6236" length="3" /><text>UMN</text></annotation><annotation id="7858"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="6906" length="3" /><text>ALS</text></annotation><annotation id="7859"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="6244" length="15" /><text>LMN dysfunction</text></annotation><annotation id="7860"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="6735" length="3" /><text>PLS</text></annotation><annotation id="7861"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="6760" length="3" /><text>PLS</text></annotation><annotation id="7862"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6336" length="8" /><text>patients</text></annotation><annotation id="7863"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="6558" length="25" /><text>primary lateral sclerosis</text></annotation><annotation id="7864"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="6073" length="21" /><text>neuronal degeneration</text></annotation><annotation id="7865"><infon key="identifier">MESH:D009358</infon><infon key="type">Disease</infon><location offset="6611" length="12" /><text>UMN disorder</text></annotation><annotation id="7866"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="6869" length="3" /><text>PMA</text></annotation><annotation id="7867"><infon key="type">Disease</infon><location offset="7071" length="3" /><text>UMN</text></annotation><annotation id="7868"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="6585" length="3" /><text>PLS</text></annotation><annotation id="7869"><infon key="identifier">MESH:D009358</infon><infon key="type">Disease</infon><location offset="6684" length="12" /><text>LMN disorder</text></annotation><annotation id="7870"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="7240" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7871"><infon key="type">Disease</infon><location offset="6130" length="3" /><text>UMN</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>7338</offset><text>Cognitive and behavioral dysfunction</text><annotation id="7872"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="7338" length="36" /><text>Cognitive and behavioral dysfunction</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7375</offset><text>Although ALS is synonymous with MND, cognitive and/or behavioral dysfunction are recognized core clinical features. Neuropsychological abnormality is associated with faster disease progression and shorter survival and occurs more frequently in advanced disease. Motor symptoms that alert patients and their care givers to a neurological disorder may overshadow antecedent or concurrent neuropsychological symptoms. Because cognitive or behavioral changes may be obscured by motor dysfunction, validated screening tests specific for ALS such as the Edinburgh Cognitive and Behavioral ALS Screen or ALS Cognitive Behavioral Screen are recommended in all patients.  If the screening test is abnormal, a more extensive neuropsychological evaluation can determine the cognitive and/or behavioral changes. ALS specific behavioral measures such as the Motor Neuron Disease Behavior Scale, the ALS-FTD-Questionnaire, or the Frontal Behavioral Inventory-ALS Version can be used to characterize and assess the severity of behavioral dysfunction.   The findings of these tests can classify patients as having ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, ALS with frontotemporal dementia (ALS-FTD) (fig 2), or none of the above (no cognitive or behavioral impairment). Approximately half of all patients with ALS will show impairment on a comprehensive assessment, with approximately 5% classified as ALS with combined cognitive and behavioral impairment, 8% as ALS with behavioral impairment, 17% as ALS with cognitive impairment, and 15-20% as ALS-FTD.    </text><annotation id="7873"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8320" length="3" /><text>ALS</text></annotation><annotation id="7874"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="7407" length="3" /><text>MND</text></annotation><annotation id="7875"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8937" length="3" /><text>ALS</text></annotation><annotation id="7876"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="7412" length="39" /><text>cognitive and/or behavioral dysfunction</text></annotation><annotation id="7877"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7663" length="8" /><text>patients</text></annotation><annotation id="7878"><infon key="identifier">MESH:D000068079</infon><infon key="type">Disease</infon><location offset="7849" length="17" /><text>motor dysfunction</text></annotation><annotation id="7879"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="8907" length="21" /><text>behavioral impairment</text></annotation><annotation id="7880"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8745" length="3" /><text>ALS</text></annotation><annotation id="7881"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="8226" length="14" /><text>Neuron Disease</text></annotation><annotation id="7882"><infon key="identifier">MESH:D009461</infon><infon key="type">Disease</infon><location offset="7699" length="21" /><text>neurological disorder</text></annotation><annotation id="7883"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8261" length="7" /><text>ALS-FTD</text></annotation><annotation id="7884"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8898" length="3" /><text>ALS</text></annotation><annotation id="7885"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="7972" length="3" /><text>ALS</text></annotation><annotation id="7886"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="8946" length="20" /><text>cognitive impairment</text></annotation><annotation id="7887"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="7384" length="3" /><text>ALS</text></annotation><annotation id="7888"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8175" length="3" /><text>ALS</text></annotation><annotation id="7889"><infon key="identifier">MESH:D000014</infon><infon key="type">Disease</infon><location offset="7491" length="30" /><text>Neuropsychological abnormality</text></annotation><annotation id="7890"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8454" length="8" /><text>patients</text></annotation><annotation id="7891"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8536" length="3" /><text>ALS</text></annotation><annotation id="7892"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8982" length="7" /><text>ALS-FTD</text></annotation><annotation id="7893"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8591" length="3" /><text>ALS</text></annotation><annotation id="7894"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8837" length="3" /><text>ALS</text></annotation><annotation id="7895"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="7958" length="3" /><text>ALS</text></annotation><annotation id="7896"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="8387" length="22" /><text>behavioral dysfunction</text></annotation><annotation id="7897"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8473" length="3" /><text>ALS</text></annotation><annotation id="7898"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="8513" length="21" /><text>behavioral impairment</text></annotation><annotation id="7899"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="8668" length="34" /><text>cognitive or behavioral impairment</text></annotation><annotation id="7900"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8027" length="8" /><text>patients</text></annotation><annotation id="7901"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8504" length="3" /><text>ALS</text></annotation><annotation id="7902"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="7907" length="3" /><text>ALS</text></annotation><annotation id="7903"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="8600" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7904"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8731" length="8" /><text>patients</text></annotation><annotation id="7905"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="8625" length="7" /><text>ALS-FTD</text></annotation><annotation id="7906"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="8482" length="20" /><text>cognitive impairment</text></annotation><annotation id="7907"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="8554" length="35" /><text>cognitive and behavioral impairment</text></annotation><annotation id="7908"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="8855" length="35" /><text>cognitive and behavioral impairment</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">kwaj075037.f2.jpg</infon><infon key="id">f2</infon><infon key="type">fig_caption</infon><offset>8995</offset><text>Amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) clinical syndromes and disease mechanisms contributing to neurodegeneration. ALS=amyotrophic lateral sclerosis; ALSbi=ALS with behavioral impairment; ALScbi=ALS with combined cognitive and behavioral impairment; ALSci=ALS with cognitive impairment; bvFTD=behavioral variant FTD; CBS=corticobasal syndrome; FTD=frontotemporal dementia; LMND=lower motor neuron predominant; nfvPPA=non-fluent variant primary progressive aphasia; PBP=progressive bulbar palsy; PLS=primary lateral sclerosis; PMA=progressive muscular atrophy; PSP=progressive supranuclear palsy; svPPA=semantic variant primary progressive aphasia; UMND=upper motor neuron predominant</text><annotation id="7909"><infon key="type">Disease</infon><location offset="9674" length="4" /><text>UMND</text></annotation><annotation id="7910"><infon key="type">Disease</infon><location offset="9176" length="5" /><text>ALSbi</text></annotation><annotation id="7911"><infon key="identifier">MESH:D018888</infon><infon key="type">Disease</infon><location offset="9462" length="27" /><text>primary progressive aphasia</text></annotation><annotation id="7912"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9182" length="3" /><text>ALS</text></annotation><annotation id="7913"><infon key="type">Disease</infon><location offset="9622" length="5" /><text>svPPA</text></annotation><annotation id="7914"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="9556" length="28" /><text>progressive muscular atrophy</text></annotation><annotation id="7915"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="9374" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="7916"><infon key="identifier">MESH:D018888</infon><infon key="type">Disease</infon><location offset="9645" length="27" /><text>primary progressive aphasia</text></annotation><annotation id="7917"><infon key="identifier">MESH:D011030</infon><infon key="type">Disease</infon><location offset="9586" length="3" /><text>PSP</text></annotation><annotation id="7918"><infon key="type">Disease</infon><location offset="9491" length="3" /><text>PBP</text></annotation><annotation id="7919"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="9338" length="3" /><text>FTD</text></annotation><annotation id="7920"><infon key="identifier">MESH:D006712</infon><infon key="type">Disease</infon><location offset="9343" length="3" /><text>CBS</text></annotation><annotation id="7921"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="9122" length="17" /><text>neurodegeneration</text></annotation><annotation id="7922"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9141" length="3" /><text>ALS</text></annotation><annotation id="7923"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9282" length="3" /><text>ALS</text></annotation><annotation id="7924"><infon key="type">Disease</infon><location offset="9399" length="4" /><text>LMND</text></annotation><annotation id="7925"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="9291" length="20" /><text>cognitive impairment</text></annotation><annotation id="7926"><infon key="identifier">MESH:D000088282</infon><infon key="type">Disease</infon><location offset="9347" length="21" /><text>corticobasal syndrome</text></annotation><annotation id="7927"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9221" length="3" /><text>ALS</text></annotation><annotation id="7928"><infon key="type">Disease</infon><location offset="9276" length="5" /><text>ALSci</text></annotation><annotation id="7929"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="9191" length="21" /><text>behavioral impairment</text></annotation><annotation id="7930"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9055" length="7" /><text>ALS-FTD</text></annotation><annotation id="7931"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="9370" length="3" /><text>FTD</text></annotation><annotation id="7932"><infon key="type">Disease</infon><location offset="9313" length="5" /><text>bvFTD</text></annotation><annotation id="7933"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="9521" length="3" /><text>PLS</text></annotation><annotation id="7934"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="9239" length="35" /><text>cognitive and behavioral impairment</text></annotation><annotation id="7935"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9145" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="7936"><infon key="identifier">OMIM:105550</infon><infon key="type">Disease</infon><location offset="8995" length="58" /><text>Amyotrophic lateral sclerosis with frontotemporal dementia</text></annotation><annotation id="7937"><infon key="identifier">MESH:D010244</infon><infon key="type">Disease</infon><location offset="9495" length="24" /><text>progressive bulbar palsy</text></annotation><annotation id="7938"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="9552" length="3" /><text>PMA</text></annotation><annotation id="7939"><infon key="identifier">MESH:D013494</infon><infon key="type">Disease</infon><location offset="9590" length="30" /><text>progressive supranuclear palsy</text></annotation><annotation id="7940"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="9525" length="25" /><text>primary lateral sclerosis</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9710</offset><text>The most commonly affected cognitive domain in ALS is executive function, with abnormal verbal fluency being a consistent and sensitive marker even after control for bulbar motor dysfunction.   In patients who develop cognitive symptoms, impaired word fluency is an early finding. Other features of executive dysfunction such as mental inflexibility, inattention and disinhibition, or inability to plan or problem solve can emerge as the disease progresses.   Impairment in multiple cognitive domains is less common in ALS and, when present, tends to involve language or memory and may be confounded by co-pathology such as Alzheimer's disease.  Isolated amnestic syndrome is not a feature in ALS and should prompt evaluation for an alternative cause. Overall, progression of cognitive dysfunction in ALS is slow and may remain stable over time. </text><annotation id="7941"><infon key="identifier">MESH:D019954</infon><infon key="type">Disease</infon><location offset="9928" length="18" /><text>cognitive symptoms</text></annotation><annotation id="7942"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="10486" length="21" /><text>cognitive dysfunction</text></annotation><annotation id="7943"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="10511" length="3" /><text>ALS</text></annotation><annotation id="7944"><infon key="identifier">MESH:D013064</infon><infon key="type">Disease</infon><location offset="9948" length="21" /><text>impaired word fluency</text></annotation><annotation id="7945"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="10403" length="3" /><text>ALS</text></annotation><annotation id="7946"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="9757" length="3" /><text>ALS</text></annotation><annotation id="7947"><infon key="identifier">MESH:D001308</infon><infon key="type">Disease</infon><location offset="10061" length="11" /><text>inattention</text></annotation><annotation id="7948"><infon key="identifier">MESH:D000425</infon><infon key="type">Disease</infon><location offset="10365" length="17" /><text>amnestic syndrome</text></annotation><annotation id="7949"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="10334" length="19" /><text>Alzheimer's disease</text></annotation><annotation id="7950"><infon key="identifier">MESH:D014854</infon><infon key="type">Disease</infon><location offset="9876" length="24" /><text>bulbar motor dysfunction</text></annotation><annotation id="7951"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="10039" length="20" /><text>mental inflexibility</text></annotation><annotation id="7952"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="10229" length="3" /><text>ALS</text></annotation><annotation id="7953"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9907" length="8" /><text>patients</text></annotation><annotation id="7954"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="10009" length="21" /><text>executive dysfunction</text></annotation><annotation id="7955"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="10170" length="40" /><text>Impairment in multiple cognitive domains</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10559</offset><text>Behavioral abnormalities are a frequent neuropsychiatric feature in ALS, apathy being the most common. Others include disinhibition, perseverative behavior, change in food preferences, loss of empathy, or impaired social cognition including emotional processing.     Pathological crying and laughing, also known as emotional lability or pseudobulbar affect, is present in approximately one in three patients with ALS and is associated with gray and white matter pathology in the cortico-cerebellar network.  Pathological crying and laughing does not correlate with neuropsychological measures and should be distinguished from other cognitive and behavioral symptoms. </text><annotation id="7956"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="10559" length="24" /><text>Behavioral abnormalities</text></annotation><annotation id="7957"><infon key="identifier">OMIM:300082</infon><infon key="type">Disease</infon><location offset="10764" length="25" /><text>impaired social cognition</text></annotation><annotation id="7958"><infon key="identifier">MESH:D016388</infon><infon key="type">Disease</infon><location offset="10744" length="15" /><text>loss of empathy</text></annotation><annotation id="7959"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="10627" length="3" /><text>ALS</text></annotation><annotation id="7960"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="10972" length="3" /><text>ALS</text></annotation><annotation id="7961"><infon key="identifier">MESH:D019954</infon><infon key="type">Disease</infon><location offset="11191" length="33" /><text>cognitive and behavioral symptoms</text></annotation><annotation id="7962"><infon key="identifier">MESH:C000631768</infon><infon key="type">Disease</infon><location offset="10599" length="16" /><text>neuropsychiatric</text></annotation><annotation id="7963"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="10958" length="8" /><text>patients</text></annotation><annotation id="7964"><infon key="type">Disease</infon><location offset="10632" length="6" /><text>apathy</text></annotation><annotation id="7965"><infon key="identifier">MESH:D020828</infon><infon key="type">Disease</infon><location offset="10896" length="19" /><text>pseudobulbar affect</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>11227</offset><text>Diagnostic criteria and disease progression measures</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11280</offset><text>ALS is a clinical diagnosis requiring findings of progressive motor neuron dysfunction in the absence of an alternative diagnosis. In typical ALS, few tests are needed to support the diagnosis and exclude mimics because other disorders rarely mimic ALS perfectly. The most common tests obtained in the diagnostic process are electrophysiology to establish a lower motor neuronopathy and neuroimaging of the brain and spine to exclude mimics causing structural abnormalities as a cause for UMN dysfunction. Routine laboratory studies are frequently obtained to exclude other causes of a patient's symptoms and are typically normal in ALS. The first widely used criteria in ALS were the El Escorial criteria, which aimed to provide a standardized diagnostic framework to conduct clinical research, with subsequent revisions and updates improving sensitivity allowing for earlier enrollment in clinical trials.  Although El Escorial and Awaji criteria are useful in clinical research, they are hampered by the heterogeneity of ALS and do not capture the full disease spectrum. For example, cognitive impairment and behavioral impairment are not included in these criteria and pure lower motor neuron variants are excluded. Furthermore, patients with ALS do not necessarily progress through the El Escorial categories of diagnostic certainty and may never attain the criteria for clinically definite ALS. The ALS-frontotemporal spectrum diagnostic (ALS-FTSD) criteria proposed by Strong and colleagues use three diagnostic axes to define MND, cognitive and behavioral dysfunction, and other non-motor features. Although the ALS-FTSD criteria more fully incorporate the ALS-FTD spectrum disorders, they still rely on El Escorial and Awaji criteria to define MND. The recently proposed Gold Coast criteria have attempted to simplify the diagnosis and recognize the potential utility of the development of biomarkers; however, further validation in different populations will be needed before routine use in clinical care or research. </text><annotation id="7966"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="13033" length="3" /><text>MND</text></annotation><annotation id="7967"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12945" length="26" /><text>ALS-FTD spectrum disorders</text></annotation><annotation id="7968"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="12392" length="21" /><text>behavioral impairment</text></annotation><annotation id="7969"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="11342" length="24" /><text>motor neuron dysfunction</text></annotation><annotation id="7970"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12900" length="3" /><text>ALS</text></annotation><annotation id="7971"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="11913" length="3" /><text>ALS</text></annotation><annotation id="7972"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="11638" length="24" /><text>lower motor neuronopathy</text></annotation><annotation id="7973"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="11769" length="15" /><text>UMN dysfunction</text></annotation><annotation id="7974"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="12814" length="3" /><text>MND</text></annotation><annotation id="7975"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12304" length="3" /><text>ALS</text></annotation><annotation id="7976"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="11952" length="3" /><text>ALS</text></annotation><annotation id="7977"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12513" length="8" /><text>patients</text></annotation><annotation id="7978"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="11280" length="3" /><text>ALS</text></annotation><annotation id="7979"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11866" length="7" /><text>patient</text></annotation><annotation id="7980"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="11422" length="3" /><text>ALS</text></annotation><annotation id="7981"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12676" length="3" /><text>ALS</text></annotation><annotation id="7982"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12527" length="3" /><text>ALS</text></annotation><annotation id="7983"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="12725" length="3" /><text>ALS</text></annotation><annotation id="7984"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="12819" length="36" /><text>cognitive and behavioral dysfunction</text></annotation><annotation id="7985"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="12367" length="20" /><text>cognitive impairment</text></annotation><annotation id="7986"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="11529" length="3" /><text>ALS</text></annotation><annotation id="7987"><infon key="identifier">OMIM:105550</infon><infon key="type">Disease</infon><location offset="12685" length="27" /><text>ALS-frontotemporal spectrum</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13311</offset><text>Variability in rate of symptom progression and survival in ALS represents a major obstacle in clinical trials. Disease progression, most often measured by the decline in the revised ALS functional rating scale (ALSFRS-R) over time, differs considerably between patients, and survival ranges from less than one year to more than 10 years.  Respiratory failure is the most common cause of death. Clinical factors that contribute to heterogeneity in survival include age at symptom onset, sex, site of symptom onset (bulbar versus spinal), time to diagnosis, respiratory measures, pre-symptomatic body mass index, cigarette use, genetics, and the diagnosis of FTD.   Neurofilament, a biomarker for neurodegeneration, is a predictor of the progression and prognosis of ALS.  A recently proposed survival prediction model for ALS identified eight prognostic predictors and generated five different survival groups applicable to European patients at the individual level. This model is an important step toward more effective stratification of patients in clinical studies, but validation in non-European groups is needed, and the model will likely evolve as other predictors are identified.</text><annotation id="7988"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14243" length="8" /><text>patients</text></annotation><annotation id="7989"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="13370" length="3" /><text>ALS</text></annotation><annotation id="7990"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="14076" length="3" /><text>ALS</text></annotation><annotation id="7991"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="13493" length="3" /><text>ALS</text></annotation><annotation id="7992"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14349" length="8" /><text>patients</text></annotation><annotation id="7993"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="14006" length="17" /><text>neurodegeneration</text></annotation><annotation id="7994"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="13698" length="5" /><text>death</text></annotation><annotation id="7995"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="13650" length="19" /><text>Respiratory failure</text></annotation><annotation id="7996"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="13572" length="8" /><text>patients</text></annotation><annotation id="7997"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="13968" length="3" /><text>FTD</text></annotation><annotation id="7998"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="14132" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14497</offset><text>Clinical staging is an important tool for research and care planning because it informs the extent and severity of disease. The two proposed staging systems are the King's staging system and the Milano-Torino staging systems.  The King's staging system is defined by the number of body regions affected and bulbar and respiratory failure, whereas the Milano-Torino system uses the number of impaired domains as delineated by the ALSFRS-R to define successive stages.  These systems provide parallel clinical information, using different measures to establish escalating stages, and both have been used to analyze patient population data and are promising endpoints for clinical trials.   A limitation of both systems is the lack of cognitive and behavioral change captured by staging, although higher disease stage portends more severe cognitive impairment. </text><annotation id="7999"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="15333" length="20" /><text>cognitive impairment</text></annotation><annotation id="8000"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15110" length="7" /><text>patient</text></annotation><annotation id="8001"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="14815" length="19" /><text>respiratory failure</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>15360</offset><text>Advances in molecular biology</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>15390</offset><text>Molecular pathology</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15410</offset><text>A new chapter in ALS pathology began in 2006 with the discovery of TDP-43 as the major constituent of ubiquinated aggregates in motor neurons of sporadic ALS and most familial ALS and in cortical neurons in a subgroup of frontotemporal dementia. TDP-43 staining is routinely done in postmortem tissue to characterize the pathology when ALS is suspected. Abnormal accumulation of the protein as either neuronal or glial cytoplasmic inclusions or aggregates is found in 97% of cases of sporadic ALS. Rarely, TDP-43 pathology is not a feature and is seen in ALS caused by superoxidase dismutase 1 (SOD1) or fused in sarcoma (FUS) gene mutations. Although accumulation of wild type TDP-43 has become the pathological hallmark of ALS, mutations in TDP-43 are rare and are found in 4-5% of dominantly inherited familial ALS and 1% of sporadic ALS. Additionally, cytoplasmic TDP-43 aggregation can be seen in Alzheimer's disease, atypical parkinsonism, dementia with Lewy bodies, and limbic predominant age related TDP-43 encephalopathy, leading to the recognition of this group of neurodegenerative disorders as TDP-43 proteinopathies.  TDP-43 was first discovered in 1995, and its function was described as a suppressor of HIV-1 expression. As an RNA/DNA binding protein, it is involved in multiple processes such as RNA processing and maturation, RNA transport, microRNA maturation, and stress granule formation. It normally shuttles between the nucleus and the cytoplasm. The cellular dysfunction leading to TDP-43 aggregation in the cytoplasm and the resultant neurodegeneration is a topic of active research.  Both loss-of-function and gain-of-function mechanisms have been proposed. An example of the loss-of-function mechanism is the TDP-43 function as a repressor of cryptic exon inclusion. As a result of depletion from the nucleus and loss of the repressor function, cryptic exons (exons that are otherwise excluded from the mRNA) are included in at least two known loci, STMN2 and UNC13A, causing reduced protein expression.    Of note, cryptic exons are not always shared between species, necessitating the development of new, humanized models. The mild motor neuron degeneration and the inability to replicate the loss of nuclear localization with concomitant cytoplasmic accumulation in animal models have been considered as evidence that these may be late events in the pathogenic cascade.</text><annotation id="8002"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="15477" length="6" /><text>TDP-43</text></annotation><annotation id="8003"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="15656" length="6" /><text>TDP-43</text></annotation><annotation id="8004"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="15916" length="6" /><text>TDP-43</text></annotation><annotation id="8005"><infon key="identifier" /><infon key="type">Gene</infon><location offset="15979" length="24" /><text>superoxidase dismutase 1</text></annotation><annotation id="8006"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="16005" length="4" /><text>SOD1</text></annotation><annotation id="8007"><infon key="identifier" /><infon key="type">Gene</infon><location offset="16023" length="7" /><text>sarcoma</text></annotation><annotation id="8008"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="16032" length="3" /><text>FUS</text></annotation><annotation id="8009"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="16088" length="6" /><text>TDP-43</text></annotation><annotation id="8010"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="16153" length="6" /><text>TDP-43</text></annotation><annotation id="8011"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="16278" length="6" /><text>TDP-43</text></annotation><annotation id="8012"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="16541" length="6" /><text>TDP-43</text></annotation><annotation id="8013"><infon key="identifier">6239</infon><infon key="type">Gene</infon><location offset="16655" length="20" /><text>/DNA binding protein</text></annotation><annotation id="8014"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="16915" length="6" /><text>TDP-43</text></annotation><annotation id="8015"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="17145" length="6" /><text>TDP-43</text></annotation><annotation id="8016"><infon key="identifier">11075</infon><infon key="type">Gene</infon><location offset="17386" length="5" /><text>STMN2</text></annotation><annotation id="8017"><infon key="identifier">23025</infon><infon key="type">Gene</infon><location offset="17396" length="6" /><text>UNC13A</text></annotation><annotation id="8020"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15965" length="3" /><text>ALS</text></annotation><annotation id="8021"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15746" length="3" /><text>ALS</text></annotation><annotation id="8022"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="16969" length="17" /><text>neurodegeneration</text></annotation><annotation id="8023"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="16312" length="19" /><text>Alzheimer's disease</text></annotation><annotation id="8024"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15564" length="3" /><text>ALS</text></annotation><annotation id="8025"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15903" length="3" /><text>ALS</text></annotation><annotation id="8026"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15427" length="3" /><text>ALS</text></annotation><annotation id="8027"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="15586" length="3" /><text>ALS</text></annotation><annotation id="8028"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="16135" length="3" /><text>ALS</text></annotation><annotation id="8029"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="15631" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8030"><infon key="identifier">OMIM:617113</infon><infon key="type">Disease</infon><location offset="16418" length="21" /><text>TDP-43 encephalopathy</text></annotation><annotation id="8031"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="16356" length="25" /><text>dementia with Lewy bodies</text></annotation><annotation id="8032"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="16485" length="27" /><text>neurodegenerative disorders</text></annotation><annotation id="8033"><infon key="identifier">MESH:D057177</infon><infon key="type">Disease</infon><location offset="16516" length="22" /><text>TDP-43 proteinopathies</text></annotation><annotation id="8034"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="16224" length="3" /><text>ALS</text></annotation><annotation id="8035"><infon key="identifier">MESH:C566823</infon><infon key="type">Disease</infon><location offset="16333" length="21" /><text>atypical parkinsonism</text></annotation><annotation id="8036"><infon key="identifier">11676</infon><infon key="type">Species</infon><location offset="16628" length="5" /><text>HIV-1</text></annotation><annotation id="8037"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="17570" length="25" /><text>motor neuron degeneration</text></annotation><annotation id="8038"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="16247" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>17811</offset><text>Genetics</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>17820</offset><text>Whereas the vast majority of ALS is classified as sporadic disease:that is, without known history of another family member with either ALS or frontotemporal dementia:approximately 10% is familial ALS, which can be autosomal dominant, autosomal recessive, or X linked. The list of different causative genes for ALS has grown tremendously (&gt;40 genes), mostly owing to advances in sequencing technologies. Genes causing two thirds of familial ALS and 10% of sporadic ALS are known. Only an overview of the genetics of ALS will be provided here (table 1), as detailed descriptions of all known ALS associated genes are beyond the scope of this review and can be found in other publications. </text><annotation id="8039"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="17849" length="3" /><text>ALS</text></annotation><annotation id="8040"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18410" length="3" /><text>ALS</text></annotation><annotation id="8041"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18016" length="3" /><text>ALS</text></annotation><annotation id="8042"><infon key="identifier">MESH:D020821</infon><infon key="type">Disease</infon><location offset="17870" length="16" /><text>sporadic disease</text></annotation><annotation id="8043"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18284" length="3" /><text>ALS</text></annotation><annotation id="8044"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18335" length="3" /><text>ALS</text></annotation><annotation id="8045"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="17962" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8046"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18260" length="3" /><text>ALS</text></annotation><annotation id="8047"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="17955" length="3" /><text>ALS</text></annotation><annotation id="8048"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18130" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="type">table_caption</infon><offset>18512</offset><text>Rare causative genes for amyotrophic lateral sclerosis (ALS)</text><annotation id="8049"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18568" length="3" /><text>ALS</text></annotation><annotation id="8050"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="18537" length="29" /><text>amyotrophic lateral sclerosis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl1.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="above" rules="groups"&gt;&lt;col width="28.05%" span="1"/&gt;&lt;col width="29.98%" span="1"/&gt;&lt;col width="41.97%" span="1"/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Gene (OMIM number)&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Protein&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Associated clinical diagnosis/feature&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td colspan="3" valign="top" align="left" scope="col" rowspan="1"&gt; &lt;bold&gt;RNA/DNA binding proteins (involved in pre-mRNA processing, metabolism, and transport)&lt;/bold&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;TARDBP&lt;/italic&gt; (*605078)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;TAR DNA binding protein 43 (TDP-43)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without FTD; FTD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;FUS (*137070)&lt;/italic&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Fused in sarcoma protein&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without FTD; hereditary essential tremor&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;hnRNPA1&lt;/italic&gt; (*164017) and &lt;italic toggle="yes"&gt;hnRNPA2B1&lt;/italic&gt; (*600124)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Heterogeneous nuclear ribonuclear protein A1 and A2B1&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS; inclusion body myopathy with early onset Paget's disease with or without frontotemporal dementia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;MATR3&lt;/italic&gt; (*164015)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Matrin 3&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without cognitive impairment or dementia; distal myopathy&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;ANG&lt;/italic&gt; (*105850)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Angiogenin&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Frequent bulbar onset ALS; co-existing parkinsonism with FTD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" valign="top" align="left" scope="col" rowspan="1"&gt; &lt;bold&gt;Genes that encode for structural proteins (cytoskeleton proteins)&lt;/bold&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;TUBA4A&lt;/italic&gt; (*191110)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Tubulin-alpha 4A (alpha tubulin)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without FTD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;ANXA11&lt;/italic&gt; (*602572)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Annexin A11&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Later onset ALS (average 67 years); inclusion body myopathy and brain white matter abnormality&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;PRPH&lt;/italic&gt; (*170710)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Peripherin&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;DCTN1&lt;/italic&gt; (*601143)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Dynactin 1&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Distal motor neuronopathy with vocal paresis&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;PFN1&lt;/italic&gt; (*176610)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Profilin 1&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;KIF5a&lt;/italic&gt; (*602821)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;KIF5a (kinesin family member 5A)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Also implicated in HSP-10, CMT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" valign="top" align="left" scope="col" rowspan="1"&gt; &lt;bold&gt;Loss-of-function mutations in genes encoding proteins important for protein degradation or autophagy pathways&lt;/bold&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;UBQLN2&lt;/italic&gt; (*300264)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Ubiquilin-2&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without FTD; X linked dominant familial ALS; onset younger in males than females&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;SQSTM1&lt;/italic&gt; (*601530)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;p62/sequestosome 1&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;FTD with or without Paget's disease of the bone; distal myopathy with rimmed vacuoles&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;OPTN&lt;/italic&gt; (*602432)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Optineurin&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;ALS with or without FTD; allelic with primary open angle glaucoma&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;VCP&lt;/italic&gt; (*601123)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Vasolin containing protein&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;FTD with or without ALS; inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD); CMT type 2Y&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;CHMP2B&lt;/italic&gt; (*609512)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Charged multivesicular body protein 2B&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;FTD with or without ALS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;VAPB/VAMP&lt;/italic&gt; (*605704)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Synatobrevin associated protein B/vesicle associated membrane protein&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Lower motor neuronopathy&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt; &lt;italic toggle="yes"&gt;TBK1&lt;/italic&gt; (*604834)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;TANK binding kinase 1&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;FTD with or without ALS&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tbl1</infon><infon key="type">table</infon><offset>18573</offset><text>Gene (OMIM number)	Protein	Associated clinical diagnosis/feature	 	RNA/DNA binding proteins (involved in pre-mRNA processing, metabolism, and transport)	 	TARDBP (*605078)	TAR DNA binding protein 43 (TDP-43)	ALS with or without FTD; FTD	 	FUS (*137070)	Fused in sarcoma protein	ALS with or without FTD; hereditary essential tremor	 	hnRNPA1 (*164017) and hnRNPA2B1 (*600124)	Heterogeneous nuclear ribonuclear protein A1 and A2B1	ALS; inclusion body myopathy with early onset Paget's disease with or without frontotemporal dementia	 	MATR3 (*164015)	Matrin 3	ALS with or without cognitive impairment or dementia; distal myopathy	 	ANG (*105850)	Angiogenin	Frequent bulbar onset ALS; co-existing parkinsonism with FTD	 	Genes that encode for structural proteins (cytoskeleton proteins)	 	TUBA4A (*191110)	Tubulin-alpha 4A (alpha tubulin)	ALS with or without FTD	 	ANXA11 (*602572)	Annexin A11	Later onset ALS (average 67 years); inclusion body myopathy and brain white matter abnormality	 	PRPH (*170710)	Peripherin	ALS	 	DCTN1 (*601143)	Dynactin 1	Distal motor neuronopathy with vocal paresis	 	PFN1 (*176610)	Profilin 1	ALS	 	KIF5a (*602821)	KIF5a (kinesin family member 5A)	Also implicated in HSP-10, CMT	 	Loss-of-function mutations in genes encoding proteins important for protein degradation or autophagy pathways	 	UBQLN2 (*300264)	Ubiquilin-2	ALS with or without FTD; X linked dominant familial ALS; onset younger in males than females	 	SQSTM1 (*601530)	p62/sequestosome 1	FTD with or without Paget's disease of the bone; distal myopathy with rimmed vacuoles	 	OPTN (*602432)	Optineurin	ALS with or without FTD; allelic with primary open angle glaucoma	 	VCP (*601123)	Vasolin containing protein	FTD with or without ALS; inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD); CMT type 2Y	 	CHMP2B (*609512)	Charged multivesicular body protein 2B	FTD with or without ALS	 	VAPB/VAMP (*605704)	Synatobrevin associated protein B/vesicle associated membrane protein	Lower motor neuronopathy	 	TBK1 (*604834)	TANK binding kinase 1	FTD with or without ALS	 	</text><annotation id="8051"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="18812" length="3" /><text>FUS</text></annotation><annotation id="8052"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="18773" length="6" /><text>TDP-43</text></annotation><annotation id="8053"><infon key="identifier">283</infon><infon key="type">Gene</infon><location offset="19203" length="3" /><text>ANG</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="type">table_foot</infon><offset>20669</offset><text>CMT=Charcot-Marie-Tooth disease; FTD=frontotemporal dementia; HSP=hereditary spastic paraplegia.</text><annotation id="8054"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="20702" length="3" /><text>FTD</text></annotation><annotation id="8055"><infon key="identifier">MESH:D015419</infon><infon key="type">Disease</infon><location offset="20735" length="29" /><text>hereditary spastic paraplegia</text></annotation><annotation id="8056"><infon key="identifier">MESH:C537989</infon><infon key="type">Disease</infon><location offset="20669" length="3" /><text>CMT</text></annotation><annotation id="8057"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="20706" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8058"><infon key="identifier">MESH:D002607</infon><infon key="type">Disease</infon><location offset="20673" length="27" /><text>Charcot-Marie-Tooth disease</text></annotation><annotation id="8059"><infon key="type">Disease</infon><location offset="20731" length="3" /><text>HSP</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>20766</offset><text>SOD1</text><annotation id="8060"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="20766" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>20771</offset><text>The earliest understanding of the pathobiology of ALS derived from disease models based on mutations in SOD1, the first gene discovered in familial ALS in 1993, which accounts for 20% of familial ALS. Several different mechanisms of neurodegeneration have been proposed, including conformational instability of SOD1 protein, interactions with other proteins, and formation of toxic aggregates, but the exact mechanism remains unclear.  The consensus is that the many mutations spanning the whole length of SOD1 confer a toxic gain of function, which has led to development of silencing mutant gene expression as a therapeutic approach.  </text><annotation id="8061"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="20875" length="4" /><text>SOD1</text></annotation><annotation id="8062"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="21082" length="4" /><text>SOD1</text></annotation><annotation id="8063"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="21277" length="4" /><text>SOD1</text></annotation><annotation id="8064"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="20967" length="3" /><text>ALS</text></annotation><annotation id="8065"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="21004" length="17" /><text>neurodegeneration</text></annotation><annotation id="8066"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="20821" length="3" /><text>ALS</text></annotation><annotation id="8067"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="20919" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>21409</offset><text>C9ORF72</text><annotation id="8068"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="21409" length="7" /><text>C9ORF72</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>21417</offset><text>The largest genetic contributor to familial ALS was not discovered until 2011 because it is an HRE in an intron of a previously unknown gene named after the region of the chromosome where it is located, C9ORF72 (chromosome 9, open reading frame 72). Repeats are typically not detectable by standard sequencing methods and require instead repeat primed polymerase chain reaction (PCR), a PCR that overcomes the limitations of standard PCR by flanking the repeat region, or a careful analysis of the reason for a drop-off in the sequence coverage of the region in standard next generation sequencing. Intronic nucleotide repeat expansions are known to occur in genes linked to different disorders including myotonic dystrophy, spinocerebellar ataxias (SCA10, SCA 31, SCA 36), and Friedreich's ataxia. In unaffected people, the C9ORF72 alleles have approximately two to 25 repeats. In contrast, ALS and/or frontotemporal dementia linked to chromosome 9 carry one normal allele and one expanded allele that can have hundreds to thousands of repeats. Somatic instability may further complicate the assessment of the repeat size, as different tissues may have different repeat sizes even within a single patient. The process by which HRE lead to neurodegeneration is not precisely known; however, three major hypotheses have been proposed: the (G4C2) repeats function similarly to repeat expansions in other disorders (myotonic dystrophy, fragile X tremor/ataxia syndrome) binding and sequestering RNA binding proteins impairing their ability to regulate RNA targets; HRE may cause epigenetic changes resulting in decreased C9ORF72 mRNA expression; and an atypical mode of polypeptide translation across expanded repeats despite absence of an initiating codon, known as repeat associated non-ATG translation, which is also seen in spinocerebellar ataxia 8 and myotonic dystrophy.  </text><annotation id="8069"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="21620" length="7" /><text>C9ORF72</text></annotation><annotation id="8070"><infon key="identifier">25814</infon><infon key="type">Gene</infon><location offset="22167" length="5" /><text>SCA10</text></annotation><annotation id="8071"><infon key="identifier">146227</infon><infon key="type">Gene</infon><location offset="22174" length="6" /><text>SCA 31</text></annotation><annotation id="8072"><infon key="identifier">10528</infon><infon key="type">Gene</infon><location offset="22182" length="6" /><text>SCA 36</text></annotation><annotation id="8073"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="22242" length="7" /><text>C9ORF72</text></annotation><annotation id="8074"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="23035" length="7" /><text>C9ORF72</text></annotation><annotation id="8075"><infon key="identifier">MESH:C564105</infon><infon key="type">Disease</infon><location offset="22850" length="16" /><text>fragile X tremor</text></annotation><annotation id="8076"><infon key="identifier">MESH:D001259</infon><infon key="type">Disease</infon><location offset="22867" length="15" /><text>ataxia syndrome</text></annotation><annotation id="8077"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="22657" length="17" /><text>neurodegeneration</text></annotation><annotation id="8078"><infon key="identifier">MESH:C537307</infon><infon key="type">Disease</infon><location offset="23242" length="24" /><text>spinocerebellar ataxia 8</text></annotation><annotation id="8079"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22615" length="7" /><text>patient</text></annotation><annotation id="8080"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="22320" length="46" /><text>frontotemporal dementia linked to chromosome 9</text></annotation><annotation id="8081"><infon key="identifier">MESH:D009223</infon><infon key="type">Disease</infon><location offset="22122" length="18" /><text>myotonic dystrophy</text></annotation><annotation id="8082"><infon key="identifier">MESH:D009223</infon><infon key="type">Disease</infon><location offset="22830" length="18" /><text>myotonic dystrophy</text></annotation><annotation id="8083"><infon key="identifier">MESH:D020754</infon><infon key="type">Disease</infon><location offset="22142" length="23" /><text>spinocerebellar ataxias</text></annotation><annotation id="8084"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="21461" length="3" /><text>ALS</text></annotation><annotation id="8085"><infon key="identifier">MESH:D005621</infon><infon key="type">Disease</infon><location offset="22195" length="19" /><text>Friedreich's ataxia</text></annotation><annotation id="8086"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="22309" length="3" /><text>ALS</text></annotation><annotation id="8087"><infon key="identifier">MESH:D009223</infon><infon key="type">Disease</infon><location offset="23271" length="18" /><text>myotonic dystrophy</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>23295</offset><text>Epigenetics</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>23307</offset><text>Similar to the growing list of familial ALS linked genes, our knowledge of genetic modifiers in sporadic ALS has increased. Expression levels of genes such as EphA4, which encodes a tyrosine kinase receptor that regulates developmental axon outgrowth, inversely correlate with age of disease onset and survival. Variants of ANG increase the risk of development of ALS and Parkinson's disease,  and variants in NEK-1 (NIMA (never in mitosis gene-A) related kinase-1) were found in nearly 3% of ALS patients. An intermediate length ataxin 2 gene (ATXN2) polyglutamine repeats (&gt;23 but &lt;34 polyglutamine repeats) was found in some patients with sporadic ALS, and this finding was later confirmed in additional cohorts.   </text><annotation id="8088"><infon key="identifier">2043</infon><infon key="type">Gene</infon><location offset="23466" length="5" /><text>EphA4</text></annotation><annotation id="8089"><infon key="identifier">283</infon><infon key="type">Gene</infon><location offset="23631" length="3" /><text>ANG</text></annotation><annotation id="8090"><infon key="identifier">4750</infon><infon key="type">Gene</infon><location offset="23717" length="5" /><text>NEK-1</text></annotation><annotation id="8091"><infon key="identifier">6311</infon><infon key="type">Gene</infon><location offset="23837" length="8" /><text>ataxin 2</text></annotation><annotation id="8092"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="23935" length="8" /><text>patients</text></annotation><annotation id="8093"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="23804" length="8" /><text>patients</text></annotation><annotation id="8094"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="23800" length="3" /><text>ALS</text></annotation><annotation id="8095"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="23958" length="3" /><text>ALS</text></annotation><annotation id="8096"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="23671" length="3" /><text>ALS</text></annotation><annotation id="8097"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="23347" length="3" /><text>ALS</text></annotation><annotation id="8098"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="23412" length="3" /><text>ALS</text></annotation><annotation id="8099"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="23679" length="19" /><text>Parkinson's disease</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>24028</offset><text>Although interactions between polymorphisms and causative genes of ALS were previously appreciated, the idea that some families with ALS can harbor more than one of these genes was new. Van Blitterwijk et al discovered mutations in more than one ALS linked gene in five out of 97 families. As our knowledge grows, we are likely to find more complex genetic interplay as the basis for disease in individual families. These genes contribute to less than 1% of familial ALS, but their discovery has identified three main cellular functions that, when abnormal, can lead to neuronal degeneration in ALS: RNA/DNA metabolism, protein turnover/autophagy, and cytoskeletal and vesicular regulation (fig 2). This will hopefully improve understanding of disease mechanisms in the search for treatable targets.</text><annotation id="8100"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="24598" length="21" /><text>neuronal degeneration</text></annotation><annotation id="8101"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24161" length="3" /><text>ALS</text></annotation><annotation id="8102"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24623" length="3" /><text>ALS</text></annotation><annotation id="8103"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24095" length="3" /><text>ALS</text></annotation><annotation id="8104"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24274" length="3" /><text>ALS</text></annotation><annotation id="8105"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24495" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>24828</offset><text>Advances in biomarkers</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>24851</offset><text>Imaging</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>24859</offset><text>Neuroimaging is used to look for structural abnormalities in the central nervous system that can mimic symptoms and signs of ALS. In most patients with ALS, the brain and spinal cord appear unremarkable or show non-specific abnormalities including corticospinal tract hyperintensity or motor cortex hypointensity in T2 weighted magnetic resonance imaging (MRI) sequences (fig 3).  Advanced imaging methods are powerful non-invasive research tools that can be used to study and quantify structural, functional, and metabolic abnormalities. For example, voxel based morphometry and surface based morphometry can determine global or regional gray matter atrophy and cortical thinning, and diffusion tensor imaging (DTI) can evaluate the integrity of white matter tracts. Task based and resting state functional MRI can identify differing patterns of blood oxygen level dependent (BOLD) activity to interrogate connectivity neural networks, and magnetic resonance spectroscopy (MRS) allows for quantification of neuronal and glial metabolites such as N-acetylaspartate, a marker of neuronal integrity, creatine, a marker of energy metabolism, choline, a marker of cell membrane, and myo-inositol, a glial marker.  Other imaging modalities such as positron emission tomography (PET) can show regional changes in brain metabolism by using different receptor ligands. The use of these tools has limitations in research, but technical improvements may prove them useful for group stratification in clinical trials, tracking disease progression, and predicting disease onset in pre-symptomatic carriers of gene mutations. Additionally, they have the potential to provide greater insight into the evolution of pathology.</text><annotation id="8106"><infon key="identifier">MESH:D063647</infon><infon key="type">Disease</infon><location offset="24903" length="43" /><text>abnormalities in the central nervous system</text></annotation><annotation id="8107"><infon key="identifier">MESH:D002794</infon><infon key="type">Chemical</infon><location offset="25998" length="7" /><text>choline</text></annotation><annotation id="8108"><infon key="identifier">MESH:D003401</infon><infon key="type">Chemical</infon><location offset="25957" length="8" /><text>creatine</text></annotation><annotation id="8109"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="24984" length="3" /><text>ALS</text></annotation><annotation id="8110"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="25712" length="6" /><text>oxygen</text></annotation><annotation id="8111"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="25011" length="3" /><text>ALS</text></annotation><annotation id="8112"><infon key="identifier">MESH:C000179</infon><infon key="type">Chemical</infon><location offset="25906" length="17" /><text>N-acetylaspartate</text></annotation><annotation id="8113"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="25510" length="7" /><text>atrophy</text></annotation><annotation id="8114"><infon key="identifier">MESH:D007294</infon><infon key="type">Chemical</infon><location offset="26038" length="12" /><text>myo-inositol</text></annotation><annotation id="8115"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="24997" length="8" /><text>patients</text></annotation><annotation id="8116"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="25373" length="23" /><text>metabolic abnormalities</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">kwaj075037.f3.jpg</infon><infon key="id">f3</infon><infon key="type">fig_caption</infon><offset>26570</offset><text>Neuroimaging changes in amyotrophic lateral sclerosis. A: motor cortex (red) atrophy. B: axial T2-FLAIR (fluid attenuated inversion recovery sequence) magnetic resonance image at level of midbrain, showing hyperintensity in cerebral peduncles corresponding to corticospinal tracts (black arrow)</text><annotation id="8117"><infon key="identifier">MESH:D000303</infon><infon key="type">Disease</infon><location offset="26628" length="12" /><text>motor cortex</text></annotation><annotation id="8118"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="26594" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="8119"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="26647" length="7" /><text>atrophy</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>26865</offset><text>The most frequent abnormal findings in structural brain imaging studies in ALS are thinning of the motor cortex and atrophy of the precentral gyrus (fig 3) and structural integrity loss in the corticospinal tract and the corpus callosum.       Morphometric changes correlate with the clinical phenotypes and the site of symptom onset, supporting the hypothesis of focal disease onset.   Another clinical-imaging correlation is the association of cognitive and/or behavioral impairment with extra-motor gray matter volume loss and white matter DTI diffusivity changes.     The structural abnormalities, however, do not consistently correlate with measures of disease progression such as the ALSFRS-R.       More widespread frontal atrophy is associated with faster disease progression and is consistent with the observation that faster disease progression occurs in patients with cognitive and behavioral impairment.  Longitudinal imaging is invaluable to track disease progression; however, studies show conflicting findings, with a few studies showing progressive gray and white matter changes over time, whereas others show no discernible changes.      The causes of these differences include unequal or small sample sizes, clinical heterogeneity, variable follow-up intervals, and different data acquisition and analysis methods. The role of neuroimaging to track clinical progression in ALS remains unresolved, but evolving imaging changes may mirror spread of pathology (for example, TDP-43).    </text><annotation id="8120"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="28354" length="6" /><text>TDP-43</text></annotation><annotation id="8121"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="27744" length="35" /><text>cognitive and behavioral impairment</text></annotation><annotation id="8122"><infon key="identifier">MESH:D016388</infon><infon key="type">Disease</infon><location offset="27379" length="11" /><text>volume loss</text></annotation><annotation id="8123"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="27311" length="38" /><text>cognitive and/or behavioral impairment</text></annotation><annotation id="8124"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="27730" length="8" /><text>patients</text></annotation><annotation id="8125"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="27587" length="15" /><text>frontal atrophy</text></annotation><annotation id="8126"><infon key="identifier">MESH:D013851</infon><infon key="type">Disease</infon><location offset="26948" length="28" /><text>thinning of the motor cortex</text></annotation><annotation id="8127"><infon key="identifier">MESH:C564353</infon><infon key="type">Disease</infon><location offset="26981" length="31" /><text>atrophy of the precentral gyrus</text></annotation><annotation id="8128"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="28256" length="3" /><text>ALS</text></annotation><annotation id="8129"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="26940" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>28367</offset><text>In ALS, MRS typically shows decreases in N-acetylaspartate or in N-acetylaspartate/creatine or N-acetylaspartate/choline in the motor cortex and brain stem corresponding to neuronal degeneration.    MRS indices correlate with clinical UMN disease burden in some studies, but their association with functional and cognitive measures are less consistent.    Additionally, longitudinal MRS studies are often limited by small sample size.   Other metabolites such as gamma-aminobutyric acid and glutamate have been examined but need further validation.  </text><annotation id="8130"><infon key="identifier">MESH:C000179</infon><infon key="type">Chemical</infon><location offset="28462" length="17" /><text>N-acetylaspartate</text></annotation><annotation id="8131"><infon key="identifier">MESH:D003401</infon><infon key="type">Chemical</infon><location offset="28450" length="8" /><text>creatine</text></annotation><annotation id="8132"><infon key="type">Disease</infon><location offset="28602" length="3" /><text>UMN</text></annotation><annotation id="8133"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="28370" length="3" /><text>ALS</text></annotation><annotation id="8134"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="28540" length="21" /><text>neuronal degeneration</text></annotation><annotation id="8135"><infon key="identifier">MESH:D018698</infon><infon key="type">Chemical</infon><location offset="28858" length="9" /><text>glutamate</text></annotation><annotation id="8136"><infon key="identifier">MESH:D005680</infon><infon key="type">Chemical</infon><location offset="28830" length="23" /><text>gamma-aminobutyric acid</text></annotation><annotation id="8137"><infon key="identifier">MESH:C000179</infon><infon key="type">Chemical</infon><location offset="28432" length="17" /><text>N-acetylaspartate</text></annotation><annotation id="8138"><infon key="identifier">MESH:D002794</infon><infon key="type">Chemical</infon><location offset="28480" length="7" /><text>choline</text></annotation><annotation id="8139"><infon key="identifier">MESH:C000179</infon><infon key="type">Chemical</infon><location offset="28408" length="17" /><text>N-acetylaspartate</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>28918</offset><text>Early PET studies in ALS using the ligand fluorodeoxyglucose show diffusely reduced uptake in the cortex and deep gray nuclei, mostly in patients who have signs of UMN dysfunction. Other studies show hypometabolism in the frontal regions and hypermetabolism in the temporal regions, cerebellum, and upper brainstem.   PET ligands binding to the dopamine D2/D3, 5-hydroxytryptamine 1A, and gamma-aminobutyric acid A receptors have been examined in ALS, suggesting widespread neuronal dysfunction or degeneration.   More recently, interest has been growing in examining the role of neuroinflammation in ALS. This has led to the development of PET ligands that bind to the 18-kDa translocator protein expressed by activated glial cells. Studies using this ligand show increased uptake in the primary motor cortex and frontal regions that also show structural and metabolic abnormalities.   Additional studies are needed to understand the complex interactions between neuronal and glial cells in ALS.</text><annotation id="8140"><infon key="identifier">706</infon><infon key="type">Gene</infon><location offset="29595" length="20" /><text>translocator protein</text></annotation><annotation id="8141"><infon key="identifier">MESH:C565498</infon><infon key="type">Disease</infon><location offset="29160" length="15" /><text>hypermetabolism</text></annotation><annotation id="8142"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="29498" length="17" /><text>neuroinflammation</text></annotation><annotation id="8143"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="29055" length="8" /><text>patients</text></annotation><annotation id="8144"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="29392" length="36" /><text>neuronal dysfunction or degeneration</text></annotation><annotation id="8145"><infon key="type">Disease</infon><location offset="29118" length="14" /><text>hypometabolism</text></annotation><annotation id="8146"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="28939" length="3" /><text>ALS</text></annotation><annotation id="8147"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="29910" length="3" /><text>ALS</text></annotation><annotation id="8148"><infon key="identifier">MESH:D019788</infon><infon key="type">Chemical</infon><location offset="28960" length="18" /><text>fluorodeoxyglucose</text></annotation><annotation id="8149"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="29365" length="3" /><text>ALS</text></annotation><annotation id="8150"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="29082" length="15" /><text>UMN dysfunction</text></annotation><annotation id="8151"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="29763" length="38" /><text>structural and metabolic abnormalities</text></annotation><annotation id="8152"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="29519" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>29915</offset><text>In ALS, task based functional MRI shows increased activation of contralateral, and sometimes ipsilateral, brain regions such as the supplementary motor areas, sensorimotor cortex, temporal regions, deep gray nuclei, and cerebellum.    These abnormalities are hypothesized to represent adaptive or compensatory responses to the neurodegenerative process. Unlike task based functional MRI, resting state functional MRI shows varying patterns of coherence in the spontaneous BOLD activity. In ALS, the functional connectivity of brain regions can increase, decrease, or be mixed within different brain networks.   The variability in findings can be attributed to methodological differences. Regional decrease in functional connectivity in default mode and sensorimotor networks correlate with greater functional impairment.  </text><annotation id="8153"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="30405" length="3" /><text>ALS</text></annotation><annotation id="8154"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="30713" length="21" /><text>functional impairment</text></annotation><annotation id="8155"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="29918" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>30738</offset><text>Electrophysiology</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>30756</offset><text>MUNE, MScanFIT, MUNIX</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>30778</offset><text>Motor unit number estimation (MUNE) is a promising electrophysiological technique to track disease progression in ALS by estimating the number of motor units in a muscle. Distal small muscles such as the intrinsic hand muscles (that is, abductor pollicis brevis) are examined. The concept of MUNE extends from the observation that incremental increases in the intensity of a stimulus delivered to the motor nerve results in stepwise increases in the amplitude of the compound muscle action potential (CMAP) recorded at the innervated muscle. If the average size of a single motor unit potential contributing to the CMAP can be determined, an estimate of the motor units in that nerve can be calculated by dividing the maximal CMAP amplitude by the average single motor unit potential amplitude. Different methods to determine the average amplitude to calculate MUNE have been developed on the basis of this principle and applied in clinical studies in ALS. Across studies using different methods, MUNE declines with disease progression and correlates with functional rating scales.   </text><annotation id="8156"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="30892" length="3" /><text>ALS</text></annotation><annotation id="8157"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="31730" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>31863</offset><text>More recently, the MScanFit MUNE method was developed to estimate the number of motor units from an objective stimulus response curve. MScanFit MUNE may be more accurate, reliable, and easier and quicker to perform and may detect earlier motor neuron loss than other MUNE methods. One limitation is the accessibility of nerves to peripheral stimulation, precluding its use to assess larger proximal muscles. The ease of applying this technique and ability to perform the study using standard electromyography machines make MUNE an attractive biomarker.</text><annotation id="8158"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="32101" length="17" /><text>motor neuron loss</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>32416</offset><text>Motor unit number index (MUNIX) is an electrophysiological method that estimates the number and size of motor units by recording the maximum CMAP and epochs of surface electromyographic interference pattern at varying force levels. MUNIX can be easily used to assess proximal and distal muscles and has been shown to track disease progression in ALS clinical trials. MUNIX values also decline before development of muscle weakness and may be more sensitive to detect early motor neuron loss.  However, the inter-rater variability across sites may limit the use of this method in clinical trials. </text><annotation id="8159"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="32889" length="17" /><text>motor neuron loss</text></annotation><annotation id="8160"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="32831" length="15" /><text>muscle weakness</text></annotation><annotation id="8161"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="32762" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>33013</offset><text>Transcranial magnetic stimulation</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>33047</offset><text>Transcranial magnetic stimulation (TMS) is a non-invasive electrophysiological technique that can objectively assess the integrity of the corticospinal motor neurons. Several different parameters can be measured, including motor threshold, motor evoked amplitude, central motor conduction time, cortical silent period, and intracortical facilitation or inhibition. Compared with controls, the motor threshold is decreased and the motor evoked amplitude is increased in early ALS.  Other TMS findings include reduced duration of the cortical silent period with increasing stimulation intensity, reduced short intracortical inhibition, and increased intracortical facilitation.  Collectively, these abnormalities reflect altered cortical excitability. The resting threshold and central motor conduction time have been shown to correlate with clinical findings of UMN dysfunction and are suggested to be useful for tracking disease progression.  Further studies are needed to establish TMS as a robust biomarker of disease progression.</text><annotation id="8162"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="33908" length="15" /><text>UMN dysfunction</text></annotation><annotation id="8163"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="33522" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>34080</offset><text>Electrical impedance myography</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>34111</offset><text>Electrical impedance electromyography (EIM) is mostly a research tool to assess the health of the muscle. It is based on recording the voltage that results from applying a weak, high frequency electrical current across sampled muscle without inducing myofiber or neuronal action potentials. The volume conduction properties of the muscle depend on how strongly muscle resists or conducts alternating electrical current (conductivity) and on its ability to store electrical charge within (relative permittivity). These properties have been shown to differ in health and disease in murine models and patients.  EIM was first used to evaluate the muscle in Duchenne muscular dystrophy, and has more recently been used in ALS. EIM parameters correlate moderately with standard ALS disease progression measures and MUNE. Surface EIM can be done at home, requires minimal training, is painless and repeatable, and has been assessed as an exploratory endpoint in different clinical trials. A motivated patient with ALS can collect surface EIM data more frequently than is done in standard clinical trials, thereby reducing the number of patients needed for a study. An in-depth discussion of the advantages and limitations of both surface and needle EIM can be found in a recent review and subsequent letters to the editor.   Overall, EIM is a tool in development that may aid ALS patients and researchers to track disease progression.</text><annotation id="8164"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="35119" length="3" /><text>ALS</text></annotation><annotation id="8165"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="35241" length="8" /><text>patients</text></annotation><annotation id="8166"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="34884" length="11" /><text>ALS disease</text></annotation><annotation id="8167"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="34829" length="3" /><text>ALS</text></annotation><annotation id="8168"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="35106" length="7" /><text>patient</text></annotation><annotation id="8169"><infon key="identifier">MESH:D020388</infon><infon key="type">Disease</infon><location offset="34765" length="27" /><text>Duchenne muscular dystrophy</text></annotation><annotation id="8170"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="35485" length="8" /><text>patients</text></annotation><annotation id="8171"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="34709" length="8" /><text>patients</text></annotation><annotation id="8172"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="34691" length="6" /><text>murine</text></annotation><annotation id="8173"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="35481" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>35540</offset><text>Fluid based biomarkers</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>35563</offset><text>Significant efforts are being made to evaluate and validate ALS biomarkers of various types (diagnostic, prognostic, predictive, and pharmacodynamic). Neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain have been examined in cerebrospinal fluid and serum in patients with ALS as a marker of neuronal injury.   Although concentrations are lower in serum than in cerebrospinal fluid, serum is more accessible and can be measured reliably using technologically advanced methods such as single molecule array technology (simoa). In simoa, single molecules are trapped individually in wells followed by a digital readout of beads that are bound to their targets, leading to increased sensitivity for detecting protein at subfemptomolar concentration. Higher neurofilament concentrations tend to correspond to faster disease progression, a feature that can be explored in the design of future clinical trials. A study of pheno-converters (pre-symptomatic carriers of causative genes for ALS who develop symptoms of ALS or frontotemporal dementia) showed increased NfL concentrations occurring at least a year before clinical disease. Once disease begins, serum NfL concentrations are stable longitudinally allowing for its use as a pharmacodynamic marker. More recently, incorporating two related plasma micro-RNAs (mir-181a-5p and mir181b-5p) to NfL concentrations improves the survival prognostication (higher concentrations correlated with shorter survival) especially in the patient group with intermediate (59-109 pg/ml) NfL concentrations. Similar approaches of combining protein(s) and/or RNA(s) biomarkers will be useful owing to enhanced prognostic power.</text><annotation id="8174"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="35714" length="25" /><text>Neurofilament light chain</text></annotation><annotation id="8175"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="35741" length="3" /><text>NfL</text></annotation><annotation id="8176"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="36646" length="3" /><text>NfL</text></annotation><annotation id="8177"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="36743" length="3" /><text>NfL</text></annotation><annotation id="8178"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="36929" length="3" /><text>NfL</text></annotation><annotation id="8179"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="37108" length="3" /><text>NfL</text></annotation><annotation id="8180"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="36597" length="3" /><text>ALS</text></annotation><annotation id="8181"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="35860" length="3" /><text>ALS</text></annotation><annotation id="8182"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="35879" length="15" /><text>neuronal injury</text></annotation><annotation id="8183"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="36569" length="3" /><text>ALS</text></annotation><annotation id="8184"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="35846" length="8" /><text>patients</text></annotation><annotation id="8185"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="37061" length="7" /><text>patient</text></annotation><annotation id="8186"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="36604" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8187"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="35623" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>37247</offset><text>As an easily accessible biofluid, the urine is an attractive option for screening for biomarkers. The p75 neurotrophin receptor is found on the surface of apoptotic motor neurons and Schwann cells. During normal processing, the ecto domain of the p75 molecule (p75ECD) is cleaved and becomes detectable in urine. It is elevated in ALS and increases further with disease progression, thereby making it a putative biomarker. The p75ECD, unlike neurofilaments, increases at the time of pheno-conversion and not before, thereby serving as a potential marker of pheno-conversion. As a marker of neuroinflammation, chitinases and related proteins (CHIT-1, CHI3L1, CHI3L2) increase in the cerebrospinal fluid as ALS progresses.  Although chitinases may be a proxy for neuroinflammation, their use as a biomarker in therapies may be hampered by accessibility (poor serum and cerebrospinal fluid correlation) and polymorphisms that may decrease the protein concentration. </text><annotation id="8188"><infon key="identifier">7133</infon><infon key="type">Gene</infon><location offset="37494" length="3" /><text>p75</text></annotation><annotation id="8189"><infon key="identifier">1118</infon><infon key="type">Gene</infon><location offset="37889" length="6" /><text>CHIT-1</text></annotation><annotation id="8190"><infon key="identifier">1116</infon><infon key="type">Gene</infon><location offset="37897" length="6" /><text>CHI3L1</text></annotation><annotation id="8191"><infon key="identifier">1117</infon><infon key="type">Gene</infon><location offset="37905" length="6" /><text>CHI3L2</text></annotation><annotation id="8192"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="37952" length="3" /><text>ALS</text></annotation><annotation id="8193"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="38008" length="17" /><text>neuroinflammation</text></annotation><annotation id="8194"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="37837" length="17" /><text>neuroinflammation</text></annotation><annotation id="8195"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="37578" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>38211</offset><text>Advances in ALS therapy</text><annotation id="8196"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="38223" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>38235</offset><text>Multidisciplinary care</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>38258</offset><text>The cornerstone of ALS care is an integrative approach because of the clinical and psychosocial complexities.  A common care model in the US consists of an ALS specialist, nurse, pulmonologist, speech and language pathologist, nutritionist, physical therapist, occupational therapist, and social worker in one clinic visit (as "one stop shop"). Other clinicians with critical roles include a psychiatrist, neuropsychologist, genetics counselor, and gastroenterologist. The ALS team collaborates and seamlessly coordinates care with the primary care clinician and other community or home based health service providers. Additional support is achieved by referral to ALS/MND organizations. This patient centric model of care enhances engagement of patients and care givers in treatment and confers benefits such as improved quality and efficiency of care, access to health and governmental agency services, quality of life, and survival.</text><annotation id="8197"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="38277" length="3" /><text>ALS</text></annotation><annotation id="8198"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="39004" length="8" /><text>patients</text></annotation><annotation id="8199"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="38731" length="3" /><text>ALS</text></annotation><annotation id="8200"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="38414" length="3" /><text>ALS</text></annotation><annotation id="8201"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="38927" length="3" /><text>MND</text></annotation><annotation id="8202"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="38923" length="3" /><text>ALS</text></annotation><annotation id="8203"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="38951" length="7" /><text>patient</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>39198</offset><text>Disease modifying therapies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>39226</offset><text>In the past 20 years, most trials evaluating ALS therapeutics aiming to slow or arrest the neurodegenerative process have failed to show efficacy. These therapies have primarily targeted excitotoxicity, oxidative stress, mitochondrial dysfunction, protein homeostasis, nucleocytoplasmic transport, neuroinflammation, cell death, cytoskeletal integrity, axonal transport, DNA repair, RNA metabolism, and stress granule regulation. As new trials are planned, a collaborative effort has been made to identify contributors to the failure of studies such as clinical and biological heterogeneity. Critical future steps for the global ALS community to accelerate successful development of ALS therapy include ensuring equity of access, optimizing study design and analysis, endpoint harmonization, and data sharing.</text><annotation id="8204"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="39447" length="25" /><text>mitochondrial dysfunction</text></annotation><annotation id="8205"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="39524" length="17" /><text>neuroinflammation</text></annotation><annotation id="8206"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="39909" length="3" /><text>ALS</text></annotation><annotation id="8207"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="39855" length="3" /><text>ALS</text></annotation><annotation id="8208"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="39271" length="3" /><text>ALS</text></annotation><annotation id="8209"><infon key="type">Disease</infon><location offset="39413" length="14" /><text>excitotoxicity</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>40036</offset><text>Three disease modifying drugs are approved by the US Food and Drug Administration (FDA) with a primary indication for the treatment of ALS (table 2). Riluzole, an anti-glutaminergic drug, increases survival and slows the decline in muscle testing score.  The most common side effects are asthenia, gastrointestinal symptoms, and an increase in liver enzymes. Edaravone, a free radical scavenger that acts to decrease oxidative stress, modestly slows ALS disease progression.  Edaravone is not approved for ALS treatment in Europe, and its role in ALS therapy continues to be a contested topic.  The combination of sodium phenylbutyrate and taurursodiol targeting mitochondrial dysfunction, endoplasmic reticulum stress, and cell death, was approved by the FDA in 2022. </text><annotation id="8210"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40171" length="3" /><text>ALS</text></annotation><annotation id="8211"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40583" length="3" /><text>ALS</text></annotation><annotation id="8212"><infon key="identifier">MESH:D001247</infon><infon key="type">Disease</infon><location offset="40324" length="8" /><text>asthenia</text></annotation><annotation id="8213"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40542" length="3" /><text>ALS</text></annotation><annotation id="8214"><infon key="identifier">MESH:D012817</infon><infon key="type">Disease</infon><location offset="40334" length="25" /><text>gastrointestinal symptoms</text></annotation><annotation id="8215"><infon key="identifier">MESH:C075773</infon><infon key="type">Chemical</infon><location offset="40650" length="21" /><text>sodium phenylbutyrate</text></annotation><annotation id="8216"><infon key="identifier">MESH:D000077553</infon><infon key="type">Chemical</infon><location offset="40395" length="9" /><text>Edaravone</text></annotation><annotation id="8217"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40486" length="11" /><text>ALS disease</text></annotation><annotation id="8218"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="40699" length="25" /><text>mitochondrial dysfunction</text></annotation><annotation id="8219"><infon key="identifier">MESH:D000077553</infon><infon key="type">Chemical</infon><location offset="40512" length="9" /><text>Edaravone</text></annotation><annotation id="8220"><infon key="identifier">MESH:C031655</infon><infon key="type">Chemical</infon><location offset="40676" length="12" /><text>taurursodiol</text></annotation><annotation id="8221"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="40186" length="8" /><text>Riluzole</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="type">table_caption</infon><offset>40806</offset><text>Clinical trials leading to US Food and Drug Administration approved therapies for amyotrophic lateral sclerosis (ALS)</text><annotation id="8222"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40888" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="8223"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="40919" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl2.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="above" rules="groups"&gt;&lt;col width="15.89%" span="1"/&gt;&lt;col width="16.23%" span="1"/&gt;&lt;col width="12.21%" span="1"/&gt;&lt;col width="18.18%" span="1"/&gt;&lt;col width="37.49%" span="1"/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Drug, study&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Design&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;No of participants&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Primary outcome(s)&lt;/th&gt;&lt;th valign="bottom" align="left" scope="col" colspan="1" rowspan="1"&gt;Result&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Riluzole&lt;xref rid="ref180" ref-type="bibr"&gt;180&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Prospective, double blind, randomized, placebo controlled&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;155&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;1: survival; 2: rate of change in functional status (limb function, bulbar function, muscle testing score)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;1: 45/78 (58%) in placebo group remained alive &lt;italic toggle="yes"&gt;v&lt;/italic&gt; 57/77 (74%) in riluzole group at 12 months (P=0.014); 2: Rate of deterioration for limb function, bulbar function, and muscle strength was slower in riluzole group, but only statistically significant for muscle testing score (P=0.028)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Riluzole&lt;xref rid="ref181" ref-type="bibr"&gt;181&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Double blind, randomized, placebo controlled&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;959&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Survival without tracheostomy on 100 mg dose&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;122 (50.4%) in placebo group and 134 (56.8%) in riluzole group survived; adjusted risk 0.65 (P=0.002)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Edaravone&lt;xref rid="ref182" ref-type="bibr"&gt;182&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Randomized, double blind, placebo controlled&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;137&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Change in ALSFRS-R score from baseline to 24 weeks&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Edaravone -5.01 &lt;italic toggle="yes"&gt;v&lt;/italic&gt; placebo -7.50; least squares mean difference 2.49 (95% CI 0.99 to 3.98; P=0.001)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Edaravone&lt;xref rid="ref183" ref-type="bibr"&gt;183&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Post hoc analysis of 24 week randomized, placebo controlled study followed by 24 weeks of open label extension study&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;88&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Change in ALSFRS-R score at week 48 in patients with FVC &gt;=80% &lt;italic toggle="yes"&gt;v&lt;/italic&gt; &amp;lt;80% (FVC assessed at week 24)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;FVC &amp;gt;80% subgroup: -7.63 &lt;italic toggle="yes"&gt;v&lt;/italic&gt; -9.69; difference 2.05 (95% CI 0.16 to 3.94; P=0.034). FVC &amp;lt;80% subgroup: -10.26 &lt;italic toggle="yes"&gt;v&lt;/italic&gt; -15.20; difference 4.94 (95% CI 1.64 to 8.25; P=0.004).&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Sodium phenylbutyrate-taurursodiol (PB-TUDCA)&lt;xref rid="ref184" ref-type="bibr"&gt;184&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Randomized, double blind; 2:1 (drug:placebo)&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;137&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Mean rate of decline in ALSFRS-R at 24 weeks&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;PB-TUDCA &lt;italic toggle="yes"&gt;v&lt;/italic&gt; placebo: -1.24/month &lt;italic toggle="yes"&gt;v&lt;/italic&gt; -1.66/month; difference 0.42 points/month (95% CI 0.03 to 0.81; P=0.03)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" align="left" scope="row" colspan="1" rowspan="1"&gt;Tofersen*&lt;xref rid="ref185" ref-type="bibr"&gt;185&lt;/xref&gt; &lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Randomized, double blind; 2:1 (drug:placebo) followed by 24 weeks of open label extension study&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;108&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Change in ALSFRS-R score at week 28, among participants predicted to have faster progressing disease&lt;/td&gt;&lt;td valign="top" align="left" colspan="1" rowspan="1"&gt;Tofersen &lt;italic toggle="yes"&gt;v&lt;/italic&gt; placebo: -6.98 &lt;italic toggle="yes"&gt;v&lt;/italic&gt; -8.14; difference 1.2 points (95% CI -3.2 to 5.5; P=0.97). In open label extension (52 weeks), early start &lt;italic toggle="yes"&gt;v&lt;/italic&gt; delayed start: -6.0 &lt;italic toggle="yes"&gt;v&lt;/italic&gt; -9.5; difference 3.5 (95% CI 0.4 to 6.7) points&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tbl2</infon><infon key="type">table</infon><offset>40924</offset><text>Drug, study	Design	No of participants	Primary outcome(s)	Result	 	Riluzole	Prospective, double blind, randomized, placebo controlled	155	1: survival; 2: rate of change in functional status (limb function, bulbar function, muscle testing score)	1: 45/78 (58%) in placebo group remained alive v 57/77 (74%) in riluzole group at 12 months (P=0.014); 2: Rate of deterioration for limb function, bulbar function, and muscle strength was slower in riluzole group, but only statistically significant for muscle testing score (P=0.028)	 	Riluzole	Double blind, randomized, placebo controlled	959	Survival without tracheostomy on 100 mg dose	122 (50.4%) in placebo group and 134 (56.8%) in riluzole group survived; adjusted risk 0.65 (P=0.002)	 	Edaravone	Randomized, double blind, placebo controlled	137	Change in ALSFRS-R score from baseline to 24 weeks	Edaravone -5.01 v placebo -7.50; least squares mean difference 2.49 (95% CI 0.99 to 3.98; P=0.001)	 	Edaravone	Post hoc analysis of 24 week randomized, placebo controlled study followed by 24 weeks of open label extension study	88	Change in ALSFRS-R score at week 48 in patients with FVC &gt;=80% v &lt;80% (FVC assessed at week 24)	FVC &gt;80% subgroup: -7.63 v -9.69; difference 2.05 (95% CI 0.16 to 3.94; P=0.034). FVC &lt;80% subgroup: -10.26 v -15.20; difference 4.94 (95% CI 1.64 to 8.25; P=0.004).	 	Sodium phenylbutyrate-taurursodiol (PB-TUDCA)	Randomized, double blind; 2:1 (drug:placebo)	137	Mean rate of decline in ALSFRS-R at 24 weeks	PB-TUDCA v placebo: -1.24/month v -1.66/month; difference 0.42 points/month (95% CI 0.03 to 0.81; P=0.03)	 	Tofersen*	Randomized, double blind; 2:1 (drug:placebo) followed by 24 weeks of open label extension study	108	Change in ALSFRS-R score at week 28, among participants predicted to have faster progressing disease	Tofersen v placebo: -6.98 v -8.14; difference 1.2 points (95% CI -3.2 to 5.5; P=0.97). In open label extension (52 weeks), early start v delayed start: -6.0 v -9.5; difference 3.5 (95% CI 0.4 to 6.7) points	 	</text><annotation id="8224"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="42041" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="type">table_foot</infon><offset>42964</offset><text>ALSFRS-R=revised ALS functional rating scale; CI=confidence interval; FVC=forced vital capacity.</text><annotation id="8225"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="42981" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="type">table_footnote</infon><offset>43061</offset><text>Did not meet primary endpoint.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>43092</offset><text>Pulmonary intervention</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>43115</offset><text>Pulmonary system complications are common in ALS, and respiratory failure is the most frequent cause of death Pulmonary studies relevant in ALS care include spirometry, nocturnal pulse oximetry, arterial blood gas, polysomnography, maximal inspiratory pressure/maximal expiratory pressure, transdiaphragmatic pressure, and sniff nasal pressure.   Serial evaluations are essential to identify respiratory muscle weakness and allow for early interventions using non-invasive ventilation, which has been shown to prolong survival with improved quality of life. Mechanical insufflation-exsufflation is routinely used by ALS patients to augment weak cough to clear airway secretions; however, no systematic study has evaluated the benefits of this intervention. Respiratory muscle training to improve cough and swallowing is an area of active research. </text><annotation id="8226"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="43255" length="3" /><text>ALS</text></annotation><annotation id="8227"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="43115" length="30" /><text>Pulmonary system complications</text></annotation><annotation id="8228"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="43731" length="3" /><text>ALS</text></annotation><annotation id="8229"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="43519" length="15" /><text>muscle weakness</text></annotation><annotation id="8230"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="43507" length="11" /><text>respiratory</text></annotation><annotation id="8231"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="43160" length="3" /><text>ALS</text></annotation><annotation id="8232"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="43735" length="8" /><text>patients</text></annotation><annotation id="8233"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="43872" length="11" /><text>Respiratory</text></annotation><annotation id="8234"><infon key="identifier">MESH:D003371</infon><infon key="type">Disease</infon><location offset="43760" length="5" /><text>cough</text></annotation><annotation id="8235"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="43219" length="5" /><text>death</text></annotation><annotation id="8236"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="43169" length="19" /><text>respiratory failure</text></annotation><annotation id="8237"><infon key="identifier">MESH:D003371</infon><infon key="type">Disease</infon><location offset="43911" length="5" /><text>cough</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>43964</offset><text>Diet and nutritional intervention</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>43998</offset><text>Weight loss (specifically fat loss) has been shown to correlate with decline in ALSFRS-R scores, and most patients are advised to adapt their diet to maintain a weight close to their premorbid state. Weight loss is multifactorial and associated with decreased food intake due to dysphagia, impaired limb dexterity in handling utensils, hypermetabolism (in about 50% of patients), loss of appetite, and fatigue. Extremes in body mass index (&lt;18, &gt;40) were associated with shorter survival, and best survival was observed for body mass index maintained in the 30-35 range. The consensus is that the diet should include fiber, carotenes, fruits, and antioxidants. However, little consensus exists on the high calorie nutritional source:that is, carbohydrates versus polyunsaturated fats. Clinical guidelines recommend discussion of gastrostomy tube insertion for patients who have symptomatic dysphagia, prolonged eating time, negative caloric balance, unintentional weight loss of greater than 5-10%, and, in some cases, declining respiratory status (forced vital capacity approaching 50%). The benefits of a gastrostomy tube vary depending on proper patient selection, timing of the procedure, careful management of the insertion process, and post-procedure tube management.</text><annotation id="8238"><infon key="identifier">MESH:D003680</infon><infon key="type">Disease</infon><location offset="44277" length="9" /><text>dysphagia</text></annotation><annotation id="8239"><infon key="identifier">MESH:D002338</infon><infon key="type">Chemical</infon><location offset="44622" length="9" /><text>carotenes</text></annotation><annotation id="8240"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="44740" length="13" /><text>carbohydrates</text></annotation><annotation id="8241"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="44198" length="11" /><text>Weight loss</text></annotation><annotation id="8242"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="43998" length="11" /><text>Weight loss</text></annotation><annotation id="8243"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="44024" length="8" /><text>fat loss</text></annotation><annotation id="8244"><infon key="identifier">MESH:C565498</infon><infon key="type">Disease</infon><location offset="44334" length="15" /><text>hypermetabolism</text></annotation><annotation id="8245"><infon key="identifier">MESH:D005221</infon><infon key="type">Disease</infon><location offset="44400" length="7" /><text>fatigue</text></annotation><annotation id="8246"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="44104" length="8" /><text>patients</text></annotation><annotation id="8247"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="44962" length="11" /><text>weight loss</text></annotation><annotation id="8248"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="44367" length="8" /><text>patients</text></annotation><annotation id="8249"><infon key="identifier">MESH:D001259</infon><infon key="type">Disease</infon><location offset="44288" length="23" /><text>impaired limb dexterity</text></annotation><annotation id="8250"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="44378" length="16" /><text>loss of appetite</text></annotation><annotation id="8251"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="45147" length="7" /><text>patient</text></annotation><annotation id="8252"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="44858" length="8" /><text>patients</text></annotation><annotation id="8253"><infon key="identifier">MESH:D003680</infon><infon key="type">Disease</infon><location offset="44888" length="9" /><text>dysphagia</text></annotation><annotation id="8254"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="44761" length="20" /><text>polyunsaturated fats</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>45274</offset><text>ALS patients often ask about over-the-counter supplements and vitamins alone or in combinations. The ALS Untangled (www.alsuntangled.com) initiative has reviewed the evidence for many vitamins and supplements and is an excellent guide for patients, care givers, and clinicians. Unfortunately, most clinical trials have not shown slower ALS progression.  A recent phase 3 trial of ultrahigh dose methylcobalamin (50 mg) compared with placebo showed a modest slowing in clinical deterioration in treated patients, and evidence suggests that vitamin E may be protective against development of ALS.  </text><annotation id="8255"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="45513" length="8" /><text>patients</text></annotation><annotation id="8256"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="45278" length="8" /><text>patients</text></annotation><annotation id="8257"><infon key="identifier">MESH:C019476</infon><infon key="type">Chemical</infon><location offset="45669" length="15" /><text>methylcobalamin</text></annotation><annotation id="8258"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="45776" length="8" /><text>patients</text></annotation><annotation id="8259"><infon key="identifier">MESH:D014810</infon><infon key="type">Chemical</infon><location offset="45813" length="9" /><text>vitamin E</text></annotation><annotation id="8260"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="45375" length="3" /><text>ALS</text></annotation><annotation id="8261"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="45274" length="3" /><text>ALS</text></annotation><annotation id="8262"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="45864" length="3" /><text>ALS</text></annotation><annotation id="8263"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="45610" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>45871</offset><text>Emerging treatments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>45891</offset><text>The modest effects of the current FDA approved therapeutics for such a devastating disease have spurred a growing pipeline of investigational agents. The development of the ALS platform trial allows for simultaneous testing of multiple agents, using a shared master protocol and central infrastructure. Investigation of at least 50 small molecules with various mechanisms is under way. The successes of therapeutics targeting pathogenic gene expression such as antisense oligonucleotides have led to growing interest in this technology in genetic forms of ALS. This is realized in the accelerated approval of tofersen by the FDA for treatment of SOD1-ALS in April 2023. Several phase 1-2 trials are under way examining the benefits of different antisense oligonucleotides targeting C9ORF72 and FUS. Vectors for gene therapy using adeno-associated virus to reduce SOD1 concentrations are also being explored in a phase 1 trial. Monoclonal antibodies targeting misfolded proteins are being evaluated in phase 2 clinical trials. </text><annotation id="8264"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="46537" length="4" /><text>SOD1</text></annotation><annotation id="8265"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="46673" length="7" /><text>C9ORF72</text></annotation><annotation id="8266"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="46685" length="3" /><text>FUS</text></annotation><annotation id="8267"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="46754" length="4" /><text>SOD1</text></annotation><annotation id="8268"><infon key="identifier">272636</infon><infon key="type">Species</infon><location offset="46721" length="22" /><text>adeno-associated virus</text></annotation><annotation id="8269"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="46447" length="3" /><text>ALS</text></annotation><annotation id="8270"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="46542" length="3" /><text>ALS</text></annotation><annotation id="8271"><infon key="identifier">MESH:D009841</infon><infon key="type">Chemical</infon><location offset="46646" length="16" /><text>oligonucleotides</text></annotation><annotation id="8272"><infon key="identifier">MESH:D009841</infon><infon key="type">Chemical</infon><location offset="46362" length="16" /><text>oligonucleotides</text></annotation><annotation id="8273"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="46064" length="3" /><text>ALS</text></annotation><annotation id="8274"><infon key="identifier">MESH:C000709090</infon><infon key="type">Chemical</infon><location offset="46500" length="8" /><text>tofersen</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>46918</offset><text>Guidelines</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>46929</offset><text>The American Academy of Neurology (AAN) practice parameters and European Federation of Neurological Societies (EFNS) guidelines review clinical management of ALS.   The AAN parameters provide a comprehensive, systematic, evidence based review of class I-III studies. However, owing to insufficient evidence for the management of certain symptoms (for example, cramps, spasticity, cognitive/behavioral impairment, pain, and dyspnea), no formal recommendations were made in these domains. The EFNS guidelines include book chapters and review papers, and final recommendations were reached by consensus. Both the AAN and EFNS recommend access to a multidisciplinary center and treatment with riluzole. The EFNS guidelines also cover effective communication of the diagnosis and guidelines for genetic testing. Both the AAN and EFNS recommend percutaneous endoscopic gastrostomy placement for symptom progression and weight stabilization before the vital capacity falls below 50% predicted to minimize procedural related risk. Both guidelines recognize non-invasive ventilation to alleviate symptoms of respiratory insufficiency and to prolong survival. The use of invasive mechanical ventilation is discussed, recognizing that this decision varies according to many factors including economic and cultural differences and that, although this prolongs survival, it may not improve quality of life. The AAN practice parameter recognizes the lack of adequate data on drug treatment for cognitive or behavioral impairment in ALS, so no formal recommendations were made.</text><annotation id="8275"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="47618" length="8" /><text>riluzole</text></annotation><annotation id="8276"><infon key="identifier">MESH:D004417</infon><infon key="type">Disease</infon><location offset="47352" length="7" /><text>dyspnea</text></annotation><annotation id="8277"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="47309" length="31" /><text>cognitive/behavioral impairment</text></annotation><annotation id="8278"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="47342" length="4" /><text>pain</text></annotation><annotation id="8279"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="47087" length="3" /><text>ALS</text></annotation><annotation id="8280"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="48447" length="3" /><text>ALS</text></annotation><annotation id="8281"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="48028" length="25" /><text>respiratory insufficiency</text></annotation><annotation id="8282"><infon key="identifier">MESH:D009128</infon><infon key="type">Disease</infon><location offset="47297" length="10" /><text>spasticity</text></annotation><annotation id="8283"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="48409" length="34" /><text>cognitive or behavioral impairment</text></annotation><annotation id="8284"><infon key="identifier">MESH:D009120</infon><infon key="type">Disease</infon><location offset="47289" length="6" /><text>cramps</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>48492</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>48504</offset><text>In the past 20 years, considerable progress has been made in basic research on ALS. However, this accumulation of knowledge has been slow to translate into effective therapies, a major source of frustration to patients and care givers. With the inclusion of biomarkers, careful and innovative clinical trial design, and targeting of early disease in pre-symptomatic gene mutation carriers, the field is closer to converting basic science discoveries into disease modifying therapies. For the larger group of patients with sporadic ALS, the hope is that by uncovering gene variants that confer risk, and finding methods to define the predominant mechanism (for example, inflammation versus retro-transposon activation versus oxidative stress pathway) as the driver of disease, a personalized approach similar to that for cancer therapeutics can turn ALS into a chronic disease with limited disability and a dignified life. </text><annotation id="8285"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49353" length="3" /><text>ALS</text></annotation><annotation id="8286"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="48714" length="8" /><text>patients</text></annotation><annotation id="8287"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="49324" length="6" /><text>cancer</text></annotation><annotation id="8288"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="48583" length="3" /><text>ALS</text></annotation><annotation id="8289"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="49173" length="12" /><text>inflammation</text></annotation><annotation id="8290"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49035" length="3" /><text>ALS</text></annotation><annotation id="8291"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="49012" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1_caption</infon><offset>49427</offset><text>Glossary of abbreviations</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49453</offset><text>AAN:American Academy of Neurology</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49489</offset><text>ALS:amyotrophic lateral sclerosis</text><annotation id="8292"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49493" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="8293"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49489" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49525</offset><text>ALSFRS-R:revised ALS functional rating scale</text><annotation id="8294"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49542" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49572</offset><text>ALS-FTD:ALS with frontotemporal dementia</text><annotation id="8295"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49580" length="3" /><text>ALS</text></annotation><annotation id="8296"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="49589" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8297"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="49572" length="7" /><text>ALS-FTD</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49615</offset><text>BOLD:blood oxygen level dependent</text><annotation id="8298"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="49620" length="12" /><text>blood oxygen</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49651</offset><text>CMAP:compound muscle action potential</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49691</offset><text>DTI:diffusion tensor imaging</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49722</offset><text>EFNS:European Federation of Neurological Societies</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49775</offset><text>EIM:electrical impedance electromyography</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49819</offset><text>FDA:Food and Drug Administration</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49854</offset><text>FUS:fused in sarcoma</text><annotation id="8299"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="49854" length="3" /><text>FUS</text></annotation><annotation id="8300"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="49867" length="7" /><text>sarcoma</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49877</offset><text>HRE:hexanucleotide repeat expansion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49915</offset><text>LMN:lower motor neuron</text><annotation id="8301"><infon key="type">Disease</infon><location offset="49915" length="3" /><text>LMN</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49940</offset><text>MND:motor neuron disease</text><annotation id="8302"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="49940" length="3" /><text>MND</text></annotation><annotation id="8303"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="49944" length="20" /><text>motor neuron disease</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>49967</offset><text>MRI:magnetic resonance imaging</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50000</offset><text>MRS:magnetic resonance spectroscopy</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50038</offset><text>MUNE:motor unit number estimation</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50074</offset><text>MUNIX:motor unit number index</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50106</offset><text>NfL:neurofilament light chain</text><annotation id="8304"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="50106" length="3" /><text>NfL</text></annotation><annotation id="8305"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="50110" length="25" /><text>neurofilament light chain</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50138</offset><text>PCR:polymerase chain reaction</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50170</offset><text>PET:positron emission tomography</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50205</offset><text>PLS:primary lateral sclerosis</text><annotation id="8306"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="50209" length="25" /><text>primary lateral sclerosis</text></annotation><annotation id="8307"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="50205" length="3" /><text>PLS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50237</offset><text>PMA:progressive muscular atrophy</text><annotation id="8308"><infon key="identifier">MESH:D009134</infon><infon key="type">Disease</infon><location offset="50237" length="3" /><text>PMA</text></annotation><annotation id="8309"><infon key="identifier">MESH:D009133</infon><infon key="type">Disease</infon><location offset="50253" length="16" /><text>muscular atrophy</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50272</offset><text>SOD1:superoxidase dismutase 1</text><annotation id="8310"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="50272" length="4" /><text>SOD1</text></annotation><annotation id="8311"><infon key="identifier" /><infon key="type">Gene</infon><location offset="50277" length="24" /><text>superoxidase dismutase 1</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50304</offset><text>TDP-43:transactive response DNA binding protein 43</text><annotation id="8312"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="50304" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50357</offset><text>TMS:transcranial magnetic stimulation</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50397</offset><text>UMN:upper motor neuron</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1_caption</infon><offset>50422</offset><text>Questions for future research</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50452</offset><text>How can diagnostic criteria for amyotrophic lateral sclerosis (ALS) be improved to fully capture motor and cognitive dysfunction?</text><annotation id="8313"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="50549" length="31" /><text>motor and cognitive dysfunction</text></annotation><annotation id="8314"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50484" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="8315"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50515" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50582</offset><text>What are the genetic contributors to sporadic ALS?</text><annotation id="8316"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50628" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50633</offset><text>Can diminishing inflammation in the brain and spinal cord of patients with ALS result in slowing of disease progression?</text><annotation id="8317"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="50649" length="12" /><text>inflammation</text></annotation><annotation id="8318"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50708" length="3" /><text>ALS</text></annotation><annotation id="8319"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="50694" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50754</offset><text>What are the major factors driving disease progression, and can they be modified?</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>50836</offset><text>What determines disease presentation (ALS versus frontotemporal dementia (FTD) versus ALS-FTD)?</text><annotation id="8320"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="50926" length="3" /><text>FTD</text></annotation><annotation id="8321"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="50885" length="23" /><text>frontotemporal dementia</text></annotation><annotation id="8322"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50922" length="3" /><text>ALS</text></annotation><annotation id="8323"><infon key="identifier">MESH:D057180</infon><infon key="type">Disease</infon><location offset="50910" length="3" /><text>FTD</text></annotation><annotation id="8324"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="50874" length="3" /><text>ALS</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>50932</offset><text>Contributors: HI and JYK were responsible for the original conception, the design and performance of initial literature search, and the preparation of the initial draft of the manuscript. MV, HI, and JYK were substantially involved in the drafting and editing of the manuscript. All authors gave final approval of the manuscript and are accountable for all portions of the manuscript.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>51317</offset><text>Funding: This work was supported in part by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health.</text><annotation id="8325"><infon key="identifier">MESH:D009461</infon><infon key="type">Disease</infon><location offset="51422" length="22" /><text>Neurological Disorders</text></annotation><annotation id="8326"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="51449" length="6" /><text>Stroke</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>51488</offset><text>Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>51623</offset><text>Patient involvement: A draft of this manuscript was provided to a patient with amyotrophic lateral sclerosis for review. The patient was satisfied with the content and did not have any major corrections.</text><annotation id="8327"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="51689" length="7" /><text>patient</text></annotation><annotation id="8328"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="51623" length="7" /><text>Patient</text></annotation><annotation id="8329"><infon key="identifier">MESH:D000690</infon><infon key="type">Disease</infon><location offset="51702" length="29" /><text>amyotrophic lateral sclerosis</text></annotation><annotation id="8330"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="51748" length="7" /><text>patient</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>51827</offset><text>Provenance and peer review: Commissioned; externally peer reviewed.</text></passage><passage><infon key="volume">83</infon><infon key="name_2">surname:Bede;given-names:P</infon><infon key="name_1">surname:Elamin;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Phukan;given-names:J</infon><infon key="fpage">102</infon><infon key="pub-id_doi">10.1136/jnnp-2011-300188</infon><infon key="pub-id_pmid">21836033</infon><infon key="year">2012</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>51895</offset><text>The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study</text></passage><passage><infon key="volume">59</infon><infon key="name_2">surname:Miller;given-names:B</infon><infon key="name_1">surname:Anderson;given-names:T</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lomen-Hoerth;given-names:C</infon><infon key="fpage">1077</infon><infon key="pub-id_doi">10.1212/WNL.59.7.1077</infon><infon key="pub-id_pmid">12370467</infon><infon key="year">2002</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>51991</offset><text>The overlap of amyotrophic lateral sclerosis and frontotemporal dementia</text></passage><passage><infon key="volume">134</infon><infon key="name_2">surname:Knopman;given-names:D</infon><infon key="name_1">surname:Hodges;given-names:JR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rascovsky;given-names:K</infon><infon key="fpage">2456</infon><infon key="pub-id_doi">10.1093/brain/awr179</infon><infon key="pub-id_pmid">21810890</infon><infon key="year">2011</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">77</infon><offset>52064</offset><text>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</text></passage><passage><infon key="volume">72</infon><infon key="name_2">surname:Waite;given-names:A</infon><infon key="name_1">surname:Majounie;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Renton;given-names:AE</infon><infon key="fpage">257</infon><infon key="pub-id_doi">10.1016/j.neuron.2011.09.010</infon><infon key="pub-id_pmid">21944779</infon><infon key="year">2011</infon><infon key="source">Neuron</infon><infon key="type">ref</infon><infon key="lpage">68</infon><offset>52162</offset><text>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD</text><annotation id="8331"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="52199" length="7" /><text>C9ORF72</text></annotation></passage><passage><infon key="volume">314</infon><infon key="name_2">surname:Kwong;given-names:LK</infon><infon key="name_1">surname:Sampathu;given-names:DM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Neumann;given-names:M</infon><infon key="fpage">130</infon><infon key="pub-id_doi">10.1126/science.1134108</infon><infon key="pub-id_pmid">17023659</infon><infon key="year">2006</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="lpage">3</infon><offset>52254</offset><text>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</text><annotation id="8332"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="52268" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="volume">67</infon><infon key="name_2">surname:Bigio;given-names:EH</infon><infon key="name_1">surname:Zhai;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Deng;given-names:HX</infon><infon key="fpage">739</infon><infon key="pub-id_doi">10.1002/ana.22051</infon><infon key="pub-id_pmid">20517935</infon><infon key="year">2010</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">48</infon><offset>52346</offset><text>FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis</text><annotation id="8333"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="52346" length="3" /><text>FUS</text></annotation><annotation id="8334"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="52417" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="volume">3</infon><infon key="name_2">surname:Chio;given-names:A</infon><infon key="name_1">surname:Al-Chalabi;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hardiman;given-names:O</infon><infon key="fpage">17071</infon><infon key="pub-id_doi">10.1038/nrdp.2017.71</infon><infon key="pub-id_pmid">28980624</infon><infon key="year">2017</infon><infon key="source">Nat Rev Dis Primers</infon><infon key="type">ref</infon><offset>52461</offset><text>Amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">388</infon><infon key="name_2">surname:Kril;given-names:JJ</infon><infon key="name_1">surname:Halliday;given-names:GM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Burrell;given-names:JR</infon><infon key="fpage">919</infon><infon key="pub-id_doi">10.1016/S0140-6736(16)00737-6</infon><infon key="pub-id_pmid">26987909</infon><infon key="year">2016</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="lpage">31</infon><offset>52491</offset><text>The frontotemporal dementia-motor neuron disease continuum</text></passage><passage><infon key="name_3">surname:Geiger;given-names:JT</infon><infon key="name_2">surname:Price;given-names:TR</infon><infon key="name_1">surname:Calvo;given-names:A</infon><infon key="name_0">surname:Arthur;given-names:KC</infon><infon key="fpage">12408</infon><infon key="pub-id_doi">10.1038/ncomms12408</infon><infon key="pub-id_pmid">27510634</infon><infon key="year">2016</infon><infon key="source">Nat Commun</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="section_type">REF</infon><infon key="name_5">surname:Traynor;given-names:BJ</infon><infon key="name_4">surname:Chio;given-names:A</infon><offset>52550</offset><text>Projected increase in amyotrophic lateral sclerosis from 2015 to 2040</text></passage><passage><infon key="volume">267</infon><infon key="name_2">surname:Liu;given-names:L</infon><infon key="name_1">surname:Liu;given-names:T</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Xu;given-names:L</infon><infon key="fpage">944</infon><infon key="pub-id_doi">10.1007/s00415-019-09652-y</infon><infon key="pub-id_pmid">31797084</infon><infon key="year">2020</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="lpage">53</infon><offset>52620</offset><text>Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis</text></passage><passage><infon key="volume">73</infon><infon key="name_1">surname:La Spada;given-names:AR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ravits;given-names:JM</infon><infon key="fpage">805</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3181b6bbbd</infon><infon key="pub-id_pmid">19738176</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">11</infon><offset>52737</offset><text>ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration</text></passage><passage><infon key="volume">390</infon><infon key="name_2">surname:Chio;given-names:A</infon><infon key="name_1">surname:Hardiman;given-names:O</infon><infon key="section_type">REF</infon><infon key="name_0">surname:van Es;given-names:MA</infon><infon key="fpage">2084</infon><infon key="pub-id_doi">10.1016/S0140-6736(17)31287-4</infon><infon key="pub-id_pmid">28552366</infon><infon key="year">2017</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="lpage">98</infon><offset>52835</offset><text>Amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">72</infon><infon key="name_2">surname:Talman;given-names:P</infon><infon key="name_1">surname:Mathers;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wijesekera;given-names:LC</infon><infon key="fpage">1087</infon><infon key="pub-id_doi">10.1212/01.wnl.0000345041.83406.a2</infon><infon key="pub-id_pmid">19307543</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">94</infon><offset>52865</offset><text>Natural history and clinical features of the flail arm and flail leg ALS variants</text></passage><passage><infon key="volume">76</infon><infon key="name_2">surname:Al-Chalabi;given-names:A</infon><infon key="name_1">surname:Gerhard;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">871</infon><infon key="pub-id_doi">10.1136/jnnp.2004.047902</infon><infon key="pub-id_pmid">15897516</infon><infon key="year">2005</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">4</infon><offset>52947</offset><text>Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET</text></passage><passage><infon key="volume">5</infon><infon key="name_2">surname:Veldink;given-names:JH</infon><infon key="name_1">surname:van den Heuvel;given-names:MP</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Verstraete;given-names:E</infon><infon key="pub-id_doi">10.1371/journal.pone.0013664</infon><infon key="pub-id_pmid">21060689</infon><infon key="year">2010</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e13664</infon><offset>53045</offset><text>Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study</text></passage><passage><infon key="volume">91</infon><infon key="name_2">surname:Corcia;given-names:P</infon><infon key="name_1">surname:Barohn;given-names:RJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">373</infon><infon key="pub-id_doi">10.1136/jnnp-2019-322541</infon><infon key="pub-id_pmid">32029539</infon><infon key="year">2020</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>53153</offset><text>Primary lateral sclerosis: consensus diagnostic criteria</text></passage><passage><infon key="volume">73</infon><infon key="name_2">surname:Sandner;given-names:J</infon><infon key="name_1">surname:Liu;given-names:X</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kim;given-names:WK</infon><infon key="fpage">1686</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3181c1dea3</infon><infon key="pub-id_pmid">19917992</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">92</infon><offset>53210</offset><text>Study of 962 patients indicates progressive muscular atrophy is a form of ALS</text></passage><passage><infon key="volume">8</infon><infon key="name_2">surname:Swash;given-names:M</infon><infon key="name_1">surname:Scotto;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:de Carvalho;given-names:M</infon><infon key="fpage">296</infon><infon key="pub-id_doi">10.1080/17482960701452902</infon><infon key="pub-id_pmid">17852011</infon><infon key="year">2007</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>53288</offset><text>Clinical patterns in progressive muscular atrophy (PMA): a prospective study</text></passage><passage><infon key="volume">10</infon><infon key="name_1">surname:Mills;given-names:R</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Floeter;given-names:MK</infon><infon key="fpage">339</infon><infon key="pub-id_doi">10.3109/17482960903171136</infon><infon key="pub-id_pmid">19922121</infon><infon key="year">2009</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>53365</offset><text>Progression in primary lateral sclerosis: a prospective analysis</text></passage><passage><infon key="volume">91</infon><infon key="name_2">surname:Lonergan;given-names:K</infon><infon key="name_1">surname:Newton;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Crockford;given-names:C</infon><infon key="fpage">e1370</infon><infon key="pub-id_doi">10.1212/WNL.0000000000006317</infon><infon key="pub-id_pmid">30209236</infon><infon key="year">2018</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">80</infon><offset>53430</offset><text>ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS</text></passage><passage><infon key="volume">82</infon><infon key="name_2">surname:Lillo;given-names:P</infon><infon key="name_1">surname:Caga;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Mioshi;given-names:E</infon><infon key="fpage">149</infon><infon key="pub-id_doi">10.1212/WNL.0000000000000023</infon><infon key="pub-id_pmid">24336140</infon><infon key="year">2014</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">55</infon><offset>53521</offset><text>Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival</text></passage><passage><infon key="name_3">surname:Foley;given-names:J</infon><infon key="name_2">surname:Niven;given-names:E</infon><infon key="name_1">surname:Newton;given-names:J</infon><infon key="name_0">surname:Abrahams;given-names:S</infon><infon key="fpage">9</infon><infon key="pub-id_doi">10.3109/21678421.2013.805784</infon><infon key="pub-id_pmid">23781974</infon><infon key="year">2014</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="section_type">REF</infon><infon key="lpage">14</infon><infon key="name_4">surname:Bak;given-names:TH</infon><offset>53611</offset><text>Screening for cognition and behaviour changes in ALS</text></passage><passage><infon key="volume">11</infon><infon key="name_2">surname:Moore;given-names:DH</infon><infon key="name_1">surname:York;given-names:MK</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Woolley;given-names:SC</infon><infon key="fpage">303</infon><infon key="pub-id_doi">10.3109/17482961003727954</infon><infon key="pub-id_pmid">20433413</infon><infon key="year">2010</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">11</infon><offset>53664</offset><text>Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS)</text></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Goldstein;given-names:LH</infon><infon key="name_1">surname:Abrahams;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Strong;given-names:MJ</infon><infon key="fpage">153</infon><infon key="pub-id_doi">10.1080/21678421.2016.1267768</infon><infon key="pub-id_pmid">28054827</infon><infon key="year">2017</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">74</infon><offset>53766</offset><text>Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria</text></passage><passage><infon key="volume">15</infon><infon key="name_2">surname:Caga;given-names:J</infon><infon key="name_1">surname:Hsieh;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Mioshi;given-names:E</infon><infon key="fpage">298</infon><infon key="pub-id_doi">10.3109/21678421.2014.896927</infon><infon key="pub-id_pmid">24863641</infon><infon key="year">2014</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">304</infon><offset>53871</offset><text>A novel tool to detect behavioural symptoms in ALS</text></passage><passage><infon key="volume">79</infon><infon key="name_2">surname:Schmand;given-names:B</infon><infon key="name_1">surname:Beeldman;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Raaphorst;given-names:J</infon><infon key="fpage">1377</infon><infon key="pub-id_doi">10.1212/WNL.0b013e31826c1aa1</infon><infon key="pub-id_pmid">22972650</infon><infon key="year">2012</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">83</infon><offset>53922</offset><text>The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS</text></passage><passage><infon key="volume">16</infon><infon key="name_2">surname:Lomen-Hoerth;given-names:C</infon><infon key="name_1">surname:Ahmed;given-names:F</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Murphy;given-names:J</infon><infon key="fpage">24</infon><infon key="pub-id_doi">10.3109/21678421.2014.960873</infon><infon key="pub-id_pmid">25301548</infon><infon key="year">2015</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">30</infon><offset>53993</offset><text>The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS</text></passage><passage><infon key="volume">90</infon><infon key="name_2">surname:Peotta;given-names:L</infon><infon key="name_1">surname:Pain;given-names:D</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Iazzolino;given-names:B</infon><infon key="fpage">734</infon><infon key="pub-id_doi">10.1136/jnnp-2018-319696</infon><infon key="pub-id_pmid">30733331</infon><infon key="year">2019</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>54094</offset><text>Validation of the revised classification of cognitive and behavioural impairment in ALS</text></passage><passage><infon key="volume">93</infon><infon key="name_2">surname:Canosa;given-names:A</infon><infon key="name_1">surname:Moglia;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chio;given-names:A</infon><infon key="fpage">e984</infon><infon key="pub-id_doi">10.1212/WNL.0000000000008063</infon><infon key="pub-id_pmid">31409738</infon><infon key="year">2019</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">94</infon><offset>54182</offset><text>Cognitive impairment across ALS clinical stages in a population-based cohort</text></passage><passage><infon key="volume">86</infon><infon key="name_2">surname:Calvo;given-names:A</infon><infon key="name_1">surname:Iazzolino;given-names:B</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Montuschi;given-names:A</infon><infon key="fpage">168</infon><infon key="pub-id_doi">10.1136/jnnp-2013-307223</infon><infon key="pub-id_pmid">24769471</infon><infon key="year">2015</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">73</infon><offset>54259</offset><text>Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy</text></passage><passage><infon key="volume">85</infon><infon key="name_2">surname:Regard;given-names:M</infon><infon key="name_1">surname:Langen;given-names:KJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ludolph;given-names:AC</infon><infon key="fpage">81</infon><infon key="pub-id_doi">10.1111/j.1600-0404.1992.tb04003.x</infon><infon key="pub-id_pmid">1574993</infon><infon key="year">1992</infon><infon key="source">Acta Neurol Scand</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>54348</offset><text>Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study</text></passage><passage><infon key="name_3">surname:Haverkamp;given-names:LJ</infon><infon key="name_2">surname:Cooke;given-names:N</infon><infon key="name_1">surname:Sims;given-names:J</infon><infon key="name_0">surname:Massman;given-names:PJ</infon><infon key="fpage">450</infon><infon key="pub-id_doi">10.1136/jnnp.61.5.450</infon><infon key="pub-id_pmid">8937336</infon><infon key="year">1996</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="section_type">REF</infon><infon key="lpage">5</infon><infon key="name_5">surname:Appel;given-names:SH</infon><infon key="name_4">surname:Appel;given-names:V</infon><offset>54462</offset><text>Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">64</infon><infon key="name_2">surname:Goldstein;given-names:LH</infon><infon key="name_1">surname:Leigh;given-names:PN</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Abrahams;given-names:S</infon><infon key="fpage">1222</infon><infon key="pub-id_doi">10.1212/01.WNL.0000156519.41681.27</infon><infon key="pub-id_pmid">15824350</infon><infon key="year">2005</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">6</infon><offset>54552</offset><text>Cognitive change in ALS: a prospective study</text></passage><passage><infon key="name_3">surname:de Visser;given-names:M</infon><infon key="name_2">surname:Klein Twennaar;given-names:M</infon><infon key="name_1">surname:Raaphorst;given-names:J</infon><infon key="name_0">surname:Beeldman;given-names:E</infon><infon key="fpage">611</infon><infon key="pub-id_doi">10.1136/jnnp-2015-310734</infon><infon key="pub-id_pmid">26283685</infon><infon key="year">2016</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><infon key="name_5">surname:de Haan;given-names:RJ</infon><infon key="name_4">surname:Schmand;given-names:BA</infon><offset>54597</offset><text>The cognitive profile of ALS: a systematic review and meta-analysis update</text></passage><passage><infon key="name_3">surname:Miller;given-names:RG</infon><infon key="name_2">surname:Bradley;given-names:WG</infon><infon key="name_1">surname:Woolley-Levine;given-names:S</infon><infon key="name_0">surname:Grossman;given-names:AB</infon><infon key="fpage">56</infon><infon key="pub-id_doi">10.1080/17482960601044106</infon><infon key="pub-id_pmid">17364437</infon><infon key="year">2007</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="section_type">REF</infon><infon key="lpage">61</infon><offset>54672</offset><text>Detecting neurobehavioral changes in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Snowden;given-names:JS</infon><infon key="name_2">surname:Neary;given-names:D</infon><infon key="name_1">surname:Richardson;given-names:A</infon><infon key="name_0">surname:Gibbons;given-names:ZC</infon><infon key="fpage">67</infon><infon key="pub-id_doi">10.1080/17482960701642437</infon><infon key="pub-id_pmid">18427998</infon><infon key="year">2008</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="lpage">74</infon><offset>54739</offset><text>Behaviour in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">17</infon><infon key="name_2">surname:Strutt;given-names:AM</infon><infon key="name_1">surname:Salamone;given-names:AR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Witgert;given-names:M</infon><infon key="fpage">103</infon><infon key="pub-id_doi">10.1111/j.1468-1331.2009.02801.x</infon><infon key="pub-id_pmid">19874396</infon><infon key="year">2010</infon><infon key="source">Eur J Neurol</infon><infon key="type">ref</infon><infon key="lpage">10</infon><offset>54782</offset><text>Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Leigh;given-names:PN</infon><infon key="name_2">surname:Thambisetty;given-names:M</infon><infon key="name_1">surname:Papps;given-names:BJ</infon><infon key="name_0">surname:Cuddy;given-names:M</infon><infon key="fpage">592</infon><infon key="pub-id_doi">10.3109/17482968.2012.708936</infon><infon key="pub-id_pmid">22873560</infon><infon key="year">2012</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="section_type">REF</infon><infon key="lpage">8</infon><infon key="name_4">surname:Goldstein;given-names:LH</infon><offset>54860</offset><text>Processing and memory for emotional and neutral material in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">11</infon><infon key="name_2">surname:Lonergan;given-names:K</infon><infon key="name_1">surname:Pinto-Grau;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Burke;given-names:T</infon><infon key="pub-id_doi">10.1371/journal.pone.0160850</infon><infon key="pub-id_pmid">27556398</infon><infon key="year">2016</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e0160850</infon><offset>54950</offset><text>Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study</text></passage><passage><infon key="volume">83</infon><infon key="name_2">surname:Kim;given-names:MP</infon><infon key="name_1">surname:Katipally;given-names:R</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Floeter;given-names:MK</infon><infon key="fpage">620</infon><infon key="pub-id_doi">10.1212/WNL.0000000000000693</infon><infon key="pub-id_pmid">25008395</infon><infon key="year">2014</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>55041</offset><text>Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders</text></passage><passage><infon key="volume">19</infon><infon key="name_2">surname:Ferentinos;given-names:P</infon><infon key="name_1">surname:Karavasilis;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Christidi;given-names:F</infon><infon key="fpage">12</infon><infon key="pub-id_doi">10.1080/21678421.2017.1386689</infon><infon key="pub-id_pmid">29034720</infon><infon key="year">2018</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">20</infon><offset>55135</offset><text>Investigating the neuroanatomical substrate of pathological laughing and crying in amyotrophic lateral sclerosis with multimodal neuroimaging techniques</text></passage><passage><infon key="volume">278</infon><infon key="name_2">surname:Soraru;given-names:G</infon><infon key="name_1">surname:Abrahams;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Palmieri;given-names:A</infon><infon key="fpage">16</infon><infon key="pub-id_doi">10.1016/j.jns.2008.10.025</infon><infon key="pub-id_pmid">19103449</infon><infon key="year">2009</infon><infon key="source">J Neurol Sci</infon><infon key="type">ref</infon><infon key="lpage">20</infon><offset>55288</offset><text>Emotional Lability in MND: Relationship to cognition and psychopathology and impact on caregivers</text></passage><passage><infon key="name_3">surname:Munsat;given-names:TL</infon><infon key="name_2">surname:Swash;given-names:M</infon><infon key="name_1">surname:Miller;given-names:RG</infon><infon key="name_0">surname:Brooks;given-names:BR</infon><infon key="fpage">293</infon><infon key="pub-id_doi">10.1080/146608200300079536</infon><infon key="pub-id_pmid">11464847</infon><infon key="year">2000</infon><infon key="source">Amyotroph Lateral Scler Other Motor Neuron Disord</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><offset>55386</offset><text>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">10</infon><infon key="name_1">surname:Swash;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Carvalho;given-names:MD</infon><infon key="fpage">53</infon><infon key="pub-id_doi">10.1080/17482960802521126</infon><infon key="pub-id_pmid">18985466</infon><infon key="year">2009</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>55477</offset><text>Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis</text></passage><passage><infon key="name_3">surname:Forde;given-names:C</infon><infon key="name_2">surname:Corr;given-names:B</infon><infon key="name_1">surname:Codd;given-names:MB</infon><infon key="name_0">surname:Traynor;given-names:BJ</infon><infon key="fpage">1171</infon><infon key="pub-id_doi">10.1001/archneur.57.8.1171</infon><infon key="pub-id_pmid">10927797</infon><infon key="year">2000</infon><infon key="source">Arch Neurol</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="section_type">REF</infon><infon key="lpage">6</infon><infon key="name_5">surname:Hardiman;given-names:OM</infon><infon key="name_4">surname:Frost;given-names:E</infon><offset>55568</offset><text>Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study</text></passage><passage><infon key="volume">131</infon><infon key="name_2">surname:Baker;given-names:MR</infon><infon key="name_1">surname:Al-Chalabi;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Shefner;given-names:JM</infon><infon key="fpage">1975</infon><infon key="pub-id_doi">10.1016/j.clinph.2020.04.005</infon><infon key="pub-id_pmid">32387049</infon><infon key="year">2020</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>55711</offset><text>A proposal for new diagnostic criteria for ALS</text></passage><passage><infon key="volume">118</infon><infon key="name_2">surname:Appel;given-names:SH</infon><infon key="name_1">surname:Appel;given-names:V</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Haverkamp;given-names:LJ</infon><infon key="fpage">707</infon><infon key="pub-id_doi">10.1093/brain/118.3.707</infon><infon key="pub-id_pmid">7600088</infon><infon key="year">1995</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">19</infon><offset>55758</offset><text>Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction</text></passage><passage><infon key="volume">10</infon><infon key="name_1">surname:Robberecht;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Swinnen;given-names:B</infon><infon key="fpage">661</infon><infon key="pub-id_doi">10.1038/nrneurol.2014.184</infon><infon key="pub-id_pmid">25311585</infon><infon key="year">2014</infon><infon key="source">Nat Rev Neurol</infon><infon key="type">ref</infon><infon key="lpage">70</infon><offset>55900</offset><text>The phenotypic variability of amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">10</infon><infon key="name_2">surname:Hardiman;given-names:O</infon><infon key="name_1">surname:Logroscino;given-names:G</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chio;given-names:A</infon><infon key="fpage">310</infon><infon key="pub-id_doi">10.3109/17482960802566824</infon><infon key="pub-id_pmid">19922118</infon><infon key="year">2009</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">23</infon><offset>55960</offset><text>Prognostic factors in ALS: A critical review</text></passage><passage><infon key="volume">80</infon><infon key="name_2">surname:Jenab;given-names:M</infon><infon key="name_1">surname:Wark;given-names:PA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gallo;given-names:V</infon><infon key="fpage">829</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3182840689</infon><infon key="pub-id_pmid">23390184</infon><infon key="year">2013</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">38</infon><offset>56005</offset><text>Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort</text></passage><passage><infon key="volume">87</infon><infon key="name_2">surname:Bertuzzo;given-names:D</infon><infon key="name_1">surname:Canosa;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Calvo;given-names:A</infon><infon key="fpage">1229</infon><infon key="pub-id_doi">10.1136/jnnp-2016-313793</infon><infon key="pub-id_pmid">27656044</infon><infon key="year">2016</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">33</infon><offset>56098</offset><text>Influence of cigarette smoking on ALS outcome: a population-based study</text></passage><passage><infon key="volume">84</infon><infon key="name_2">surname:Gray;given-names:E</infon><infon key="name_1">surname:Macdonald-Wallis;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lu;given-names:CH</infon><infon key="fpage">2247</infon><infon key="pub-id_doi">10.1212/WNL.0000000000001642</infon><infon key="pub-id_pmid">25934855</infon><infon key="year">2015</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">57</infon><offset>56170</offset><text>Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis</text><annotation id="8335"><infon key="identifier">4747</infon><infon key="type">Gene</infon><location offset="56170" length="25" /><text>Neurofilament light chain</text></annotation></passage><passage><infon key="volume">95</infon><infon key="name_2">surname:Wang;given-names:L</infon><infon key="name_1">surname:Zhang;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Benatar;given-names:M</infon><infon key="fpage">e59</infon><infon key="pub-id_doi">10.1212/WNL.0000000000009559</infon><infon key="pub-id_pmid">32385188</infon><infon key="year">2020</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">69</infon><offset>56253</offset><text>Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS</text></passage><passage><infon key="volume">17</infon><infon key="name_2">surname:Visser;given-names:AE</infon><infon key="name_1">surname:Debray;given-names:TPA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Westeneng;given-names:HJ</infon><infon key="fpage">423</infon><infon key="pub-id_doi">10.1016/S1474-4422(18)30089-9</infon><infon key="pub-id_pmid">29598923</infon><infon key="year">2018</infon><infon key="source">Lancet Neurol</infon><infon key="type">ref</infon><infon key="lpage">33</infon><offset>56351</offset><text>Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model</text></passage><passage><infon key="volume">135</infon><infon key="name_2">surname:Scott;given-names:KM</infon><infon key="name_1">surname:Rojas-Garcia;given-names:R</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Roche;given-names:JC</infon><infon key="fpage">847</infon><infon key="pub-id_doi">10.1093/brain/awr351</infon><infon key="pub-id_pmid">22271664</infon><infon key="year">2012</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">52</infon><offset>56472</offset><text>A proposed staging system for amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Bonito;given-names:V</infon><infon key="name_2">surname:Mora;given-names:G</infon><infon key="name_1">surname:Hammond;given-names:ER</infon><infon key="name_0">surname:Chio;given-names:A</infon><infon key="fpage">38</infon><infon key="pub-id_doi">10.1136/jnnp-2013-306589</infon><infon key="pub-id_pmid">24336810</infon><infon key="year">2015</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="section_type">REF</infon><infon key="lpage">44</infon><infon key="name_4">surname:Filippini;given-names:G</infon><offset>56532</offset><text>Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Al-Chalabi;given-names:A</infon><infon key="name_2">surname:Fang;given-names:T</infon><infon key="name_1">surname:Al Khleifat;given-names:A</infon><infon key="name_0">surname:Balendra;given-names:R</infon><infon key="fpage">159</infon><infon key="pub-id_doi">10.1080/21678421.2018.1556696</infon><infon key="pub-id_pmid">30773950</infon><infon key="year">2019</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="section_type">REF</infon><infon key="lpage">64</infon><offset>56622</offset><text>A standard operating procedure for King's ALS clinical staging</text></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Stahl;given-names:DR</infon><infon key="name_1">surname:Al Khleifat;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Fang;given-names:T</infon><infon key="fpage">227</infon><infon key="pub-id_doi">10.1080/21678421.2016.1265565</infon><infon key="pub-id_pmid">28054828</infon><infon key="year">2017</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">32</infon><offset>56687</offset><text>Comparison of the King's and MiToS staging systems for ALS</text></passage><passage><infon key="volume">86</infon><infon key="name_2">surname:Jivraj;given-names:N</infon><infon key="name_1">surname:Jones;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Balendra;given-names:R</infon><infon key="fpage">45</infon><infon key="pub-id_doi">10.1136/jnnp-2013-306865</infon><infon key="pub-id_pmid">24463480</infon><infon key="year">2015</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>56748</offset><text>Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials</text></passage><passage><infon key="name_3">surname:Fasano;given-names:A</infon><infon key="name_2">surname:Fini;given-names:N</infon><infon key="name_1">surname:Consonni;given-names:D</infon><infon key="name_0">surname:Ferraro;given-names:D</infon><infon key="fpage">1426</infon><infon key="pub-id_doi">10.1111/ene.13053</infon><infon key="pub-id_pmid">27238551</infon><infon key="year">2016</infon><infon key="source">Eur J Neurol</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="section_type">REF</infon><infon key="lpage">32</infon><infon key="name_5">surname:Mandrioli;given-names:J</infon><infon key="name_4">surname:Del Giovane;given-names:C</infon><offset>56833</offset><text>Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study</text></passage><passage><infon key="volume">128</infon><infon key="name_2">surname:Del Tredici;given-names:K</infon><infon key="name_1">surname:Arai;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Brettschneider;given-names:J</infon><infon key="fpage">423</infon><infon key="pub-id_doi">10.1007/s00401-014-1299-6</infon><infon key="pub-id_pmid">24916269</infon><infon key="year">2014</infon><infon key="source">Acta Neuropathol</infon><infon key="type">ref</infon><infon key="lpage">37</infon><offset>56928</offset><text>TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord</text><annotation id="8336"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="56928" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="volume">13</infon><infon key="name_2">surname:Trojanowski;given-names:JQ</infon><infon key="name_1">surname:Lee;given-names:VM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lee;given-names:EB</infon><infon key="fpage">38</infon><infon key="pub-id_doi">10.1038/nrn3121</infon><infon key="pub-id_pmid">22127299</infon><infon key="year">2011</infon><infon key="source">Nat Rev Neurosci</infon><infon key="type">ref</infon><infon key="lpage">50</infon><offset>57008</offset><text>Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration</text></passage><passage><infon key="volume">92</infon><infon key="name_2">surname:Williams;given-names:T</infon><infon key="name_1">surname:Orie;given-names:VK</infon><infon key="section_type">REF</infon><infon key="name_0">surname:de Boer;given-names:EMJ</infon><infon key="fpage">86</infon><infon key="pub-id_doi">10.1136/jnnp-2020-322983</infon><infon key="pub-id_pmid">33177049</infon><infon key="year">2020</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">95</infon><offset>57082</offset><text>TDP-43 proteinopathies: a new wave of neurodegenerative diseases</text><annotation id="8337"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57082" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="volume">79</infon><infon key="name_2">surname:Cleveland;given-names:DW</infon><infon key="name_1">surname:Polymenidou;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ling;given-names:SC</infon><infon key="fpage">416</infon><infon key="pub-id_doi">10.1016/j.neuron.2013.07.033</infon><infon key="pub-id_pmid">23931993</infon><infon key="year">2013</infon><infon key="source">Neuron</infon><infon key="type">ref</infon><infon key="lpage">38</infon><offset>57147</offset><text>Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis</text></passage><passage><infon key="volume">99</infon><infon key="name_2">surname:Fratta;given-names:P</infon><infon key="name_1">surname:Bentham;given-names:MP</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Birsa;given-names:N</infon><infon key="fpage">193</infon><infon key="pub-id_doi">10.1016/j.semcdb.2019.05.023</infon><infon key="pub-id_pmid">31132467</infon><infon key="year">2020</infon><infon key="source">Semin Cell Dev Biol</infon><infon key="type">ref</infon><infon key="lpage">201</infon><offset>57223</offset><text>Cytoplasmic functions of TDP-43 and FUS and their role in ALS</text><annotation id="8338"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="57259" length="3" /><text>FUS</text></annotation><annotation id="8339"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57248" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="name_3">surname:Wong;given-names:PC</infon><infon key="name_2">surname:Troncoso;given-names:JC</infon><infon key="name_1">surname:Pletnikova;given-names:O</infon><infon key="name_0">surname:Ling;given-names:JP</infon><infon key="fpage">650</infon><infon key="pub-id_doi">10.1126/science.aab0983</infon><infon key="pub-id_pmid">26250685</infon><infon key="year">2015</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">349</infon><infon key="section_type">REF</infon><infon key="lpage">5</infon><offset>57285</offset><text>TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD</text><annotation id="8340"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57285" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="volume">22</infon><infon key="name_2">surname:Limone;given-names:F</infon><infon key="name_1">surname:Williams;given-names:LA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Klim;given-names:JR</infon><infon key="fpage">167</infon><infon key="pub-id_doi">10.1038/s41593-018-0300-4</infon><infon key="pub-id_pmid">30643292</infon><infon key="year">2019</infon><infon key="source">Nat Neurosci</infon><infon key="type">ref</infon><infon key="lpage">79</infon><offset>57359</offset><text>ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair</text><annotation id="8341"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57382" length="6" /><text>TDP-43</text></annotation><annotation id="8342"><infon key="identifier">11075</infon><infon key="type">Gene</infon><location offset="57408" length="5" /><text>STMN2</text></annotation></passage><passage><infon key="volume">22</infon><infon key="name_2">surname:Baughn;given-names:MW</infon><infon key="name_1">surname:Lopez-Erauskin;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Melamed;given-names:Z</infon><infon key="fpage">180</infon><infon key="pub-id_doi">10.1038/s41593-018-0293-z</infon><infon key="pub-id_pmid">30643298</infon><infon key="year">2019</infon><infon key="source">Nat Neurosci</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>57460</offset><text>Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration</text><annotation id="8343"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57531" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="name_2">surname:Keuss;given-names:MJ</infon><infon key="name_1">surname:Wilkins;given-names:OG</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Brown;given-names:A-L</infon><infon key="year">2021</infon><infon key="source">bioRxiv</infon><infon key="type">ref</infon><infon key="elocation-id">2021.04.02.438170</infon><offset>57566</offset><text>Common ALS/FTD risk variants in UNC13A exacerbate its cryptic splicing and loss upon TDP-43 mislocalization.</text><annotation id="8344"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57651" length="6" /><text>TDP-43</text></annotation><annotation id="8345"><infon key="identifier">23025</infon><infon key="type">Gene</infon><location offset="57598" length="6" /><text>UNC13A</text></annotation></passage><passage><infon key="volume">603</infon><infon key="name_2">surname:Koike;given-names:Y</infon><infon key="name_1">surname:Prudencio;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ma;given-names:XR</infon><infon key="fpage">124</infon><infon key="pub-id_doi">10.1038/s41586-022-04424-7</infon><infon key="pub-id_pmid">35197626</infon><infon key="year">2022</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="lpage">30</infon><offset>57675</offset><text>TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A</text><annotation id="8346"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="57675" length="6" /><text>TDP-43</text></annotation><annotation id="8347"><infon key="identifier">23025</infon><infon key="type">Gene</infon><location offset="57735" length="6" /><text>UNC13A</text></annotation></passage><passage><infon key="volume">8</infon><infon key="name_2">surname:Phatnani;given-names:H</infon><infon key="name_1">surname:Fagegaltier;given-names:D</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gregory;given-names:JM</infon><infon key="fpage">121</infon><infon key="pub-id_doi">10.1007/s40142-020-00194-8</infon><infon key="year">2020</infon><infon key="source">Curr Genet Med Rep</infon><infon key="type">ref</infon><infon key="lpage">31</infon><offset>57742</offset><text>Genetics of Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="volume">362</infon><infon key="name_2">surname:Patterson;given-names:D</infon><infon key="name_1">surname:Siddique;given-names:T</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rosen;given-names:DR</infon><infon key="fpage">59</infon><infon key="pub-id_doi">10.1038/362059a0</infon><infon key="pub-id_pmid">8446170</infon><infon key="year">1993</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="lpage">62</infon><offset>57784</offset><text>Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">85</infon><infon key="name_1">surname:Talbot;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:BJ</infon><infon key="fpage">94</infon><infon key="pub-id_doi">10.1016/j.pneurobio.2008.01.001</infon><infon key="pub-id_pmid">18282652</infon><infon key="year">2008</infon><infon key="source">Prog Neurobiol</infon><infon key="type">ref</infon><infon key="lpage">134</infon><offset>57888</offset><text>Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS</text><annotation id="8348"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="57954" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="volume">636</infon><infon key="name_1">surname:Brown;given-names:RH;suffix:Jr</infon><infon key="section_type">REF</infon><infon key="name_0">surname:van Zundert;given-names:B</infon><infon key="fpage">32</infon><infon key="pub-id_doi">10.1016/j.neulet.2016.07.059</infon><infon key="pub-id_pmid">27507699</infon><infon key="year">2017</infon><infon key="source">Neurosci Lett</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>57981</offset><text>Silencing strategies for therapy of SOD1-mediated ALS</text><annotation id="8349"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="58017" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="volume">383</infon><infon key="name_2">surname:Shaw;given-names:PJ</infon><infon key="name_1">surname:Cudkowicz;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Miller;given-names:T</infon><infon key="fpage">109</infon><infon key="pub-id_doi">10.1056/NEJMoa2003715</infon><infon key="pub-id_pmid">32640130</infon><infon key="year">2020</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">19</infon><offset>58035</offset><text>Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS</text><annotation id="8350"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="58093" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="volume">116</infon><infon key="name_2">surname:Yamanaka;given-names:K</infon><infon key="name_1">surname:Miller;given-names:TM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Smith;given-names:RA</infon><infon key="fpage">2290</infon><infon key="pub-id_doi">10.1172/JCI25424</infon><infon key="pub-id_pmid">16878173</infon><infon key="year">2006</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">6</infon><offset>58102</offset><text>Antisense oligonucleotide therapy for neurodegenerative disease</text></passage><passage><infon key="volume">72</infon><infon key="name_2">surname:Boeve;given-names:BF</infon><infon key="name_1">surname:Mackenzie;given-names:IR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:DeJesus-Hernandez;given-names:M</infon><infon key="fpage">245</infon><infon key="pub-id_doi">10.1016/j.neuron.2011.09.011</infon><infon key="pub-id_pmid">21944778</infon><infon key="year">2011</infon><infon key="source">Neuron</infon><infon key="type">ref</infon><infon key="lpage">56</infon><offset>58166</offset><text>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</text><annotation id="8351"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="58227" length="7" /><text>C9ORF72</text></annotation></passage><passage><infon key="volume">138</infon><infon key="name_1">surname:Petrucelli;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Todd;given-names:TW</infon><infon key="fpage">145</infon><infon key="issue">Suppl 1</infon><infon key="pub-id_doi">10.1111/jnc.13623</infon><infon key="pub-id_pmid">27016280</infon><infon key="year">2016</infon><infon key="source">J Neurochem</infon><infon key="type">ref</infon><infon key="lpage">62</infon><offset>58275</offset><text>Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions</text><annotation id="8352"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="58354" length="7" /><text>C9orf72</text></annotation></passage><passage><infon key="volume">15</infon><infon key="name_2">surname:Latouche;given-names:M</infon><infon key="name_1">surname:Banchi;given-names:EG</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Smeyers;given-names:J</infon><infon key="pub-id_doi">10.3389/fncel.2021.661447</infon><infon key="pub-id_pmid">34025358</infon><infon key="year">2021</infon><infon key="source">Front Cell Neurosci</infon><infon key="type">ref</infon><infon key="elocation-id">661447</infon><offset>58381</offset><text>C9ORF72: What It Is, What It Does, and Why It Matters</text><annotation id="8353"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="58381" length="7" /><text>C9ORF72</text></annotation></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Lemmens;given-names:R</infon><infon key="name_1">surname:Schoonaert;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Van Hoecke;given-names:A</infon><infon key="fpage">1418</infon><infon key="pub-id_doi">10.1038/nm.2901</infon><infon key="pub-id_pmid">22922411</infon><infon key="year">2012</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="lpage">22</infon><offset>58435</offset><text>EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans</text><annotation id="8354"><infon key="identifier">2043</infon><infon key="type">Gene</infon><location offset="58435" length="5" /><text>EPHA4</text></annotation></passage><passage><infon key="volume">62</infon><infon key="name_2">surname:Kishikawa;given-names:H</infon><infon key="name_1">surname:Yu;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wu;given-names:D</infon><infon key="fpage">609</infon><infon key="pub-id_doi">10.1002/ana.21221</infon><infon key="pub-id_pmid">17886298</infon><infon key="year">2007</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">17</infon><offset>58527</offset><text>Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Agar;given-names:JN</infon><infon key="volume">10</infon><infon key="name_2">surname:Prehn;given-names:JHM</infon><infon key="name_1">surname:Salisbury;given-names:JP</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Aluri;given-names:KC</infon><infon key="fpage">3715</infon><infon key="pub-id_doi">10.1038/s41598-020-60431-6</infon><infon key="pub-id_pmid">32111867</infon><infon key="year">2020</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><offset>58598</offset><text>Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration</text></passage><passage><infon key="volume">48</infon><infon key="name_2">surname:Dekker;given-names:AM</infon><infon key="name_1">surname:van Doormaal;given-names:PT</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kenna;given-names:KP</infon><infon key="fpage">1037</infon><infon key="pub-id_doi">10.1038/ng.3626</infon><infon key="pub-id_pmid">27455347</infon><infon key="year">2016</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">42</infon><offset>58701</offset><text>NEK1 variants confer susceptibility to amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">20</infon><infon key="name_2">surname:Ingre;given-names:C</infon><infon key="name_1">surname:Li;given-names:YR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lee;given-names:T</infon><infon key="fpage">1697</infon><infon key="pub-id_doi">10.1093/hmg/ddr045</infon><infon key="pub-id_pmid">21292779</infon><infon key="year">2011</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="lpage">700</infon><offset>58770</offset><text>Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients</text></passage><passage><infon key="volume">466</infon><infon key="name_2">surname:Hart;given-names:MP</infon><infon key="name_1">surname:Kim;given-names:HJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Elden;given-names:AC</infon><infon key="fpage">1069</infon><infon key="pub-id_doi">10.1038/nature09320</infon><infon key="pub-id_pmid">20740007</infon><infon key="year">2010</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="lpage">75</infon><offset>58849</offset><text>Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS</text></passage><passage><infon key="name_3">surname:Singh;given-names:I</infon><infon key="name_2">surname:Bhatia;given-names:R</infon><infon key="name_1">surname:Gomes;given-names:J</infon><infon key="name_0">surname:Narain;given-names:P</infon><infon key="fpage">211.e9</infon><infon key="pub-id_doi">10.1016/j.neurobiolaging.2017.04.011</infon><infon key="pub-id_pmid">28527524</infon><infon key="year">2017</infon><infon key="source">Neurobiol Aging</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="section_type">REF</infon><infon key="lpage">14</infon><infon key="name_4">surname:Vivekanandan;given-names:P</infon><offset>58946</offset><text>C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis</text><annotation id="8355"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="58946" length="7" /><text>C9orf72</text></annotation><annotation id="8356"><infon key="identifier">6311</infon><infon key="type">Gene</infon><location offset="58991" length="8" /><text>Ataxin 2</text></annotation></passage><passage><infon key="volume">21</infon><infon key="name_2">surname:Hennekam;given-names:EA</infon><infon key="name_1">surname:van Es;given-names:MA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:van Blitterswijk;given-names:M</infon><infon key="fpage">3776</infon><infon key="pub-id_doi">10.1093/hmg/dds199</infon><infon key="pub-id_pmid">22645277</infon><infon key="year">2012</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="lpage">84</infon><offset>59092</offset><text>Evidence for an oligogenic basis of amyotrophic lateral sclerosis</text></passage><passage><infon key="name_2">surname:Fifita;given-names:JA</infon><infon key="name_1">surname:Henden;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:McCann;given-names:EP</infon><infon key="pub-id_pmid">32409511</infon><infon key="year">2020</infon><infon key="source">J Med Genet</infon><infon key="type">ref</infon><infon key="elocation-id">jmedgenet-2020-106866</infon><offset>59158</offset><text>Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">9</infon><infon key="name_2">surname:Feldman;given-names:EL</infon><infon key="name_1">surname:Welsh;given-names:RC</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Foerster;given-names:BR</infon><infon key="fpage">513</infon><infon key="pub-id_doi">10.1038/nrneurol.2013.153</infon><infon key="pub-id_pmid">23917850</infon><infon key="year">2013</infon><infon key="source">Nat Rev Neurol</infon><infon key="type">ref</infon><infon key="lpage">24</infon><offset>59255</offset><text>25 years of neuroimaging in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">7</infon><infon key="name_2">surname:Van Gelderen;given-names:P</infon><infon key="name_1">surname:Jeong;given-names:SY</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kwan;given-names:JY</infon><infon key="pub-id_doi">10.1371/journal.pone.0035241</infon><infon key="pub-id_pmid">22529995</infon><infon key="year">2012</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e35241</infon><offset>59313</offset><text>Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology</text></passage><passage><infon key="name_3">surname:Filippi;given-names:M</infon><infon key="name_2">surname:Grosskreutz;given-names:J</infon><infon key="name_1">surname:Agosta;given-names:F</infon><infon key="name_0">surname:Menke;given-names:RA</infon><infon key="fpage">11</infon><infon key="pub-id_doi">10.1007/s13311-016-0484-9</infon><infon key="pub-id_pmid">27752938</infon><infon key="year">2017</infon><infon key="source">Neurotherapeutics</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="section_type">REF</infon><infon key="lpage">23</infon><infon key="name_4">surname:Turner;given-names:MR</infon><offset>59439</offset><text>Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="name_3">surname:Govind;given-names:V</infon><infon key="name_2">surname:Bede;given-names:P</infon><infon key="name_1">surname:Agosta;given-names:F</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">319</infon><infon key="pub-id_doi">10.2217/bmm.12.26</infon><infon key="pub-id_pmid">22731907</infon><infon key="year">2012</infon><infon key="source">Biomark Med</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="section_type">REF</infon><infon key="lpage">37</infon><infon key="name_5">surname:Verstraete;given-names:E</infon><infon key="name_4">surname:Lule;given-names:D</infon><offset>59495</offset><text>Neuroimaging in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">10</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kalra;given-names:S</infon><infon key="fpage">482</infon><infon key="pub-id_doi">10.3389/fneur.2019.00482</infon><infon key="pub-id_pmid">31133975</infon><infon key="year">2019</infon><infon key="source">Front Neurol</infon><infon key="type">ref</infon><offset>59541</offset><text>Magnetic Resonance Spectroscopy in ALS</text></passage><passage><infon key="volume">1</infon><infon key="name_1">surname:Leigh;given-names:PN</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">S17</infon><infon key="issue">Suppl 2</infon><infon key="pub-id_doi">10.1080/54-14660820050515665</infon><infon key="pub-id_pmid">11464936</infon><infon key="year">2000</infon><infon key="source">Amyotroph Lateral Scler Other Motor Neuron Disord</infon><infon key="type">ref</infon><infon key="lpage">22</infon><offset>59580</offset><text>Positron emission tomography (PET)--its potential to provide surrogate markers in ALS</text></passage><passage><infon key="volume">28</infon><infon key="name_2">surname:Rocca;given-names:MA</infon><infon key="name_1">surname:Pagani;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Agosta;given-names:F</infon><infon key="fpage">1430</infon><infon key="pub-id_doi">10.1002/hbm.20364</infon><infon key="pub-id_pmid">17370339</infon><infon key="year">2007</infon><infon key="source">Hum Brain Mapp</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>59666</offset><text>Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability</text></passage><passage><infon key="volume">8</infon><infon key="name_2">surname:Allsop;given-names:J</infon><infon key="name_1">surname:Hammers;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">343</infon><infon key="pub-id_doi">10.1080/17482960701538734</infon><infon key="pub-id_pmid">18033592</infon><infon key="year">2007</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>59794</offset><text>Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Wu;given-names:T</infon><infon key="name_2">surname:Danielian;given-names:LE</infon><infon key="name_1">surname:Meoded;given-names:A</infon><infon key="name_0">surname:Kwan;given-names:JY</infon><infon key="fpage">151</infon><infon key="pub-id_doi">10.1016/j.nicl.2012.12.003</infon><infon key="pub-id_pmid">24179768</infon><infon key="year">2012</infon><infon key="source">Neuroimage Clin</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="section_type">REF</infon><infon key="lpage">60</infon><infon key="name_4">surname:Floeter;given-names:MK</infon><offset>59874</offset><text>Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Knight;given-names:S</infon><infon key="name_2">surname:Mackay;given-names:CE</infon><infon key="name_1">surname:Douaud;given-names:G</infon><infon key="name_0">surname:Filippini;given-names:N</infon><infon key="fpage">1645</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3181fb84d1</infon><infon key="pub-id_pmid">21041787</infon><infon key="year">2010</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="volume">75</infon><infon key="section_type">REF</infon><infon key="lpage">52</infon><infon key="name_5">surname:Turner;given-names:MR</infon><infon key="name_4">surname:Talbot;given-names:K</infon><offset>59993</offset><text>Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">134</infon><infon key="name_2">surname:Danielian;given-names:LE</infon><infon key="name_1">surname:Kwan;given-names:JY</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Iwata;given-names:NK</infon><infon key="fpage">2642</infon><infon key="pub-id_doi">10.1093/brain/awr178</infon><infon key="pub-id_pmid">21798965</infon><infon key="year">2011</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">55</infon><offset>60078</offset><text>White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">134</infon><infon key="name_2">surname:Caan;given-names:MW</infon><infon key="name_1">surname:Sage;given-names:CA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:van der Graaff;given-names:MM</infon><infon key="fpage">1211</infon><infon key="pub-id_doi">10.1093/brain/awr016</infon><infon key="pub-id_pmid">21362631</infon><infon key="year">2011</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">28</infon><offset>60173</offset><text>Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study</text></passage><passage><infon key="volume">260</infon><infon key="name_2">surname:Machts;given-names:J</infon><infon key="name_1">surname:Kasper;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Schuster;given-names:C</infon><infon key="fpage">2856</infon><infon key="pub-id_doi">10.1007/s00415-013-7083-z</infon><infon key="pub-id_pmid">23996101</infon><infon key="year">2013</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="lpage">64</infon><offset>60274</offset><text>Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study</text></passage><passage><infon key="volume">86</infon><infon key="name_2">surname:Verstraete;given-names:E</infon><infon key="name_1">surname:Westeneng;given-names:HJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Walhout;given-names:R</infon><infon key="fpage">288</infon><infon key="pub-id_doi">10.1136/jnnp-2013-306839</infon><infon key="pub-id_pmid">25121571</infon><infon key="year">2015</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">94</infon><offset>60411</offset><text>Cortical thickness in ALS: towards a marker for upper motor neuron involvement</text></passage><passage><infon key="volume">259</infon><infon key="name_2">surname:Glass;given-names:A</infon><infon key="name_1">surname:Bissbort;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Prudlo;given-names:J</infon><infon key="fpage">1848</infon><infon key="pub-id_doi">10.1007/s00415-012-6420-y</infon><infon key="pub-id_pmid">22349938</infon><infon key="year">2012</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="lpage">59</infon><offset>60490</offset><text>White matter pathology in ALS and lower motor neuron ALS variants: a diffusion tensor imaging study using tract-based spatial statistics</text></passage><passage><infon key="name_3">surname:Kiernan;given-names:MC</infon><infon key="name_2">surname:Burrell;given-names:JR</infon><infon key="name_1">surname:Mioshi;given-names:E</infon><infon key="name_0">surname:Lillo;given-names:P</infon><infon key="pub-id_doi">10.1371/journal.pone.0043993</infon><infon key="pub-id_pmid">22952843</infon><infon key="year">2012</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e43993</infon><infon key="volume">7</infon><infon key="section_type">REF</infon><infon key="name_5">surname:Hornberger;given-names:M</infon><infon key="name_4">surname:Hodges;given-names:JR</infon><offset>60627</offset><text>Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum</text></passage><passage><infon key="volume">14</infon><infon key="name_2">surname:Caiazzo;given-names:G</infon><infon key="name_1">surname:Corbo;given-names:D</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Trojsi;given-names:F</infon><infon key="fpage">553</infon><infon key="pub-id_doi">10.3109/21678421.2013.785569</infon><infon key="pub-id_pmid">23586325</infon><infon key="year">2013</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">61</infon><offset>60732</offset><text>Motor and extramotor neurodegeneration in amyotrophic lateral sclerosis: a 3T high angular resolution diffusion imaging (HARDI) study</text></passage><passage><infon key="volume">17</infon><infon key="name_2">surname:Watanabe;given-names:H</infon><infon key="name_1">surname:Senda;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Masuda;given-names:M</infon><infon key="fpage">571</infon><infon key="pub-id_doi">10.1080/21678421.2016.1211151</infon><infon key="pub-id_pmid">27684890</infon><infon key="year">2016</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>60866</offset><text>Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum</text></passage><passage><infon key="name_3">surname:Henderson;given-names:R</infon><infon key="name_2">surname:Coulthard;given-names:A</infon><infon key="name_1">surname:Pannek;given-names:K</infon><infon key="name_0">surname:Alruwaili;given-names:AR</infon><infon key="fpage">41</infon><infon key="pub-id_doi">10.1016/j.neurad.2017.03.007</infon><infon key="pub-id_pmid">28802959</infon><infon key="year">2018</infon><infon key="source">J Neuroradiol</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="section_type">REF</infon><infon key="lpage">8</infon><infon key="name_5">surname:McCombe;given-names:P</infon><infon key="name_4">surname:Kurniawan;given-names:ND</infon><offset>60999</offset><text>A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis</text></passage><passage><infon key="name_3">surname:Dengler;given-names:R</infon><infon key="name_2">surname:Fradrich;given-names:J</infon><infon key="name_1">surname:Kaufmann;given-names:J</infon><infon key="name_0">surname:Grosskreutz;given-names:J</infon><infon key="fpage">17</infon><infon key="pub-id_doi">10.1186/1471-2377-6-17</infon><infon key="pub-id_pmid">16638121</infon><infon key="year">2006</infon><infon key="source">BMC Neurol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="section_type">REF</infon><infon key="name_5">surname:Peschel;given-names:T</infon><infon key="name_4">surname:Heinze;given-names:HJ</infon><offset>61169</offset><text>Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="volume">12</infon><infon key="name_2">surname:Woolley;given-names:SC</infon><infon key="name_1">surname:Schuff;given-names:N</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Zhang;given-names:Y</infon><infon key="fpage">421</infon><infon key="pub-id_doi">10.3109/17482968.2011.593036</infon><infon key="pub-id_pmid">21745124</infon><infon key="year">2011</infon><infon key="source">Amyotroph Lateral Scler</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>61255</offset><text>Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study</text></passage><passage><infon key="volume">70</infon><infon key="name_2">surname:Okabe;given-names:S</infon><infon key="name_1">surname:Aoki;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Iwata;given-names:NK</infon><infon key="fpage">528</infon><infon key="pub-id_doi">10.1212/01.wnl.0000299186.72374.19</infon><infon key="pub-id_pmid">18268244</infon><infon key="year">2008</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">32</infon><offset>61363</offset><text>Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation</text></passage><passage><infon key="name_3">surname:Hartung;given-names:V</infon><infon key="name_2">surname:Peschel;given-names:T</infon><infon key="name_1">surname:Prell;given-names:T</infon><infon key="name_0">surname:Keil;given-names:C</infon><infon key="fpage">141</infon><infon key="pub-id_doi">10.1186/1471-2202-13-141</infon><infon key="pub-id_pmid">23134591</infon><infon key="year">2012</infon><infon key="source">BMC Neurosci</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="section_type">REF</infon><infon key="name_5">surname:Grosskreutz;given-names:J</infon><infon key="name_4">surname:Dengler;given-names:R</infon><offset>61457</offset><text>Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">87</infon><infon key="name_2">surname:Grosskreutz;given-names:J</infon><infon key="name_1">surname:Turner;given-names:MR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Muller;given-names:HP</infon><infon key="fpage">570</infon><infon key="pub-id_doi">10.1136/jnnp-2015-311952</infon><infon key="pub-id_pmid">26746186</infon><infon key="year">2016</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>61528</offset><text>A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">8</infon><infon key="name_2">surname:Tortelli;given-names:R</infon><infon key="name_1">surname:D'Errico;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Mezzapesa;given-names:DM</infon><infon key="pub-id_doi">10.1371/journal.pone.0080748</infon><infon key="pub-id_pmid">24278317</infon><infon key="year">2013</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e80748</infon><offset>61627</offset><text>Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Hutchinson;given-names:S</infon><infon key="name_1">surname:Finegan;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Omer;given-names:T</infon><infon key="fpage">611</infon><infon key="pub-id_doi">10.1080/21678421.2017.1332077</infon><infon key="pub-id_pmid">28562080</infon><infon key="year">2017</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">23</infon><offset>61705</offset><text>Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study</text></passage><passage><infon key="volume">11</infon><infon key="name_2">surname:Acosta-Cabronero;given-names:J</infon><infon key="name_1">surname:Machts;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Cardenas-Blanco;given-names:A</infon><infon key="fpage">408</infon><infon key="pub-id_doi">10.1016/j.nicl.2016.03.011</infon><infon key="pub-id_pmid">27104135</infon><infon key="year">2016</infon><infon key="source">Neuroimage Clin</infon><infon key="type">ref</infon><infon key="lpage">14</infon><offset>61787</offset><text>Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:van den Heuvel;given-names:MP</infon><infon key="name_2">surname:van den Berg;given-names:LH</infon><infon key="name_1">surname:Veldink;given-names:JH</infon><infon key="name_0">surname:Verstraete;given-names:E</infon><infon key="fpage">1351</infon><infon key="pub-id_doi">10.1002/hbm.22258</infon><infon key="pub-id_pmid">23450820</infon><infon key="year">2014</infon><infon key="source">Hum Brain Mapp</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="section_type">REF</infon><infon key="lpage">61</infon><offset>61888</offset><text>Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">137</infon><infon key="name_2">surname:Del Tredici;given-names:K</infon><infon key="name_1">surname:Muller;given-names:HP</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kassubek;given-names:J</infon><infon key="fpage">1733</infon><infon key="pub-id_doi">10.1093/brain/awu090</infon><infon key="pub-id_pmid">24736303</infon><infon key="year">2014</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">40</infon><offset>62004</offset><text>Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology</text><annotation id="8357"><infon key="identifier">23435</infon><infon key="type">Gene</infon><location offset="62127" length="6" /><text>TDP-43</text></annotation></passage><passage><infon key="name_3">surname:Ludolph;given-names:AC</infon><infon key="name_2">surname:Hubers;given-names:A</infon><infon key="name_1">surname:Muller;given-names:HP</infon><infon key="name_0">surname:Rosenbohm;given-names:A</infon><infon key="fpage">2430</infon><infon key="pub-id_doi">10.1007/s00415-016-8281-2</infon><infon key="pub-id_pmid">27624123</infon><infon key="year">2016</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="volume">263</infon><infon key="section_type">REF</infon><infon key="lpage">7</infon><infon key="name_4">surname:Kassubek;given-names:J</infon><offset>62144</offset><text>Corticoefferent pathways in pure lower motor neuron disease: a diffusion tensor imaging study</text></passage><passage><infon key="volume">74</infon><infon key="name_2">surname:Toledo;given-names:JB</infon><infon key="name_1">surname:Del Tredici;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Brettschneider;given-names:J</infon><infon key="fpage">20</infon><infon key="pub-id_doi">10.1002/ana.23937</infon><infon key="pub-id_pmid">23686809</infon><infon key="year">2013</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">38</infon><offset>62238</offset><text>Stages of pTDP-43 pathology in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">21</infon><infon key="name_2">surname:Bradley;given-names:WG</infon><infon key="name_1">surname:Pattany;given-names:PM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Bowen;given-names:BC</infon><infon key="fpage">647</infon><infon key="pub-id_pmid">10782773</infon><infon key="year">2000</infon><infon key="source">AJNR Am J Neuroradiol</infon><infon key="type">ref</infon><infon key="lpage">58</infon><offset>62299</offset><text>MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Gelinas;given-names:DF</infon><infon key="name_2">surname:Schuff;given-names:N</infon><infon key="name_1">surname:Suhy;given-names:J</infon><infon key="name_0">surname:Rule;given-names:RR</infon><infon key="fpage">141</infon><infon key="pub-id_doi">10.1080/14660820410017109</infon><infon key="pub-id_pmid">15512902</infon><infon key="year">2004</infon><infon key="source">Amyotroph Lateral Scler Other Motor Neuron Disord</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><infon key="name_5">surname:Weiner;given-names:MW</infon><infon key="name_4">surname:Miller;given-names:RG</infon><offset>62401</offset><text>Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study</text></passage><passage><infon key="volume">12</infon><infon key="name_2">surname:Triantafyllou;given-names:C</infon><infon key="name_1">surname:Xu;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Atassi;given-names:N</infon><infon key="pub-id_doi">10.1371/journal.pone.0177680</infon><infon key="pub-id_pmid">28498852</infon><infon key="year">2017</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e0177680</infon><offset>62525</offset><text>Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="name_3">surname:Eberly;given-names:LE</infon><infon key="name_2">surname:Deelchand;given-names:DK</infon><infon key="name_1">surname:Marjanska;given-names:M</infon><infon key="name_0">surname:Cheong;given-names:I</infon><infon key="fpage">1833</infon><infon key="pub-id_doi">10.1007/s11064-017-2248-2</infon><infon key="pub-id_pmid">28367604</infon><infon key="year">2017</infon><infon key="source">Neurochem Res</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="section_type">REF</infon><infon key="lpage">44</infon><infon key="name_5">surname:Oz;given-names:G</infon><infon key="name_4">surname:Walk;given-names:D</infon><offset>62616</offset><text>Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="volume">32</infon><infon key="name_2">surname:Camicioli;given-names:R</infon><infon key="name_1">surname:Choi;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Usman;given-names:U</infon><infon key="fpage">1677</infon><infon key="pub-id_doi">10.3174/ajnr.A2590</infon><infon key="pub-id_pmid">21778247</infon><infon key="year">2011</infon><infon key="source">AJNR Am J Neuroradiol</infon><infon key="type">ref</infon><infon key="lpage">80</infon><offset>62701</offset><text>Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study</text></passage><passage><infon key="volume">58</infon><infon key="name_2">surname:Rule;given-names:R</infon><infon key="name_1">surname:Miller;given-names:RG</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Suhy;given-names:J</infon><infon key="fpage">773</infon><infon key="pub-id_doi">10.1212/WNL.58.5.773</infon><infon key="pub-id_pmid">11889242</infon><infon key="year">2002</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>62815</offset><text>Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI</text></passage><passage><infon key="volume">68</infon><infon key="name_2">surname:Pullman;given-names:SL</infon><infon key="name_1">surname:Ulug;given-names:AM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Mitsumoto;given-names:H</infon><infon key="fpage">1402</infon><infon key="pub-id_doi">10.1212/01.wnl.0000260065.57832.87</infon><infon key="pub-id_pmid">17452585</infon><infon key="year">2007</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">10</infon><offset>62902</offset><text>Quantitative objective markers for upper and lower motor neuron dysfunction in ALS</text></passage><passage><infon key="volume">1</infon><infon key="name_2">surname:Dwamena;given-names:BA</infon><infon key="name_1">surname:Carlos;given-names:RC</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Foerster;given-names:BR</infon><infon key="fpage">107</infon><infon key="pub-id_doi">10.1002/acn3.30</infon><infon key="pub-id_pmid">25356389</infon><infon key="year">2014</infon><infon key="source">Ann Clin Transl Neurol</infon><infon key="type">ref</infon><infon key="lpage">14</infon><offset>62985</offset><text>Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">145</infon><infon key="name_2">surname:Lee;given-names:SE</infon><infon key="name_1">surname:Chu;given-names:SA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hakkinen;given-names:S</infon><infon key="pub-id_doi">10.1016/j.nbd.2020.105063</infon><infon key="pub-id_pmid">32890771</infon><infon key="year">2020</infon><infon key="source">Neurobiol Dis</infon><infon key="type">ref</infon><infon key="elocation-id">105063</infon><offset>63060</offset><text>Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">71</infon><infon key="name_2">surname:Verschueren;given-names:J</infon><infon key="name_1">surname:Vanhee;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Van Laere;given-names:K</infon><infon key="fpage">553</infon><infon key="pub-id_doi">10.1001/jamaneurol.2014.62</infon><infon key="pub-id_pmid">24615479</infon><infon key="year">2014</infon><infon key="source">JAMA Neurol</infon><infon key="type">ref</infon><infon key="lpage">61</infon><offset>63142</offset><text>Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study</text></passage><passage><infon key="volume">83</infon><infon key="name_2">surname:Valentini;given-names:MC</infon><infon key="name_1">surname:Chio;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Pagani;given-names:M</infon><infon key="fpage">1067</infon><infon key="pub-id_doi">10.1212/WNL.0000000000000792</infon><infon key="pub-id_pmid">25122207</infon><infon key="year">2014</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">74</infon><offset>63255</offset><text>Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">37</infon><infon key="name_2">surname:De Carli;given-names:F</infon><infon key="name_1">surname:Oberg;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Pagani;given-names:M</infon><infon key="fpage">942</infon><infon key="pub-id_doi">10.1002/hbm.23078</infon><infon key="pub-id_pmid">26703938</infon><infon key="year">2016</infon><infon key="source">Hum Brain Mapp</infon><infon key="type">ref</infon><infon key="lpage">53</infon><offset>63324</offset><text>Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis</text></passage><passage><infon key="name_3">surname:Al-Chalabi;given-names:A</infon><infon key="name_2">surname:Brooks;given-names:DJ</infon><infon key="name_1">surname:Richardson;given-names:MP</infon><infon key="name_0">surname:Lloyd;given-names:CM</infon><infon key="fpage">2289</infon><infon key="pub-id_doi">10.1093/brain/123.11.2289</infon><infon key="pub-id_pmid">11050028</infon><infon key="year">2000</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="volume">123</infon><infon key="section_type">REF</infon><infon key="lpage">96</infon><infon key="name_4">surname:Leigh;given-names:PN</infon><offset>63434</offset><text>Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil</text></passage><passage><infon key="volume">377</infon><infon key="name_2">surname:Guo;given-names:Z</infon><infon key="name_1">surname:Zhu;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Fu;given-names:X</infon><infon key="fpage">79</infon><infon key="pub-id_doi">10.1016/j.jns.2017.03.013</infon><infon key="pub-id_pmid">28477714</infon><infon key="year">2017</infon><infon key="source">J Neurol Sci</infon><infon key="type">ref</infon><infon key="lpage">84</infon><offset>63519</offset><text> 18F-fallypride PET-CT of dopamine D2/D3 receptors in patients with sporadic amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">128</infon><infon key="name_2">surname:Hammers;given-names:A</infon><infon key="name_1">surname:Rabiner;given-names:EA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Turner;given-names:MR</infon><infon key="fpage">896</infon><infon key="pub-id_doi">10.1093/brain/awh428</infon><infon key="pub-id_pmid">15689356</infon><infon key="year">2005</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">905</infon><offset>63626</offset><text>[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS</text></passage><passage><infon key="volume">7</infon><infon key="name_2">surname:Lawson;given-names:R</infon><infon key="name_1">surname:Loggia;given-names:ML</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Zurcher;given-names:NR</infon><infon key="fpage">409</infon><infon key="pub-id_doi">10.1016/j.nicl.2015.01.009</infon><infon key="pub-id_pmid">25685708</infon><infon key="year">2015</infon><infon key="source">Neuroimage Clin</infon><infon key="type">ref</infon><infon key="lpage">14</infon><offset>63706</offset><text>Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28</text></passage><passage><infon key="volume">83</infon><infon key="name_2">surname:Loggia;given-names:ML</infon><infon key="name_1">surname:Zurcher;given-names:NR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Alshikho;given-names:MJ</infon><infon key="fpage">1186</infon><infon key="pub-id_doi">10.1002/ana.25251</infon><infon key="pub-id_pmid">29740862</infon><infon key="year">2018</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">97</infon><offset>63817</offset><text>Integrated magnetic resonance imaging and [11 C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">20</infon><infon key="name_2">surname:Zurcher;given-names:NR</infon><infon key="name_1">surname:Alshikho;given-names:MJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ratai;given-names:EM</infon><infon key="fpage">357</infon><infon key="pub-id_doi">10.1016/j.nicl.2018.08.007</infon><infon key="pub-id_pmid">30112276</infon><infon key="year">2018</infon><infon key="source">Neuroimage Clin</infon><infon key="type">ref</infon><infon key="lpage">64</infon><offset>63943</offset><text>Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">252</infon><infon key="name_2">surname:Gaul;given-names:C</infon><infon key="name_1">surname:Tempelmann;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Schoenfeld;given-names:MA</infon><infon key="fpage">944</infon><infon key="pub-id_doi">10.1007/s00415-005-0787-y</infon><infon key="pub-id_pmid">15750701</infon><infon key="year">2005</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="lpage">52</infon><offset>64071</offset><text>Functional motor compensation in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">172</infon><infon key="name_2">surname:Henningsen;given-names:H</infon><infon key="name_1">surname:Jansen;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Konrad;given-names:C</infon><infon key="fpage">361</infon><infon key="pub-id_doi">10.1007/s00221-006-0352-7</infon><infon key="pub-id_pmid">16463149</infon><infon key="year">2006</infon><infon key="source">Exp Brain Res</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>64134</offset><text>Subcortical reorganization in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">254</infon><infon key="name_2">surname:Leigh;given-names:PN</infon><infon key="name_1">surname:Williams;given-names:VC</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Stanton;given-names:BR</infon><infon key="fpage">1260</infon><infon key="pub-id_doi">10.1007/s00415-006-0513-4</infon><infon key="pub-id_pmid">17385077</infon><infon key="year">2007</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>64194</offset><text>Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways</text></passage><passage><infon key="volume">27</infon><infon key="name_2">surname:Couillandre;given-names:A</infon><infon key="name_1">surname:de Marco;given-names:G</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Abidi;given-names:M</infon><infon key="fpage">121</infon><infon key="pub-id_doi">10.1111/ene.14042</infon><infon key="pub-id_pmid">31310452</infon><infon key="year">2020</infon><infon key="source">Eur J Neurol</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>64295</offset><text>Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes</text></passage><passage><infon key="name_3">surname:Talbot;given-names:K</infon><infon key="name_2">surname:Knight;given-names:S</infon><infon key="name_1">surname:Filippini;given-names:N</infon><infon key="name_0">surname:Douaud;given-names:G</infon><infon key="fpage">3470</infon><infon key="pub-id_doi">10.1093/brain/awr279</infon><infon key="pub-id_pmid">22075069</infon><infon key="year">2011</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="volume">134</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><infon key="name_4">surname:Turner;given-names:MR</infon><offset>64413</offset><text>Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Turner;given-names:MR</infon><infon key="name_2">surname:Talbot;given-names:K</infon><infon key="name_1">surname:Proudfoot;given-names:M</infon><infon key="name_0">surname:Menke;given-names:RAL</infon><infon key="fpage">953</infon><infon key="pub-id_doi">10.1016/j.nicl.2017.12.025</infon><infon key="pub-id_pmid">29321969</infon><infon key="year">2017</infon><infon key="source">Neuroimage Clin</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="lpage">61</infon><offset>64514</offset><text>The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">21</infon><infon key="name_2">surname:Absinta;given-names:M</infon><infon key="name_1">surname:Valsasina;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Agosta;given-names:F</infon><infon key="fpage">2291</infon><infon key="pub-id_doi">10.1093/cercor/bhr002</infon><infon key="pub-id_pmid">21368084</infon><infon key="year">2011</infon><infon key="source">Cereb Cortex</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>64614</offset><text>Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">50</infon><infon key="name_2">surname:Chan;given-names:KM</infon><infon key="name_1">surname:Doherty;given-names:TJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gooch;given-names:CL</infon><infon key="fpage">884</infon><infon key="pub-id_doi">10.1002/mus.24442</infon><infon key="pub-id_pmid">25186553</infon><infon key="year">2014</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">93</infon><offset>64692</offset><text>Motor unit number estimation: a technology and literature review</text></passage><passage><infon key="volume">10</infon><infon key="name_2">surname:Sassani;given-names:M</infon><infon key="name_1">surname:Shepheard;given-names:SR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Verber;given-names:NS</infon><infon key="fpage">291</infon><infon key="pub-id_doi">10.3389/fneur.2019.00291</infon><infon key="pub-id_pmid">31001186</infon><infon key="year">2019</infon><infon key="source">Front Neurol</infon><infon key="type">ref</infon><offset>64757</offset><text>Biomarkers in Motor Neuron Disease: A State of the Art Review</text></passage><passage><infon key="name_3">surname:Schoenfeld;given-names:D</infon><infon key="name_2">surname:Zhang;given-names:H</infon><infon key="name_1">surname:Cudkowicz;given-names:ME</infon><infon key="name_0">surname:Shefner;given-names:JM</infon><infon key="fpage">463</infon><infon key="pub-id_doi">10.1002/mus.20120</infon><infon key="pub-id_pmid">15316983</infon><infon key="year">2004</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><infon key="name_4">surname:Jillapalli;given-names:D</infon><offset>64819</offset><text>The use of statistical MUNE in a multicenter clinical trial</text></passage><passage><infon key="volume">41</infon><infon key="name_1">surname:Swash;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:de Carvalho;given-names:M</infon><infon key="fpage">208</infon><infon key="pub-id_pmid">19697379</infon><infon key="year">2010</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">11</infon><offset>64879</offset><text>Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: a six-month longitudinal study</text></passage><passage><infon key="volume">77</infon><infon key="name_2">surname:Simionescu;given-names:L</infon><infon key="name_1">surname:Watson;given-names:ML</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Shefner;given-names:JM</infon><infon key="fpage">235</infon><infon key="pub-id_doi">10.1212/WNL.0b013e318225aabf</infon><infon key="pub-id_pmid">21676915</infon><infon key="year">2011</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">41</infon><offset>65005</offset><text>Multipoint incremental motor unit number estimation as an outcome measure in ALS</text></passage><passage><infon key="volume">53</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Bostock;given-names:H</infon><infon key="fpage">889</infon><infon key="pub-id_doi">10.1002/mus.24945</infon><infon key="pub-id_pmid">26479267</infon><infon key="year">2016</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">96</infon><offset>65086</offset><text>Estimating motor unit numbers from a CMAP scan</text></passage><passage><infon key="volume">128</infon><infon key="name_2">surname:Fuglsang-Frederiksen;given-names:A</infon><infon key="name_1">surname:Bostock;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Jacobsen;given-names:AB</infon><infon key="fpage">1380</infon><infon key="pub-id_doi">10.1016/j.clinph.2017.03.045</infon><infon key="pub-id_pmid">28461135</infon><infon key="year">2017</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>65133</offset><text>Reproducibility, and sensitivity to motor unit loss in amyotrophic lateral sclerosis, of a novel MUNE method: MScanFit MUNE</text></passage><passage><infon key="volume">42</infon><infon key="name_2">surname:Stalberg;given-names:EV</infon><infon key="name_1">surname:Barkhaus;given-names:PE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Nandedkar;given-names:SD</infon><infon key="fpage">798</infon><infon key="pub-id_doi">10.1002/mus.21824</infon><infon key="pub-id_pmid">20976783</infon><infon key="year">2010</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">807</infon><offset>65257</offset><text>Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease</text></passage><passage><infon key="volume">86</infon><infon key="name_2">surname:Burkhardt;given-names:C</infon><infon key="name_1">surname:Barkhaus;given-names:PE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Neuwirth;given-names:C</infon><infon key="fpage">1172</infon><infon key="pub-id_doi">10.1136/jnnp-2015-310509</infon><infon key="pub-id_pmid">25935892</infon><infon key="year">2015</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>65384</offset><text>Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial</text></passage><passage><infon key="volume">129</infon><infon key="name_2">surname:Claeys;given-names:KG</infon><infon key="name_1">surname:Braun;given-names:N</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Neuwirth;given-names:C</infon><infon key="fpage">1756</infon><infon key="pub-id_doi">10.1016/j.clinph.2018.04.614</infon><infon key="pub-id_pmid">29803404</infon><infon key="year">2018</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="lpage">62</infon><offset>65553</offset><text>Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres</text></passage><passage><infon key="volume">58</infon><infon key="name_2">surname:Nunes;given-names:KF</infon><infon key="name_1">surname:Abrahao;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Escorcio-Bezerra;given-names:ML</infon><infon key="fpage">204</infon><infon key="pub-id_doi">10.1002/mus.26087</infon><infon key="pub-id_pmid">29381812</infon><infon key="year">2018</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">12</infon><offset>65663</offset><text>Motor unit number index and neurophysiological index as candidate biomarkers of presymptomatic motor neuron loss in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Hallett;given-names:M</infon><infon key="name_2">surname:Eisen;given-names:A</infon><infon key="name_1">surname:Ziemann;given-names:U</infon><infon key="name_0">surname:Vucic;given-names:S</infon><infon key="fpage">1161</infon><infon key="pub-id_doi">10.1136/jnnp-2012-304019</infon><infon key="pub-id_pmid">23264687</infon><infon key="year">2013</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="section_type">REF</infon><infon key="lpage">70</infon><infon key="name_4">surname:Kiernan;given-names:MC</infon><offset>65809</offset><text>Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights</text></passage><passage><infon key="volume">129</infon><infon key="name_1">surname:Kiernan;given-names:MC</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Vucic;given-names:S</infon><infon key="fpage">2436</infon><infon key="pub-id_doi">10.1093/brain/awl172</infon><infon key="pub-id_pmid">16835248</infon><infon key="year">2006</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>65906</offset><text>Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease</text></passage><passage><infon key="name_3">surname:Refatti;given-names:N</infon><infon key="name_2">surname:Manganotti;given-names:P</infon><infon key="name_1">surname:Tamburin;given-names:S</infon><infon key="name_0">surname:Zanette;given-names:G</infon><infon key="fpage">1723</infon><infon key="pub-id_doi">10.1007/s00415-002-0926-7</infon><infon key="pub-id_pmid">12529797</infon><infon key="year">2002</infon><infon key="source">J Neurol</infon><infon key="type">ref</infon><infon key="volume">249</infon><infon key="section_type">REF</infon><infon key="lpage">8</infon><infon key="name_5">surname:Rizzuto;given-names:N</infon><infon key="name_4">surname:Forgione;given-names:A</infon><offset>66026</offset><text>Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">72</infon><infon key="name_2">surname:Piboolnurak;given-names:P</infon><infon key="name_1">surname:Yu;given-names:QP</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Floyd;given-names:AG</infon><infon key="fpage">498</infon><infon key="pub-id_doi">10.1212/01.wnl.0000341933.97883.a4</infon><infon key="pub-id_pmid">19204259</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">504</infon><offset>66118</offset><text>Transcranial magnetic stimulation in ALS: utility of central motor conduction tests</text></passage><passage><infon key="name_3">surname:Sanchez;given-names:B</infon><infon key="volume">6</infon><infon key="name_2">surname:Rutkove;given-names:SB</infon><infon key="name_1">surname:DiDonato;given-names:CJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Nagy;given-names:JA</infon><infon key="fpage">37</infon><infon key="pub-id_doi">10.1038/s41597-019-0045-2</infon><infon key="pub-id_pmid">31000708</infon><infon key="year">2019</infon><infon key="source">Sci Data</infon><infon key="type">ref</infon><offset>66202</offset><text>Permittivity of ex vivo healthy and diseased murine skeletal muscle from 10 kHz to 1 MHz</text></passage><passage><infon key="volume">9</infon><infon key="name_1">surname:Sanchez;given-names:B</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rutkove;given-names:SB</infon><infon key="pub-id_doi">10.1101/cshperspect.a034405</infon><infon key="pub-id_pmid">30291145</infon><infon key="year">2019</infon><infon key="source">Cold Spring Harb Perspect Med</infon><infon key="type">ref</infon><infon key="elocation-id">a034405</infon><offset>66295</offset><text>Electrical Impedance Methods in Neuromuscular Assessment: An Overview</text></passage><passage><infon key="volume">7</infon><infon key="name_2">surname:Berisha;given-names:V</infon><infon key="name_1">surname:Narayanaswami;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rutkove;given-names:SB</infon><infon key="fpage">1148</infon><infon key="pub-id_doi">10.1002/acn3.51096</infon><infon key="pub-id_pmid">32515889</infon><infon key="year">2020</infon><infon key="source">Ann Clin Transl Neurol</infon><infon key="type">ref</infon><infon key="lpage">57</infon><offset>66365</offset><text>Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study</text></passage><passage><infon key="volume">132</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Sanchez;given-names:B</infon><infon key="fpage">1754</infon><infon key="pub-id_doi">10.1016/j.clinph.2021.03.019</infon><infon key="pub-id_pmid">33941477</infon><infon key="year">2021</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="lpage">5</infon><offset>66461</offset><text>Reply to "Putting the patient first: The validity and value of surface-based electrical impedance myography techniques"</text></passage><passage><infon key="volume">132</infon><infon key="name_2">surname:David Arnold;given-names:W</infon><infon key="name_1">surname:Narayanaswami;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rutkove;given-names:SB</infon><infon key="fpage">1752</infon><infon key="pub-id_doi">10.1016/j.clinph.2021.03.020</infon><infon key="pub-id_pmid">33896693</infon><infon key="year">2021</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="lpage">3</infon><offset>66585</offset><text>Putting the patient first: The validity and value of surface-based electrical impedance myography techniques</text></passage><passage><infon key="name_3">surname:Furse;given-names:CM</infon><infon key="name_2">surname:Freeborn;given-names:TJ</infon><infon key="name_1">surname:Martinsen;given-names:OG</infon><infon key="name_0">surname:Sanchez;given-names:B</infon><infon key="fpage">338</infon><infon key="pub-id_doi">10.1016/j.clinph.2020.11.014</infon><infon key="pub-id_pmid">33450556</infon><infon key="year">2021</infon><infon key="source">Clin Neurophysiol</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="section_type">REF</infon><infon key="lpage">44</infon><offset>66694</offset><text>Electrical impedance myography: A critical review and outlook</text></passage><passage><infon key="volume">53</infon><infon key="name_2">surname:Jeromin;given-names:A</infon><infon key="name_1">surname:Boylan;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Benatar;given-names:M</infon><infon key="fpage">169</infon><infon key="pub-id_doi">10.1002/mus.24979</infon><infon key="pub-id_pmid">26574709</infon><infon key="year">2016</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">82</infon><offset>66756</offset><text>ALS biomarkers for therapy development: State of the field and future directions</text></passage><passage><infon key="volume">82</infon><infon key="name_2">surname:Heckman;given-names:MG</infon><infon key="name_1">surname:Daughrity;given-names:LM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gendron;given-names:TF</infon><infon key="fpage">139</infon><infon key="pub-id_doi">10.1002/ana.24980</infon><infon key="pub-id_pmid">28628244</infon><infon key="year">2017</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>66837</offset><text>Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis</text><annotation id="8358"><infon key="identifier">203228</infon><infon key="type">Gene</infon><location offset="66907" length="7" /><text>C9ORF72</text></annotation></passage><passage><infon key="volume">84</infon><infon key="name_2">surname:Crook;given-names:JE</infon><infon key="name_1">surname:Glass;given-names:JD</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Boylan;given-names:KB</infon><infon key="fpage">467</infon><infon key="pub-id_doi">10.1136/jnnp-2012-303768</infon><infon key="pub-id_pmid">23117489</infon><infon key="year">2013</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="lpage">72</infon><offset>66956</offset><text>Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Lombardi;given-names:V</infon><infon key="name_2">surname:Andersen;given-names:PM</infon><infon key="name_1">surname:Wuu;given-names:J</infon><infon key="name_0">surname:Benatar;given-names:M</infon><infon key="fpage">130</infon><infon key="pub-id_doi">10.1002/ana.25276</infon><infon key="pub-id_pmid">30014505</infon><infon key="year">2018</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><infon key="name_4">surname:Malaspina;given-names:A</infon><offset>67104</offset><text>Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion</text></passage><passage><infon key="volume">28</infon><infon key="name_2">surname:Campbell;given-names:TG</infon><infon key="name_1">surname:Kan;given-names:CW</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rissin;given-names:DM</infon><infon key="fpage">595</infon><infon key="pub-id_doi">10.1038/nbt.1641</infon><infon key="pub-id_pmid">20495550</infon><infon key="year">2010</infon><infon key="source">Nat Biotechnol</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>67215</offset><text>Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations</text></passage><passage><infon key="volume">88</infon><infon key="name_2">surname:Stubendorff;given-names:B</infon><infon key="name_1">surname:De Schaepdryver;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Poesen;given-names:K</infon><infon key="fpage">2302</infon><infon key="pub-id_doi">10.1212/WNL.0000000000004029</infon><infon key="pub-id_pmid">28500227</infon><infon key="year">2017</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>67320</offset><text>Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease</text></passage><passage><infon key="volume">24</infon><infon key="name_2">surname:Yanowski;given-names:E</infon><infon key="name_1">surname:Yacovzada;given-names:NS</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Magen;given-names:I</infon><infon key="fpage">1534</infon><infon key="pub-id_doi">10.1038/s41593-021-00936-z</infon><infon key="pub-id_pmid">34711961</infon><infon key="year">2021</infon><infon key="source">Nat Neurosci</infon><infon key="type">ref</infon><infon key="lpage">41</infon><offset>67412</offset><text>Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Rush;given-names:RA</infon><infon key="name_2">surname:Schultz;given-names:DW</infon><infon key="name_1">surname:Chataway;given-names:T</infon><infon key="name_0">surname:Shepheard;given-names:SR</infon><infon key="pub-id_doi">10.1371/journal.pone.0087398</infon><infon key="pub-id_pmid">24475283</infon><infon key="year">2014</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e87398</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="name_4">surname:Rogers;given-names:ML</infon><offset>67492</offset><text>The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis</text><annotation id="8359"><infon key="identifier">7133</infon><infon key="type">Gene</infon><location offset="67542" length="3" /><text>p75</text></annotation></passage><passage><infon key="name_3">surname:Gendron;given-names:T</infon><infon key="name_2">surname:Kovalik;given-names:T</infon><infon key="name_1">surname:An;given-names:J</infon><infon key="name_0">surname:Vu;given-names:L</infon><infon key="fpage">350</infon><infon key="pub-id_doi">10.1136/jnnp-2019-321916</infon><infon key="pub-id_pmid">31937582</infon><infon key="year">2020</infon><infon key="source">J Neurol Neurosurg Psychiatry</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="section_type">REF</infon><infon key="lpage">8</infon><infon key="name_5">surname:Bowser;given-names:R</infon><infon key="name_4">surname:Petrucelli;given-names:L</infon><offset>67605</offset><text>Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes</text><annotation id="8360"><infon key="identifier">1116</infon><infon key="type">Gene</infon><location offset="67720" length="6" /><text>CHI3L1</text></annotation></passage><passage><infon key="volume">7</infon><infon key="name_2">surname:Wuu;given-names:J</infon><infon key="name_1">surname:Thompson;given-names:AG</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gray;given-names:E</infon><infon key="fpage">1296</infon><infon key="pub-id_doi">10.1002/acn3.51114</infon><infon key="pub-id_pmid">32666680</infon><infon key="year">2020</infon><infon key="source">Ann Clin Transl Neurol</infon><infon key="type">ref</infon><infon key="lpage">306</infon><offset>67751</offset><text>CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">273</infon><infon key="name_2">surname:Verhoek;given-names:M</infon><infon key="name_1">surname:Renkema;given-names:GH</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Boot;given-names:RG</infon><infon key="fpage">25680</infon><infon key="pub-id_doi">10.1074/jbc.273.40.25680</infon><infon key="pub-id_pmid">9748235</infon><infon key="year">1998</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="lpage">5</infon><offset>67830</offset><text>The human chitotriosidase gene. Nature of inherited enzyme deficiency</text></passage><passage><infon key="volume">73</infon><infon key="name_2">surname:Kasarskis;given-names:EJ</infon><infon key="name_1">surname:Jackson;given-names:CE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Miller;given-names:RG</infon><infon key="fpage">1227</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3181bc01a4</infon><infon key="pub-id_pmid">19822873</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">33</infon><offset>67900</offset><text>Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</text></passage><passage><infon key="volume">19</infon><infon key="name_2">surname:Borasio;given-names:GD</infon><infon key="name_1">surname:Abrahams;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Andersen;given-names:PM</infon><infon key="fpage">360</infon><infon key="pub-id_doi">10.1111/j.1468-1331.2011.03501.x</infon><infon key="pub-id_pmid">21914052</infon><infon key="year">2012</infon><infon key="source">Eur J Neurol</infon><infon key="type">ref</infon><infon key="lpage">75</infon><offset>68177</offset><text>EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force</text></passage><passage><infon key="volume">167</infon><infon key="name_2">surname:Mora;given-names:G</infon><infon key="name_1">surname:Mazzini;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chio;given-names:A</infon><infon key="pub-id_doi">10.1016/j.neuropharm.2020.107986</infon><infon key="pub-id_pmid">32062193</infon><infon key="year">2020</infon><infon key="source">Neuropharmacology</infon><infon key="type">ref</infon><infon key="elocation-id">107986</infon><offset>68298</offset><text>Disease-modifying therapies in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">330</infon><infon key="name_2">surname:Meininger;given-names:V</infon><infon key="name_1">surname:Lacomblez;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Bensimon;given-names:G</infon><infon key="fpage">585</infon><infon key="pub-id_doi">10.1056/NEJM199403033300901</infon><infon key="pub-id_pmid">8302340</infon><infon key="year">1994</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">91</infon><offset>68359</offset><text>A controlled trial of riluzole in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Guillet;given-names:P</infon><infon key="name_2">surname:Leigh;given-names:PN</infon><infon key="name_1">surname:Bensimon;given-names:G</infon><infon key="name_0">surname:Lacomblez;given-names:L</infon><infon key="fpage">1425</infon><infon key="pub-id_doi">10.1016/S0140-6736(96)91680-3</infon><infon key="pub-id_pmid">8676624</infon><infon key="year">1996</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">347</infon><infon key="section_type">REF</infon><infon key="lpage">31</infon><infon key="name_4">surname:Meininger;given-names:V</infon><offset>68423</offset><text>Dose-ranging study of riluzole in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">16</infon><infon key="section_type">REF</infon><infon key="fpage">505</infon><infon key="pub-id_doi">10.1016/S1474-4422(17)30115-1</infon><infon key="pub-id_pmid">28522181</infon><infon key="year">2017</infon><infon key="source">Lancet Neurol</infon><infon key="type">ref</infon><infon key="lpage">12</infon><offset>68487</offset><text>Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial</text></passage><passage><infon key="name_3">surname:Liu;given-names:S</infon><infon key="name_2">surname:Wiedau-Pazos;given-names:M</infon><infon key="name_1">surname:Heiman-Patterson;given-names:T</infon><infon key="name_0">surname:Brooks;given-names:BR</infon><infon key="pub-id_doi">10.1371/journal.pone.0258614</infon><infon key="pub-id_pmid">35700157</infon><infon key="year">2022</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e0258614</infon><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="comment">[clinical trial NCT01492686]</infon><infon key="name_5">surname:Apple;given-names:S</infon><infon key="name_4">surname:Zhang;given-names:J</infon><offset>68634</offset><text>Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]</text></passage><passage><infon key="volume">383</infon><infon key="name_2">surname:Hendrix;given-names:S</infon><infon key="name_1">surname:Macklin;given-names:EA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Paganoni;given-names:S</infon><infon key="fpage">919</infon><infon key="pub-id_doi">10.1056/NEJMoa1916945</infon><infon key="pub-id_pmid">32877582</infon><infon key="year">2020</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">30</infon><offset>68793</offset><text>Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="volume">387</infon><infon key="name_2">surname:Genge;given-names:A</infon><infon key="name_1">surname:Cudkowicz;given-names:ME</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Miller;given-names:TM</infon><infon key="fpage">1099</infon><infon key="pub-id_doi">10.1056/NEJMoa2204705</infon><infon key="pub-id_pmid">36129998</infon><infon key="year">2022</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">110</infon><offset>68871</offset><text>Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS</text><annotation id="8361"><infon key="identifier">6647</infon><infon key="type">Gene</infon><location offset="68919" length="4" /><text>SOD1</text></annotation></passage><passage><infon key="name_3">surname:Palumbo;given-names:J</infon><infon key="name_2">surname:Tsuda;given-names:K</infon><infon key="name_1">surname:Takei;given-names:K</infon><infon key="name_0">surname:Takahashi;given-names:F</infon><infon key="fpage">32</infon><infon key="issue">sup1</infon><infon key="pub-id_doi">10.1080/21678421.2017.1361442</infon><infon key="pub-id_pmid">28872914</infon><infon key="year">2017</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="section_type">REF</infon><infon key="lpage">9</infon><offset>68928</offset><text>Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Chandran;given-names:S</infon><infon key="name_1">surname:Andersen;given-names:PM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Al-Chalabi;given-names:A</infon><infon key="fpage">471</infon><infon key="pub-id_doi">10.1080/21678421.2017.1369125</infon><infon key="pub-id_pmid">28975816</infon><infon key="year">2017</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">4</infon><offset>69112</offset><text>July 2017 ENCALS statement on edaravone</text></passage><passage><infon key="volume">79</infon><infon key="name_1">surname:Fournier;given-names:CN</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Glass;given-names:JD</infon><infon key="fpage">117</infon><infon key="pub-id_doi">10.1001/jamaneurol.2021.4193</infon><infon key="pub-id_pmid">35006259</infon><infon key="year">2022</infon><infon key="source">JAMA Neurol</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>69152</offset><text>Unintended Consequences of Approving Unproven Treatments-Hope, Hype, or Harm?</text></passage><passage><infon key="volume">73</infon><infon key="name_2">surname:Kasarskis;given-names:EJ</infon><infon key="name_1">surname:Jackson;given-names:CE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Miller;given-names:RG</infon><infon key="fpage">1218</infon><infon key="pub-id_doi">10.1212/WNL.0b013e3181bc0141</infon><infon key="pub-id_pmid">19822872</infon><infon key="year">2009</infon><infon key="source">Neurology</infon><infon key="type">ref</infon><infon key="lpage">26</infon><offset>69230</offset><text>Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</text></passage><passage><infon key="volume">19</infon><infon key="name_2">surname:de Carvalho;given-names:M</infon><infon key="name_1">surname:Cudkowicz;given-names:ME</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lechtzin;given-names:N</infon><infon key="fpage">321</infon><infon key="pub-id_doi">10.1080/21678421.2018.1452945</infon><infon key="pub-id_pmid">29566571</infon><infon key="year">2018</infon><infon key="source">Amyotroph Lateral Scler Frontotemporal Degener</infon><infon key="type">ref</infon><infon key="lpage">30</infon><offset>69472</offset><text>Respiratory measures in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Bullock;given-names:RE</infon><infon key="name_2">surname:Williams;given-names:TL</infon><infon key="name_1">surname:Tomlinson;given-names:M</infon><infon key="name_0">surname:Bourke;given-names:SC</infon><infon key="fpage">140</infon><infon key="pub-id_doi">10.1016/S1474-4422(05)70326-4</infon><infon key="pub-id_pmid">16426990</infon><infon key="year">2006</infon><infon key="source">Lancet Neurol</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="section_type">REF</infon><infon key="lpage">7</infon><infon key="name_5">surname:Gibson;given-names:GJ</infon><infon key="name_4">surname:Shaw;given-names:PJ</infon><offset>69526</offset><text>Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial</text></passage><passage><infon key="volume">54</infon><infon key="name_2">surname:Tabor;given-names:L</infon><infon key="name_1">surname:Watts;given-names:SA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Plowman;given-names:EK</infon><infon key="fpage">48</infon><infon key="pub-id_doi">10.1002/mus.24990</infon><infon key="pub-id_pmid">26599236</infon><infon key="year">2016</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="lpage">53</infon><offset>69672</offset><text>Impact of expiratory strength training in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">16</infon><infon key="name_2">surname:McPherson;given-names:T</infon><infon key="name_1">surname:Kazamel;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lee;given-names:I</infon><infon key="pub-id_doi">10.1371/journal.pone.0251087</infon><infon key="pub-id_pmid">33956876</infon><infon key="year">2021</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e0251087</infon><offset>69744</offset><text>Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy x-ray absorptiometry in a prospective study</text></passage><passage><infon key="name_3">surname:Loeffler;given-names:JP</infon><infon key="name_2">surname:Ludolph;given-names:AC</infon><infon key="name_1">surname:Pradat;given-names:PF</infon><infon key="name_0">surname:Dupuis;given-names:L</infon><infon key="fpage">75</infon><infon key="pub-id_doi">10.1016/S1474-4422(10)70224-6</infon><infon key="pub-id_pmid">21035400</infon><infon key="year">2011</infon><infon key="source">Lancet Neurol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><infon key="lpage">82</infon><offset>69925</offset><text>Energy metabolism in amyotrophic lateral sclerosis</text></passage><passage><infon key="name_3">surname:Cudkowicz;given-names:ME</infon><infon key="name_2">surname:Jaffa;given-names:M</infon><infon key="name_1">surname:Deng;given-names:J</infon><infon key="name_0">surname:Paganoni;given-names:S</infon><infon key="fpage">20</infon><infon key="pub-id_doi">10.1002/mus.22114</infon><infon key="pub-id_pmid">21607987</infon><infon key="year">2011</infon><infon key="source">Muscle Nerve</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="section_type">REF</infon><infon key="lpage">4</infon><infon key="name_4">surname:Wills;given-names:AM</infon><offset>69976</offset><text>Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis</text></passage><passage><infon key="volume">73</infon><infon key="name_2">surname:Factor-Litvak;given-names:P</infon><infon key="name_1">surname:Gennings;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Nieves;given-names:JW</infon><infon key="fpage">1425</infon><infon key="pub-id_doi">10.1001/jamaneurol.2016.3401</infon><infon key="pub-id_pmid">27775751</infon><infon key="year">2016</infon><infon key="source">JAMA Neurol</infon><infon key="type">ref</infon><infon key="lpage">32</infon><offset>70084</offset><text>Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis</text></passage><passage><infon key="volume">15</infon><infon key="name_1">surname:Grosskreutz;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Prell;given-names:T</infon><infon key="pub-id_doi">10.1371/journal.pone.0237175</infon><infon key="pub-id_pmid">32790757</infon><infon key="year">2020</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="elocation-id">e0237175</infon><offset>70165</offset><text>Use of vitamins by participants in amyotrophic lateral sclerosis clinical trials</text></passage><passage><infon key="volume">66</infon><infon key="name_2">surname:Levy;given-names:G</infon><infon key="name_1">surname:Thompson;given-names:JL</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kaufmann;given-names:P</infon><infon key="fpage">235</infon><infon key="pub-id_doi">10.1002/ana.21743</infon><infon key="pub-id_pmid">19743457</infon><infon key="year">2009</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">44</infon><offset>70246</offset><text>Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III</text></passage><passage><infon key="volume">79</infon><infon key="name_2">surname:Fujita;given-names:K</infon><infon key="name_1">surname:Izumi;given-names:Y</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Oki;given-names:R</infon><infon key="fpage">575</infon><infon key="pub-id_doi">10.1001/jamaneurol.2022.0901</infon><infon key="pub-id_pmid">35532908</infon><infon key="year">2022</infon><infon key="source">JAMA Neurol</infon><infon key="type">ref</infon><infon key="lpage">83</infon><offset>70327</offset><text>Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial</text></passage><passage><infon key="volume">173</infon><infon key="name_2">surname:Weisskopf;given-names:MG</infon><infon key="name_1">surname:O'Reilly;given-names:EJ</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wang;given-names:H</infon><infon key="fpage">595</infon><infon key="pub-id_doi">10.1093/aje/kwq416</infon><infon key="pub-id_pmid">21335424</infon><infon key="year">2011</infon><infon key="source">Am J Epidemiol</infon><infon key="type">ref</infon><infon key="lpage">602</infon><offset>70455</offset><text>Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies</text></passage><passage><infon key="volume">91</infon><infon key="name_2">surname:Quintana;given-names:M</infon><infon key="name_1">surname:Berry;given-names:JD</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Paganoni;given-names:S</infon><infon key="fpage">165</infon><infon key="pub-id_doi">10.1002/ana.26285</infon><infon key="pub-id_pmid">34935174</infon><infon key="year">2022</infon><infon key="source">Ann Neurol</infon><infon key="type">ref</infon><infon key="lpage">75</infon><offset>70575</offset><text>Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development</text></passage><passage><infon key="volume">82</infon><infon key="name_2">surname:De Marchi;given-names:F</infon><infon key="name_1">surname:Fang;given-names:T</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Johnson;given-names:SA</infon><infon key="fpage">1367</infon><infon key="pub-id_doi">10.1007/s40265-022-01769-1</infon><infon key="pub-id_pmid">36121612</infon><infon key="year">2022</infon><infon key="source">Drugs</infon><infon key="type">ref</infon><infon key="lpage">88</infon><offset>70663</offset><text>Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents</text></passage><passage><infon key="volume">29</infon><infon key="name_2">surname:Shaw;given-names:R</infon><infon key="name_1">surname:Rozhkov;given-names:NV</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Tam;given-names:OH</infon><infon key="fpage">1164</infon><infon key="pub-id_doi">10.1016/j.celrep.2019.09.066</infon><infon key="pub-id_pmid">31665631</infon><infon key="year">2019</infon><infon key="source">Cell Rep</infon><infon key="type">ref</infon><infon key="lpage">1177.e5</infon><offset>70755</offset><text>Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia</text></passage></document>
</collection>